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Abstract
Cervical ripening is fondamental to the process of parturition. Recent animal studies have 
suggested that the inflammatory mediator nitric oxide is involved in this process. The aim 
of the studies reported in this thesis was to investigate the potential role of the L-arginine- 
nitric oxide system in ripening the cervix in humans.
The nitric oxide donor isosorbide mononitrate (IMN) administered per vaginam has 
previously been shown to ripen the human cervix. The studies reported in chapter 2 were 
performed in order to compare the effectiveness and side effect profile of the nitric oxide 
donor (IMN) with the prostaglandin analogue gemeprost. 66 primigravid women in the 
first trimester of pregnancy were therefore recruited to this randomised controlled trial. A 
significantly greater percentage of women remained asymptomatic following IMN (64%) 
than following gemeprost (14%). Pre-treatment with gemeprost resulted in abdominal pain 
in 73% of women and vaginal bleeding in 32% compared with 3% and 0% respectively 
following IMN. These data suggested that IMN could be used as an alternative to 
gemeprost for this indication.
A further randomised controlled trial is reported in chapter 3. This explored the hypothesis 
that combined therapy with IMN (40mg) and the prostaglandin analogue misoprostol 
(400pg) for preoperative cervical ripening in the first trimester would result in improved 
clinical effectiveness and fewer side effects compared to each agent used alone. There was 
no difference in the number of women remaining asymptomatic following either IMN or 
misoprostol or combination therapy (14/22 [64%] vs 11/21 [52%] vs 11/22 [50%], Fisher’s 
exact test). Pre-treatment with misoprostol used alone resulted in lower cervical resistance 
than IMN (18.5 N (Newtons) vs 39 N, p=0.04, Mann-Whitney U). The cervical resistance 
following combination therapy with IMN and misoprostol was not significantly lower than 
following misoprostol alone (24.5 N vs 18.5 N). These data suggest that the nitric oxide
donor IMN alone or in combination with misoprostol has no advantages over misoprostol 
alone for preoperative cervical ripening in the first trimester.
The studies reported in chapter 4 were performed to investigate whether an increase in 
nitric oxide production occurs in the human cervix in conjunction with cervical ripening. 
Using Western blotting and immunohistochemistry, the expression and localisation of the 
enzymes responsible for the production of nitric oxide, inducible nitric oxide synthase 
(iNOS), endothelial nitric oxide synthase (eNOS) and neuronal nitric oxide synthase 
(bNOS) were determined in the human uterine cervix during pregnancy and parturition. 
The expression of each of the NOS isoforms was greater in cervical tissue from pregnant 
women compared to non-pregnant. iNOS and bNOS protein expression increased in the 
first trimester of pregnancy compared to non-pregnant samples (p<0.005 for iNOS and 
bNOS respectively). iNOS was further upregulated in the third trimester of pregnancy prior 
to the onset of labour (p<0.01). These data indicate that expression of NOS is increased in 
the ceivix during pregnancy and that iNOS in particular may play a role in spontaneous 
cervical ripening during human pregnancy.
The mechanism by which nitric oxide ripens the cervix is unclear. Data presented in 
chapter 5 demonstrate the effect of nitric oxide donors administered in the first trimester of 
pregnancy on the secretion of MMPs (Matrix Metalloproteinases) -2  and -9  and their 
tissue inhibitors (TIMPs) in the human cervix. MMP-2 and MMP-9 were expressed in 
conditioned explants of cervical tissue from non-pregnant women. MMP-9 secretion was 
only detected in explants from pregnant women. Treatment with the nitric oxide donors 
spermine nonoate in vitro (non-pregnant ceivical biopsies) and isosorbide mononiti’ate in 
vivo (pregnant cervical biopsies) had no effect on the secretion of MMPs and TIMPs 
studied. The mechanism of action of nitric oxide donors in inducing cervical ripening must 
therefore be attributable to other mechanisms.
The mechanism of action of nitric oxide donors was further investigated in chapter 6. 
Cervical biopsies were obtained from pregnant women randomised to receive IMN or no 
treatment prior to suction termination. ELISAs were performed on culture supernatant for 
interleukin (IL)-l, IL-6, IL-8, IL-10, IL-15, TNFa, MCP-1 and prostaglandin metabolites. 
Biopsies treated with IMN produced significantly greater amounts of PGF-2CX in culture 
and lower amounts of thromboxane B% than controls (572.8 pg/ml vs 34.9 pg/ml, p<0.05: 
53.3 pg/ml vs 530.9 pg/ml, p<0.01 respectively). Treatment with nitric oxide had no effect 
on the release of cytokines or other prostaglandin metabolites. These data suggest that the 
mechanism of action of NO induced cervical ripening during pregnancy may be mediated 
in part via increased prostaglandin synthesis.
Cervical ripening is an inflammatory process involving leukocyte recruitment. These 
leukocytes appear to be the source of nitric oxide involved in the cervical ripening process, 
as demonstrated in the studies described in chapter 4. The factors controlling the 
infiltration of leukocytes in the cervix are poorly understood. However in other tissues 
leukocyte infiltration from the vasculature is controlled by the expresssion of a number of 
cell adhesion molecules. In chapter 7 the expression and localisation of the cell adhesion 
molecules intracellular adhesion molecule-1 (ICAM-1), E-selectin, platelet endothelial cell 
adhesion molecule (PECAM) and vascular cell adhesion molecule (VCAM) in the ceivix 
and myometrium during pregnancy and labour were investigated. Biopsies of cervix and 
myometrium were obtained from non-pregnant women and from pregnant women before 
and after the onset of labour at term. Expression of cell adhesion molecule mRNA was 
determined using Northern blotting and localisation of cell adhesion molecule protein was 
achieved using immunohistochemistry. ICAM-1 mRNA was upregulated in the cervix 
(p<0.01) and myometrium (p<0.01) during labour. VCAM mRNA was upregulated in the 
cervix during pregnancy with no further change with labour. PECAM mRNA was 
upregulated in myometiium with pregnancy but did not change with labour. Changes in the
expression of these cell adhesion molecules are likely to control the infiltration of 
leukocytes into these tissues during pregnancy and parturition.
In summary, these data suggest that nitric oxide is fundamentally involved in the process 
of cervical ripening in human pregnancy. There is an upregulation of the L-arginine-nitric 
oxide system in the third trimester of pregnancy at the time when cervical ripening takes 
place. Further evidence for the importance of nitric oxide in this process is generated from 
the studies presented here demonstrating that nitric oxide donors ripen the cervix in the 
first trimester of pregnancy with fewer side effects than prostaglandins. Combining nitric 
oxide donors with prostaglandin analogues however does not seem to improve the clinical 
effectiveness of these agents. Further insights into the involvement of the nitric oxide 
system in pregnancy and parturition may improve our treatment of preterm and post-dates 
pregnancy.
Chapter 1 
Literature Review
“If a man will begin with certainties, he shall end in doubts; but if he will be content to 
begin with doubts, he shall end in certainties.”
Francis Bacon, The Advancement o f Learning (1605).
Introduction
The uterine cervix plays a fundamental role in the process of human pregnancy 
maintenance and parturition. Its unique structure allows the fetus to remain within the 
uterine cavity until maturity is complete, whilst facilitating changes at the time of labour to 
effect the passage of the infant vaginally. The mechanisms which control the changes in 
the cervix and which trigger the onset of labour in humans remain poorly understood. 
However an understanding of these events is clearly important in clinical practice where 
premature and post-dates deliveries have important effects on neonatal outcome.
Premature labour (labour occurring prior to 37 weeks completed gestation) remains the 
leading cause of infant morbidity and mortality (Pitman M.C, and P.J., 1996). The 
incidence of premature delivery has remained relatively stable over the past 20 years at 
around 5-10% of all pregnancies, despite the widespread use of tocolytic agents (Danielian
and Hall, 1996). Further, despite improvements in neonatal intensive care, survival is
associated with considerable morbidity. Short-term outcomes include respiratory distress, 
persistent fetal circulation, necrotising enterocolitis, intraventricular haemorrhage and 
hypoxic ischaemic haemorrhage. In long term survivors, bronchopulmonary dysplasia, 
retinopathy, sensorineural deafoess and neurological handicap are all common (Johnson, et
al., 1993; MacGülivary and Campbell, 1995; McCormick, 1985). A UK study recently 
reported that 39.1% of cases of cerebral palsy occurred in children delivered prematurely 
and 23% of infants delivered before 29 weeks had significant morbidity (MacGillivary and
Campbell, 1995).
Preterm birth can be iatrogenic associated with such complications as pre-eclampsia, 
antepartum haemorrhage, fetal growth retardation and isoimmunisation. However up to 
38% of preterm deliveries are associated with spontaneous labour without associated 
pregnancy related problems (Olah and Gee, 1992). Factors such as intrauterine infection,
maternal and fetal stress, low socio-economic class, previous cervical damage and 
anatomical abnormality of the uterine cavity are clearly associated with prematurity. 
However in the majority of patients presenting with this problem there is no such defined 
underlying cause and as a result the condition remains poorly understood and inadequately 
treated.
It is now evident that prolonged gestation is also associated with an increase in neonatal 
and post neonatal mortality (Crowley, 1989; Hilder, et al., 1998). When induction of labour 
is considered it can be mediated with a variety of agents, prostaglandins being the most 
commonly used (MacKenzie and Embrey, 1979). The Royal College of Obstetricians and
Gynaecologists recently issued a recommendation that induction of labour should be 
offered routinely to all women after 41 weeks gestation (The Royal College of 
Obstetricians and Gynaecologists, 1998).
Improvements in the management of both preterm and post dates pregnancy are hampered 
by our limited understanding of the events controlling the onset of parturition in the 
human. Both term and preterm labour share a final pathway of cervical ripening, activation
of the fetal membranes and the onset of regular uterine activity. Previous research 
examining the pathophysiology of labour has largely concentrated on the mechanics and 
control of uterine activity, with the role of the cervix being largely ignored (Olah and Gee,
1992). However, the active biological changes occurring within the cervix during
pregnancy would suggest that this organ plays an active role in the labouring process. 
Improvements in the management of both preterm and post dates pregnancy will not occur 
until we develop a better understanding of the events occun ing in both the uterus and the 
cervix at this time.
Part I: Control of the onset of labour
“ Nothing begins, and nothing ends,
That is not paid with moan;
For we are bom in other’s pain.
And perish in our own.”
Francis Thompson, Daisy (1913)
The timing of parturition is a crucial event in the survival of any species, and it seems
unlikely therefore to be controlled by a single biochemical pathway. It has been proposed
that labour occurs due to the transition of the myometrium from an inactive to an active 
muscle either due to the withdrawal of inhibitoiy agents or by the addition of uterotonins. 
A number of agents have been thought to be involved in maintaining the uterus in its state 
of quiescence during pregnancy including progesterone, prostacyclin, relaxin, nitric oxide, 
parathyroid hormone related peptide, human placental lactogen, corticotrophin releasing
hormone, calcitonin gene related peptide and vasoactive intestinal peptide (Challis, 1998; 
Lopez, et al., 1995). It is thought that prior to the onset of labour the uterus becomes
activated in response to uterotrophins such as oestrogen. This results in increased 
formation of gap junctions, activation of voltage dependent calcium ion channels, and an 
increase in expression of myométrial contraction related proteins (including receptors for 
prostaglandins and oxytocin) (Garfield, et al., 1988; Gaifield, et al., 1980). Following 
activation, the uterus then becomes responsive to uterotonins such as oxytocin, 
prostaglandin E2 and prostaglandin F2C1 (Norwitz, et al., 1999) which stimulate uterine 
activity in the responsive myometrium.
In human pregnancy, the specific triggering mechanisms for the onset of labour and the 
means by which these factors are integrated remains unclear. However, in most viviparous
animals it is the fetus that seems to control the onset of parturition. From an evolutionary 
viewpoint this would seem appropriate, allowing labour to occur at a time when fetal 
maturity was adequate for extra-uterine survival. This is certainly the case in the sheep 
where the trigger for the onset of labour is dependent on activation of the hypothalamic- 
pituitary-adrenal axis resulting in increased cortisol production. Fetal cortisol increases the 
activity of placental enzymes including 17-alpha hydroxylase and P450 C-17,20 Lyase, 
producing increased synthesis of oestrogen and decreased synthesis of progesterone (Flint, 
et al., 1975; Liggins, 1989; Nathanielsz, 1998). The alteration in oestrogen to progesterone 
ratio in turn causes gap junction formation in the myometrium, stimulation of oxytocin 
receptors and activation of the phospholipase A2 pathway, leading to the onset of labour 
(Challis and Olson 1988; Garfield, et a l, 1979).
In man, there is also a rise in fetal cortisol and placental oestrogen production with the 
onset of labour, however there is no measurable change in plasma progesterone levels. 
This is because the target enzyme for cortisol action, 17-alpha hydroxylase is absent in the 
human placenta (Flint, et a l, 1986). Furthermore, in anencephalic fetuses, the mean 
gestational length is 40 weeks (Honnebier and Swaab, 1973). This would suggest that a
functioning hypothalamic-pituitary-adrenal axis is not necessary for the onset of labour in 
man. Cortisol may have a role in the onset of parturition in the human, however the 
available evidence would suggest that the means by which it exerts its effects is more 
complicated than in the sheep model
It has also been suggested that the endocrine control of parturition may stem from signals 
produced within the fetal lung. Platelet Activating Factor (PAF) is produced in human fetal 
lung explants and in vitro has been shown to increase production of prostaglandin E2 in 
human amnion (Johnston, et a l, 1987). In rabbits, increased surfactant production in the 
lung is associated with an increase in PAF. Thus is would seem reasonable that PAF is 
involved in the initiation of parturition once fetal lung maturity is complete. However in
cases of congenital bilateral pulmonary agenesis, where lung tissue is obviously absent, 
there is no associated increase in the incidence of premature labour or prolonged 
pregnancy (Glaireux and Ferreira, 1958). This would suggest that while factors produced 
by the mature fetal limg may be supportive, they are not sufficient to control labour in man.
While it is unclear whether the fetus triggers the onset of labour in man, there is good 
evidence that prostaglandins play a role in the control of parturition. Prostaglandins are 
capable of inducing labour (Calder, 1990) and prostaglandin synthase inhibitors have been 
used in clinical practice as tocolytic agents due their inhibitory effects on myométrial 
contractility (Wiqvist, 1979). Following the onset of labour, there is an increased 
production of prostaglandin E2 and prostaglandin p2„ in the amnion and chorlo-decidua 
(Keirse, 1979; Mitchell, 1984; Skinner and Challis, 1985). Prostaglandin production also 
increases in the cervix during the period of ceivical ripening which occurs prior to the 
onset of uterine activity (Ellwood, et al., 1980; MacKenzie, 1981). Taken together, these
findings suggest that prostglandins are intimately involved in the initiation and progression 
of labour.
Prostaglandins are synthesised from arachidonic acid by the enzyme cyclo-oxygenase 
(COX). Two isofoms of this enzyme have been identified, COX-1, the constitutively 
expressed form and COX-2, the inducible isoform. COX-2 expression is induced in 
mammalian tissues by growth factors and various cytokines and inhibited by 
glucocorticoids (Masferrer and Seibert, 1994; Xie, et al., 1991). Recent work has shown 
that there is an increase in expression of COX-2 in the amnion and chorio-decidua with the 
onset of labour at term (Slater, et al., 1998; Slater, et al., 1995). Premature prostaglandin 
release has been implicated in the aetiology of preterm labour. This is thought to occur 
secondary to intrauterine infection (Romero, et al., 1989) and activation of fetal cortisol-
placental corticotrophin releasing hormone (CRH) under fetal compromise (McLean, et ah, 
1995). This has prompted suggestions that specific inhibitors of COX-2 may be of future 
value in the treatment of preterm labour.
While it has been shown that there is no fall in serum progesterone levels in humans with 
the onset of labour, there remains good evidence that progesterone is fundamentally 
involved in maintaining uterine quiescence at this time. Progesterone exerts an overall 
quiescent effect by (i) suppressing genes in the myometrium necessary for uterine 
contractility (connexin 43, calcium channels, oxytocin receptors), (ii) upregulating 
relaxation mechanisms and (iii) suppressing release of pro-inflammatory cytokines and 
decreasing the availability of prostaglandins (Garfield, Radideau et al. 1979; Chwalisz and 
Garfield 1994; Chwalisz 1994). The administration of antiprogesterones such as RU486 
therefore results in activation of uterine activity by increasing myométrial responsiveness
to uterotonic agents and in addition causes cervical ripening in humans (Chwalisz, 1994). 
Labour has been likened to an inflammatory process (Kelly, 1994) and progesterone is a
powerful anti-inflammatory agent. Hence it would appear that progesterone is involved in 
the maintenance of human pregnancy in a similar manner to that of the sheep. Various 
attempts have been made to explain the observed lack of fall in progesterone levels in the 
case of the human. Theories include local modulation of oestrogen and progesterone 
biosynthesis in fetal membranes at levels which would be undetectable in the maternal 
chculation (Mitchell and Challis, 1988), progesterone inactivation by specific binding
proteins (Westphal, et al., 1977) and changes in the expression of the progesterone
receptors (Allport, et al., 2000; Pieber, et al., 2000; Winkler, 2000). While further evidence
is needed to support the theory of local progesterone withdrawal, it remains an attractive 
theory, which would link parturition in the human to that of other species.
Corticotrophin releasing hormone (CRH) has also been proposed as the initiator of labour 
in man (Challis, 1998; Jones and Challis, 1990). CRH is a 41 amino acid peptide hormone,
which has similar structure to hypothalamic releasing factor. It was originally thought to be 
a product of the placental cytotrophoblast but is now known to be expressed in the 
syneytiotrophoblast where it is stored in granules and released into the maternal 
compartment (Keelan, et al., 1997; Riley, et al., 1991). Recently the endometrium has also
been identified as a source of CRH (DiBlasio, et al., 1996). CRH receptors are present in 
the human myometrium and in late pregnancy the affinity of these receptors for CRH 
increases (Grammatopolous, et al., 1995; Hillhouse, et al., 1993). At term, in the presence 
of oxytocin, activation of these receptors by CRH causes a decrease in myométrial cAMP 
levels resulting in an increase in contractility (McLean, et al., 1994). The bioavailability of 
CRH is affected by binding to a specific binding protein (CRH-BP). This is present in 
relatively stable eoneentrations in maternal plasma during pregnancy until about 4 weeks 
prior to the onset of labour when the levels of CRH-BP decline, probably as a result of
increased hepatic clearance (Linton, et al., 1993; McLean, et al., 1995). Hence in the final
few weeks of pregnancy, rising CRH concentrations accompanied by a fall in CRH-BP 
levels may both promote final fetal organ maturation through stimulation of fetal adrenal 
cortisol production and also stimulate the onset of regular uterine activity (Challis, 1998).
Historically oxytocin has been recognised as a primary factor involved in the control of 
parturition (Hirst, et al., 1993). However, its exact role remains controversial due to the 
failure to observe any increase in oxytocin levels in the maternal plasma with the onset of 
labour (Dawood and Khan-Dawood, 1985). The role of oxytocin may therefore be to 
intensify labour once contractions have started, since agents such as CRH are known to 
sensitise the uterus to the uterotonic effects of oxytocin (McLean, et al., 1994).
Alternatively, increased myométrial sensitivity to oxytocin through the activation of 
specific oxytocin receptors (OTRs) could provide another mechanism whereby oxytocin 
could influence parturition. OTR mRNA is expressed in human decidual cells, chorionic 
trophoblasts and myometrium and levels increase during labour (Fuchs, et al., 1984; Fuchs,
et al., 1991; Kimura, et al., 1996). Furthermore oxytocin can stimulate prostaglandin
production in fetal membranes (Fuchs, et ah, 1984). It is therefore possible that oxytocin
may be important in stimulating intrauterine prostaglandin production at term, amplifying 
uterine contractile activity.
It is now known that labour is an inflammatory process involving leukocytic influx of the 
myometrium, cervix and fetal membranes with the subsequent release of various cytokines 
(Bokstrom, et al., 1997; Kelly, 1994; Liggins, 1981; Rosenberg, et al., 1996; Thomson, et 
al., 1999). As discussed already, there is also evidence that inflammatory cytokines may 
have a pivotal role in infection induced preterm labour (Baumann and Romero, 1995; 
Romero, et al., 1994; Romero, et al., 1994). Levels of interleukin-1 (IL-1), IL-6 and 
tumour necrosis factor-a (TNF-a) are increased in the amniotic fluid of women with 
infection induced preterm labour and may act synergistically with prostaglandins to 
stimulate parturition (Romero, et al., 1991; Romero, et al., 1989; Romero, et al., 1989). 
The role of cytokines in the process of cervical ripening is discussed later in this review.
Thus, human labour is a physiological process involving the integration of a series of 
changes within the uterus occurring over a period of days or even weeks. Numerous factors 
have been implicated in controlling the switch to active labour and it is likely that complex 
endocrine, paracrine and autocrine mechanisms are involved. The uterus is more than a 
mere sac, which functions to contain the growing conceptus, and allows it to be expelled at 
the time of parturition. Furthermore, the active physiological processes that occur within
the uterus at parturition are dependent on changes, which take place in the uterine cervix in 
the last few weeks of gestation.
Part II: The cervix in pregnancy and parturition
Cervical ripening, the process whereby the cervix undergoes softening, effacement and 
dilatation, is a gradual process occurring in the 4-6 weeks prior to the onset of labour. The 
exact mechanisms involved and the factors which control this process remain poorly 
understood. As clinicians, much of our interest in this process has focused on the 
therapeutic manipulation of cervical ripening to induce labour at terra. Although preterm 
labour, as in normal labour at term, involves complex changes in cervical structure prior to 
the onset of uterine activity, research and therapeutic strategies for the management of this 
condition have largely ignored the important role played by the cervix (Olah and Gee,
1992). Current tocolytic therapies for preterm labour, involving beta sympathomimetics
and calcium antagonists, have been shown to be ineffective at prolonging gestation for 
>48hours and are associated with substantial risks for both mother and fetus (Higby K et al
1993). The failure of these agents is perhaps due to their inability to influence cervical 
compliance, as changes in the cervix take place at least concurrently with, if not prior to, 
the onset of uterine activity. A better understanding of the events involved in cervical 
ripening may therefore allow us to develop better strategies for the management of preterm 
labour.
Structure o f  the cervix
The uterus is divided anatomically into 2 basic parts-the uterine body, or corpus, and the 
cylindrical neck, or cervix. It is said to have the shape of a flattened pear and in the
nulliparous woman measures 8x5x3cm (3x2x1 in) (McMinn, 1990) and weighs in the 
region of 50-70g (Leppert, 1995). In multiparous women, the uterus has an average length
of 9-10 cm and weighs about 80g. Age as well as parity influences the relative dimensions 
of the uterus and cervix. In the infant, the cervix is long and comprises 2/3 of the total size,
whereas in the multiparous female, the cervix makes up only 1/3 of the length (Calder,
1994).
The cervix extends into the vagina and classical teaching states that it is joined to the body 
of the uterus via a narrow central constricted area traditionally known as the isthmus 
(Vellacott, 1992). The concept of an isthmic portion has been long challenged however
since the publication of Danforth’s work in 1947. At this time he stated “it is believed that 
the concept of the isthmic uteri as a separate distinct entity should be eliminated and that, 
rather, the uterus should be considered as being composed of 2 major parts, corpus and 
cervix, according to whether the fundamental structure is chiefly muscular or chiefly
fibrous.” (Danforth, 1947). The upper part of the cervix, or supravaginal portion, lies deep
to the vesicouterine pouch and is connected to the bladder above the level of the trigone by 
dense connective tissue. Posteriorly, the cervix forms the anterior wall of the pouch of 
Douglas and is covered by peritoneum. The lower part extends into the vagina and is 
surrounded by the vaginal fornices on all sides, the deepest lying posteriorly. The 
endocervical canal, which opens into the vagina, is bound by the internal os cephalically 
and the external os caudally. It is lined by a tall columnar mucus secreting epithelium with 
highly branched glands. At the external os the epithelium becomes stratified squamous and 
is in continuity with that of the vagina.
Beneath the epithelium lies a dense connective tissue stroma composed of mainly 
extracellular matrix. The matrix consists chiefly of type I (66 percent) and type III (33 
percent) collagen, with a small amount of type IV present in the basement membrane
(Miramoto, et al., 1982). The collagen fibres within the cervix are arranged in dense
bundles and play a role in the maintenance of pregnancy by means of their functional 
rigidity. Elastin fibres are also present and seem to be important due to their recoil
properties in returning the cervix to its original shape after delivery. The fibrous 
component of the extracellular matrix is embedded in ground substance, made up 
principally of proteoglycans containing a number of glycosaminoglycans (GAGs). The 
GAGs are negatively charged large molecular weight mucopolysaccharides with repeating 
dissacharide subunits. These contain either one hexosamine (glucosamine or 
gaiactosamine) or one uronic acid (glucuronic or iduronic) repeating unit. The main GAGs 
in the cervix are chondroitin and and its epimer dermatan sulphate, but there are a number 
of others including heparan sulphate and hyaluronic acid. The GAGs vary in size and in the 
proportion of the various subunits present. Except in the case of hyaluronic acid, they bind 
to a protein core to form proteoglycans.
Collagen fibres within the cervix are bound by the proteoglycan protein cores. The GAG 
side chains of the proteoglycan can also bind to collagen and to one another. The binding 
of the glycosaminogiycan molecules to collagen varies with their chain length and charge 
density. Hence it is possible to vary the strength of the matrix by altering the 
glycosaminoglycans present. Hyaluronic acid binds loosely to collagen and hence will 
destabilise the matrix if present in large quantities. Other molecules such as dermatin 
sulphate bind strongly to collagen and provide structural rigidity.
The major cell type present in the connective tissue stroma is the fibroblast, which is 
responsible for the continual turnover of the extracellular matrix. It is postulated that these 
cells may also have a role in the reduction of cervical circumference after delivery by 
means of their contractile properties (Liggins, 1981). Smooth muscle fibres make up
approximately 10 percent of the cervical tissue’s composition (Liggins, 1981). These fibres
may contribute to the spatial organisation of collagen fibres and be in some way 
responsible for the control of cervical rigidity, as cervices from women with incompetent 
cervices have been shown to have an increased smooth muscle component (Leppert, 1995).
The cervical smooth muscle has some contractile properties (Hillier and Karim, 1970) but
it is unlikely that it functions primarily as a sphincter during pregnancy. Recently it has 
been suggested that the smooth muscle may in fact play an active role in the process of
cervical ripening, by means of apoptosis, the process of programmed cell death (Leppert, 
1998). Further investigators have suggested that smooth muscle contractions may actively
influence the course of labour, with the circular muscle fibres contributing to constriction 
of the cervical canal and the longitudinal fibres contributing to cervical dilatation (Rudel, 
2000).
Changes in the Cervix during Pregnancy.
During gestation there are profound changes which take place within the cervix. In the 
non-pregnant woman the cervical canal is fusiform and firm, with the consistency of nasal 
cartilage. During pregnancy, the cervix gradually changes its consistency, becoming soft 
and compliant as pregnancy advances. These changes occur as a result of alterations in the 
biochemical composition of the cervix and the reaiTangement and realignment of collagen 
fibres.
The water content of the cervix increases from 80 percent in early pregnancy to around 87 
percent at term (Uldbjerg, et al., 1981). As GAGs are highly hydrophilic, increased binding 
of water to these molecules may destabilise the connective tissue matrix and hence the 
cervix may be physically altered. There does not seem, however, to be a change in the 
water content of the cervix in humans immediately before delivery or in the postpartum
period (Leppert, 1998). The elastin concentration does not change despite there being an 
increase in messenger RNA for tropoelastin in pregnancy (Leppert, 1998). There is also an 
increase in the smooth muscle component of the cervix with these cell becoming more
prominent and presumably as a result also affecting the arrangement of collagen fibres 
within the tissue.
Collagen concentration is markedly altered during pregnancy. At 10 weeks gestation, the 
collagen concentration is 70 percent and this drops to around 30 percent at term (Ekman, et
al., 1983; Rath, et al., 1994; Uldbjerg, et al., 1983). The collagen fibrils become dissociated
and the spaces between them become dilated from about 8-14 weeks gestation (Kokenyesi
and Woessner, 1990). Although the collagen concentration is decreased, there is an overall
increase in the amount of collagen present, as the other components of the cervix such as 
water and glycosaminoglycans increase in relatively greater amounts. The fall in collagen 
concentration during pregnancy may also be attributable to increased turnover of collagen.
Enzymatic degradation of collagen is brought about by the action of proteolytic enzymes. 
These include several collagenases (MMP-1, MMP-8 and MMP-13) which have the ability 
to cleave fibrillar as well as non-fibrillar collagen and are all members of the matrix 
metalloprotease (MMP) family (Hulboy, et al., 1997). The enzymes are secreted in a latent
pro form and are activated by other MMPs or in some cases plasmin to form the active 
enzyme. Enzyme activity can be inhibited by either tissue or plasma inhibitors. Tissue 
inhibitors of the matrix metalloproteases (TIMPS) are found bound to either the ‘active’ or 
the ‘pro’ forms of the enzyme. The plasma inhibitors, known as the plasma a  
macroglobulins, are cleaved by MMPs and the resulting covalently bound complex is then 
subject to intracellular degradation. Tissue and plasma inhibitors play a fundamental role 
in controlling MMP activity. During pregnancy, increased activity of MMP-1 (tissue and 
macrophage collagenase) and MMP-8 (neutrophil collagenase) results in hydrolysis of 
peptide bonds and subsequent dissociation of the collagen fibrils (Leppert, 1995). These 
enzymes are released by polymorphonuclear leukocytes which infiltrate the cervix from
the blood vessels during the later stages of pregnancy and also by fibroblasts (Bokstrom, et 
al., 1997; Junquiera, et al., 1980; Osmers, et al., 1995).
Collagen breakdown can also occur due the action of elastase, an enzyme produced by 
neutrophils, macrophages and eosinophils. This enzyme can also break down elastin and 
proteoglycans and thus can markedly contribute to changes in biochemical composition of 
the cervix. Elastase breaks down collagen by its action on the teleopeptide non-helical 
domains. There is an increase in cervical collagenase and elastase activities in the cervix 
during pregnancy as the cervical collagen content decreases (Uldbjerg, et al., 1983).
There are marked changes in the structure of the collagen that is produced during 
pregnancy. Histochemical studies have shown that the concentration of collagen arranged 
in fibrils postpartum is only 8 percent of that in comparison to samples from non pregnant 
women (Junquiera, et al., 1980). During pregnancy, the amount of soluble collagen, which
represents partly degraded collagen, in the tissue increases (Uldbjerg, et al., 1983;
Uldbjerg, et al., 1983). The collagen produced during pregnancy seems to be of an
immature nature with fewer crosslinks, making it more amenable to breakdown by
proteolytic enzymes (Ito, et ai., 1979). There is also an alteration in the GAGs in the cervix
as pregnancy advances. The total amount of GAGs increases, indicating active synthesis. 
However, there is also a change in the specific GAGs present, which has an effect on the 
tissue’s properties. The amount of hyaluronic acid present may increase, remain unchanged
or decrease (Leppert, 1995; Uldbjerg, et al., 1991; Von Maillot, et al., 1979). Hyaluronic
acid interacts weakly with collagen and fibronectin and the increase in this
glycosaminogiycan can help loosen the collagenous network of the cervix (Uldbjerg, et al.,
1991).
In the non-pregnant cervix, the predominant proteoglycan is dermatan sulphate (DPSG II 
or decorin). Decorin both coats the collagen fibres, thus maintaining the collagen at small 
diameter, and helps to separate the fibrils, by coming between the fibres that make up their 
fibrils. There are three dermatan sulphates, deeorin, biglycan (DSPG I), (which has two 
dermatan sulphate side chains) and PGL, which is a larger molecule with 
chondroitin/dermatan sulphate side chains. As pregnancy advances the concentration of 
decorin increases (Leppert, 1995; Uldbjerg, et al., 1991), presumably contributing to the 
ripening process. Cervical dilation is also associated with changes in the amounts of the 
other proteoglycans present (Noiman, et al., 1991).
Changes involved in cervical ripening.
In the final few weeks prior to the onset of labour and delivery, the cervix undergoes final 
maturationai change. These changes are a prerequisite for spontaneous labour and normal 
vaginal delivery. Clinically the cervix is said to ‘ripen’, becoming softened, effaced and 
undergoing the early stages of dilatation. These changes occur secondary to further 
changes in the extracellular matrix at this time. There is an increase in the water content, a
reduction in collagen and a change in the constituent GAGs (Calder, 1986; Greer, 1992).
The collagen fibres become realigned and dissociated and the amount of ground substance 
present increases. At this time there is also an influx of inflammatory cells into the 
connective tissue stroma, with the release and activation of degradative enzymes
(Bokstrom, et al., 1997; Junquiera, et al., 1980; Liggins, 1981; Osmers, et al., 1995).
Whilst we are aware that these biochemical changes occur in the cervix at this time, we 
have an incomplete understanding of the mechanisms which control them. Studies, which 
have been conducted on the human cervix to address this issue, have a number of
methodological problems. Firstly, we are unable to study intact cervical tissue during 
pregnancy at a biochemical level except in the rare cases where hysterectomy is performed 
due to intractable bleeding with removal of the intact uterine organ. Secondly, small biopsy 
samples obtained during pregnancy and labour may not represent changes oecuring in the 
cervix as a whole and thirdly, conflicting study results may arise from sampling different 
parts of the cervix, especially when lower segment myometrium is confused with cervical 
tissue. Also, while tissue culture studies provide us with invaluable information, they are 
no substitute for in vivo findings, especially since the conditions in which these 
experiments are performed are somewhat different to that found in human tissue. However, 
information from various sources, in both animal and human studies, have allowed some 
tmderstanding of the factors involved.
Factors involved in cervical ripening.
There are a number of factors that may be involved in cervical ripening. The means by 
which these factors interact and the relative importance of each is poorly understood. 
However it is interesting to note that cervical ripening can occur in the cervix which has
been physically separated fi'om the uterus (Stys, et al., 1980). Improved understanding of
the mechanisms controlling cervical change in the later part of pregnancy will undoubtedly 
improve our management o f both preterm and post-dates pregnancy.
Prostaglandins
Prostaglandins are the most comprehensively studied factors involved in cervical ripening 
and seem to be produced physiologically during the ripening process (Ellwood, et al.,
1979). These agents are widely used pharmacologically to cause cervical ripening prior to
induction of labour (Calder, 1997) and for first trimester suction termination of pregnancy
(El Refaey, et af, 1994). The prostaglandins PGE2, PGI2 and PGF2„ are produced in the
cervix during pregnancy and parturition (Ellwood, et al., 1979), but it seems that
physiologically PGE2 is the most important of these. Receptors for prostaglandins are
present in the human cervix (Crankshaw, et al., 1979) and amniotic fluid concentrations of
PGE2 and PGp2ct correlate directly with cervical ripeness in women at term, not in labour
(Calder, 1980). The means by which prostaglandins cause cervical ripening has been the
subject of much research. Prostaglandins may effect ripening by inducing collagen 
breakdown or by modifying the GAG composition of the cervix. In inflammatory 
situations, PG is thought to act as a powerful vasoactive agent, facilitating inflammatory 
cell influx.
Although prostaglandins have been for a long time thought of as the key mediators of the 
ripening process in humans, other agents also appear to be involved. In the physiological 
setting, cervical ripening occurs independently of uterine activity, i.e. prior to the onset of 
labour and prostaglandin release. Studies in rats and guinea pigs (Chwalisz, et al., 1991)
(Shi, et al., 1996) have demonstrated that the ceivix softens in mid to late pregnancy long
before the onset of labour. In addition, neither the non selective COX nor specific COX-2 
inhibitors are able to inhibit antiprogesterone induced cervical ripening in humans, rats and 
guinea pigs (Chwalisz, 1994) suggesting that other agents must be important in addition to 
prostaglandins in the ripening process.
Steroid hormones
Both oestrogen and progesterone have an effect on the ripening mechanism. Oestrogens 
have been shown to be capable of ripening the unfavourable cervix when applied locally
(Alien, et al,, 1989; Gordon and Calder, 1977) and their action may in part be mediated by 
prostaglandin release (Fitzpatrick and Dobson, 1981). Oestrogens may also mediate 
cervical ripening by means of programmed cell death or apoptosis (Leppert and Yu, 1994) 
due to the down regulation of oestrogen receptors.
Progesterone appears to have an inhibitory effect on cervical ripening and parturition in 
animals where a fall in progesterone at term results in the onset of labour. In humans, this 
fall is not present, but progesterone must also have some effect on the control of cervical 
ripening, as demonstrated by the action of various antiprogesterones in the cervix and by 
the observation that progesterone receptors are down regulated in the human cervix at term 
(Chwalisz and Garfield, 1994; Chwalisz, et al., 1991; Garfield and Baulieu, 1987;
Radestad and Bygdeman, 1992; Stjernholm, et al., 1997; Winkler, et al., 2000). In fact, 
antiprogestins are effective agents in mediating cervical ripening in all species studied to 
date (Chwalisz and Garfield, 1994). In guinea pigs, the progesterone antagonists have been 
shown to decrease cervical collagen and glycosaminogiycan concentration via an effect on 
the progesterone receptor (Leppert, 1995). Studies in humans have also shown that anti­
progestins stimulate collagenolysis within the cervix after their local application (Radestad,
et al., 1993). Progesterone, as already stated, is a powerful anti-inflammatory agent and 
could be important in the cervix during pregnancy in preventing neutrophil influx into the 
tissue (Jeffrey and Koob, 1980). Furthermore, the effects of anti-progestins in the cervix 
may in part relate to an increase in prostaglandin production as they can stimulate 
prostaglandin synthesis and decrease prostaglandin catabolism in vitro (Kelly and Bukman,
1990). This may reflect an interaction with the transcription factor NF-kappa B, as
progesterone can act through NF-kappa B to inhibit COX-2 expression (Kalkhoven, et al..
19%). However, this finding has not been consistently reported in other studies (Norman,
1993).
Cytokines
Consistent with the hypothesis that cervical ripening represents an inflammatory reaction, 
there is evidence that various cytokines are also involved. IL-8, a C-X-C chemokine which
promotes neutrophil chemotaxis, has been shown in vivo (Sennstrom, et al., 1997) and in 
vitro (Barclay, et al., 1993) to be produced in the cervix and to be capable of causing 
ripening when artificially applied to the cervix. IL-8 may have a synergistic role with 
prostaglandins in inducing cervical ripening (Colditz, 1990). IL-1 can induce cervical
ripening in animal models (El Maradny, et al., 1995) and its mechanism of action may
involve the co-induction of IL-8 (Uchiyama, et al., 1992; Winkler, et al., 2000). Other 
cytokines, such as TNFa have also been shown to be involved, the local application of this 
cytokine in guinea pigs causing a ripening effect (Chwalisz, et al., 1994). In this situation 
TNFa may act in concert with IL-6 to facilitate neutrophil chemotaxis, IL-1 gene 
expression and endothelial adhesion molecule upregulation (Rees, 1992). Recent studies
have suggested that the release of pro-inflammatory cytokines in the cervix may cause 
cervical smooth muscle cells to induce the expression of degradative enzymes including 
MMP-1, MMP-3, MMP-9 and cathespin-S (Watari, et al., 1999).
Cytokine production within the cervix and uterus seems to be regulated by progesterone. 
Progesterone inhibits and antiprogesterones stimulate IL-8 release in choriodecidual cells 
in vitro (Kelly, et al., 1994). Hence during pregnancy progesterone may act as an 
immunosuppressant in the cervix and decidua. Antiprogestin treatment may therefore
promote cytokine release, prostaglandin release, as well as promoting neutrophil influx 
into the tissue.
Relaxin
Relaxin is another agent which may have a role in ripening (Evans, et al., 1983;
MacLennan, et al., 1986; Weiss, 1995). Relaxin is a peptide hormone which is an insulin
derivative. It is synthesised as precursor molecule and undergoes metabolic cleavage to the 
active form. Expression of relaxin is controlled by two human relaxin genes, which reside 
on chromosome 9. Relaxin has two biological effects during pregnancy: it causes uterine 
quiescence and promotes remodelling of the extracellular matrix of the reproductive tract 
to accommodate pregnancy (Sherwood, 1988).
In rats, relaxin is clearly needed for cervical dilatation, as animals deprived of their relaxin 
secreting ovaries but given progesterone will go into labour but cannot deliver as the cervix 
remains rigidly closed (Sherwood, 1988). There is a close correlation in the rat between
cervical softening and serum relaxin levels from day 12 until term (Sherwood, 1988). 
Animal studies have also shown that the cervix can be ripened pharmacologically using 
this agent (MacLennan, et al., 1986). The human cervix has also been ripened using
porcine relaxin (Evans, et al., 1983) although recombinant human relaxin seems to have 
little effect (Brennand, et al., 1997; Petersen, et al.; Weiss, 1995).
Receptors for relaxin have been demonstrated in the human female reproductive tissues, 
including the cervix, during pregnancy. The effect of relaxin on the cervix may be 
secondary to an increase in collagenase activity, as fibroblasts are known to exhibit relaxin
receptors (McMurty, et al., 1980) and relaxin has been shown in rats to promote the
widespread reorganisation of collagen fibres in the cervix (Luque, et al., 1998). Of further 
interest is the fact that relaxin has the potential to induce gap junction formation (Liggins, 
1981). Gap junctions have been described in the cervix between the cytoplasmic processes 
of neighbouring fibroblasts (Ferenczy and Richart, 1974), although their function is 
unknown. In the porcine cervix, relaxin has been shown to increase the formation of gap 
junction proteins in pregnancy (Lenhart, et al., 1999). Several recent studies have also 
indicated that relaxin stimulates nitric oxide synthesis in a number of tissues including the 
cervix (Shi, et al., 2000). Our understanding of the mechanism of action of relaxin in the 
human cervix remains unclear however.
Inhibitors of cervical ripening
More recent studies have shown that various inhibitors of cervical ripening may be present 
in the cervix during pregnancy and this opens further avenues for therapeutic intervention. 
The anti-inflammatory mediator, secretory leukocyte protease inhibitor, is present in 
cervical mucus during normal pregnancy (Helmig, et al., 1995) and may be important in
the inhibition of cervical ripening brought about by PGEz (Denison, et al., 1999). 
Aminopeptidase N/CD 13 is present on tissue fibroblasts and has been shown to cleave and 
inactivate IL-8 in vivo (Kanayama, et al., 1995), and the combination of IL-8 with the 
aminopeptidase inhibitor, bestatin, potentiates the effect of IL-8 on ceiwical ripening in 
rabbits (Elmaradny, et al., 1995).
Urinary trypsin inhibitor (UTI) has also been implicated in the control of ripening. This 
enzyme is capable of inhibiting various enzymes including elastase, hyaluronidase and 
plasmin. It is also capable of inhibiting cytokines, including IL-1 and IL-8. Increased
levels o f this enzyme have been found in the cervix and myometrium during pregnancy 
and studies in rabbits have shown that UTI is capable of suppressing premature cervical
ripening (Kanayama, et al., 1995).
Apoptosis
It has also been postulated that the biological changes in the uterine cervix prior to labour 
result from the proliferation of fibroblasts and smooth muscle cells followed by their 
programmed cell death, or apoptosis (Leppert and Yu, 1994). Apoptosis is highly
organised and follows a universal pattern characterised by chromatin condensation, DNA 
cleavage by endonucleases, cell shrinkage, membrane blebbing and redistribution of 
phospatidylserine from the inner to the outer leaflet of the cell membrane, an important 
mechanism for the recognition of apoptotic cells by surrounding phagocytes. It is induced 
by stimuli such as oestrogens and other steroid hormones as well as by inflammatory 
cytokines (Cohen and Duke, 1984; Sandford, et al., 1984) and involves accumulation of
p53 and activation of various caspases (Mebmer, et al., 1998). It has been hypothesised
that in response to apoptosis within the smooth muscle cells and fibroblasts of the cervix, 
biochemical pathways could be induced, such as activation of cytokines and MMPs, 
resulting in alterations in the collagen structure and changes in the proteoglycan
composition of the cervix (Leppert, 1998). Recent studies in the human cervix before and
after the onset of labour have demonstrated an increase in apoptosis in cervical stromal
cells in pregnancy and following labour (Allaire, et al., 2000). Apoptosis is a genetically
timed event and this may explain why the onset of labour is time specific for different 
species.
Nitric oxide
Recently the inflammatory mediator nitric oxide has been implicated in the ripening 
process. The involvement of nitric oxide in pregnancy and ripening will be discussed in 
more detail in the following sections of this thesis.
Part III: Nitric oxide
In 1987, Moncada and his colleagues showed that nitric oxide (NO) accounted for the 
biological activity of endothelium-derived relaxing factor and was responsible for the 
conti ol of vascular tone (Palmer, et al., 1987; Palmer, et al., 1988). Since its discovery, NO
has been identified as a crucial biological mediator, involved in diverse activities such as 
smooth muscle relaxation, neurotransmission, inflammation and regulation of the immune
response (Nathan, 1992). In 1998, Furchgott, Ignano and Murad were awarded the Nobel
Prize for their contribution to science in the field of NO research.
NO is known to play a crucial role in several aspects of female reproductive physiology 
[for review see Chwalisz 1996 (Chwalisz, et al., 1996) and Rosselli 1997 (Rosselli, 1997)].
These include menstruation (Cicinelli, et al., 1996; Teller, et al., 1995; Tschugguel, et al.,
1998;Tshugguel et al., 1999) and conception by means of its effects on LHRH release
(McCann, et al., 1998) sperm motility (Lewis, et al., 1996) ovarian function (Eliman, et al.,
1993; Jablonka-Shariff and Olson, 1998; Rosselli, et al., 1998) and implantation (Chwalisz,
et al., 1999; Purcell, et al., 1998). Increased NO production may also be inherently
involved in the normal haemodynamic changes of pregnancy, in the maintenance of the 
uteroplacental circulation and the control of maternal vascular tone, while a deficit of NO 
may contribute to the pathophysiology of intrauterine growth restriction and pre-eclampsia 
(Izumi, et al., 1993; Sladek, et al., 1997).
Biosynthesis and release o f  NO
NO is a reactive gas with a very short physiological half-life. It is synthesised from L- 
arginine by the enzyme nitric oxide synthase (NOS), of which three isoforms have been 
identified at present (Figure 1.1). These isoenzymes have common features with the
respiratory chain enzyme cytochrome P450 reductase and contain oxidative and reductive 
domains. The three isoforms of NOS are known as endothelial NOS, (eNOS; NOS III), 
neuronal or brain NOS, (bNOS; NOS I) and macrophage or inducible NOS, (iNOS; NOS 
II), and the genes for each of these enzymes has been localised to chromosome 7, 12 and 
17 respectively. There is significant homology between the amino acid sequences of NOS 
from different species and between each of the different isoforms. Whilst the isoforms of 
NOS are named after the cell type in which they were first identified, it is now recognised 
that the three isoforms are widely distributed in a variety of tissues. bNOS was originally 
purified and cloned from neuronal tissues but is now known to have an important level of 
expression in skeletal muscle, neutrophils, pancreatic cells and respiratory and 
gastrointestinal epithelia (Nathan and Xie, 1994). iNOS was originally purified and cloned
from an immunoactivated macrophage cell line, and has since been identified in 
neutrophils, mast cells, endothelial cells, vascular smooth muscle, cardiac muscle and
hepatocytes (Nathan, 1997). eNOS, the last of the three mammalian NOS isoforms to be
isolated, was originally purified and cloned fr om vascular endothelium, but has since been
identified in cardiac myocytes, blood platelets, brain and elsewhere (Michel and Feron,
1997).
For all three NOS isoforms, NO synthesis depends upon the enzyme's binding of the 
calcium regulatory protein, calmodulin. For eNOS and bNOS, increases in intracellular 
calcium concentrations are required for their binding to calmodulin, and consequently for 
their full activation. By contrast, iNOS appears able to bind calmodulin with extremely 
high affinity, even at the low intracellular concentrations characteristic of resting cells. 
Thus, in contr ast to iNOS, the activity of eNOS and bNOS may be closely regulated by 
changes in intracellular calcium. eNOS and bNOS are constitutively expressed by cells 
although their expression can be induced or up regulated. When cells containing
constitutive NOS (cNOS), that is eNOS and bNOS, are stimulated by for example, 
acetylcholine, bradykinin, glutamate, thrombin, ADP, physical pressure and shear stress, 
activation leads to an increase in cytosolic calcium, which activates the cNOS to produce 
NO. In general, expression of iNOS occurs after activation of cells with stimuli, including 
bacterial endotoxin or exotoxin, and inflammatory mediators, including the cytokines 
tumour necrosis factor (TNF) and interleukin (IL)-l, However, iNOS may also function as
a "constitutive" enzyme under physiological conditions in some cells (Guo, et al., 1995). 
iNOS produces larger amounts of NO than the other NOS isofoims (Anggard, 1994).
The initial step in NO biosynthesis is hydroxylation of the nitrogen in the guanidino group 
of L-arginine (Figure 1.1). This step incorporates molecular oxygen into NO and citrulline 
and requires cofactors including reduced pyridine nucleotides, reduced biopteridines and 
calmodulin. Whilst levels of L-arginine are normally sufficient for continuous secretory 
NO biosynthesis, under certain conditions the local cellular L-arginine levels may be
insufficient (Anggard, 1994). Furthermore, the limited availability of cofactors in vivo can 
attenuate the production of NO (Sladek and Roberts, 1996; Wemer-Felmayer, et al., 1993).
Figure 1.1 Biosynthesis of nitric oxide 
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NO is a free radical having an unpaired electron, and has a very short physiological half 
life of a few seconds, since it readily combines with other free radicals (Beckman and 
Crow, 1993). NO is rapidly converted in biological systems to nitrate and nitrite, a
reaction that is catalysed by transition metals including iron. Under anaerobic conditions, 
haemoglobin inactivates NO by binding it to form nitrosohaemoglobin whilst 
methaemoglobin is formed by this reaction in the presence of oxygen. The breakdown of 
NO to nitrate and nitrite may represent separate oxidative reactions, the metabolite ratio
being dependent on the redox conditions in the cell microenvironment (Kelm, 1999). The
very short half life of NO and its reactivity mean that it is most likely to act as a local 
messenger transferring messages within and between individual cells.
Sites o f  action o f  NO
NO has several targets of action at a cellular level. The effects of NO on smooth muscle 
relaxation, inhibition of platelet aggregation and signal transduction within the central 
nervous system are mediated by activation of the enzyme guanylate cyclase and 
subsequent formation of cyclic GMP (Ignarro, 1992). Cyclic GMP activates protein
kinases and leads in turn to the dephosphorylation of myosin light chains and smooth 
muscle relaxation.
NO can also mediate its effects through a number of cGMP independent mechanisms. One 
of the most important of these is termed “nitrosative stress” and involves the nitrosylation 
of other target proteins. In this way NO can influence other enzymes such as cytochrome 
oxidase (Ignarro, 1992), ribonucleotide reductase (Lepoivre, et al., 1990) and 
cyclooxygenase (COX) (Salvemini, 1997) and hence influence cellular respiration, DNA 
synthesis and inflammatory and immune responses. NO is also able to promote the direct 
ADP-ribosylation of proteins, i.e. the direct covalent binding of an ADP-ribose to a 
number of amino-acids. ADP-ribosylation may be an important mechanism whereby NO 
regulates the state of actin polymerisation and thereby regulates cell adhesion, signalling 
from the extracellular matrix, cell migration and phagocytosis (Clancy, et ai., 1995; 
Clancy, et al., 1997; Frenkel, et al., 1996). NO may also affect smooth muscle relaxation, 
cell signalling and phagocytosis by the direct activation of gene transcription factors
(Nathan, 1992; Umansky, et al., 1988). Increasing evidence suggests that NO preferentially 
affects transcription factors that are sensitive to changes in cellular redox status, 
particularly NF-kB and activator protein-1 (AP I) (Sen and Packer, 1996). These 
transcription factors are intimately involved in inflammatory responses and regulate the 
expression of chemoattractants, cytokines, cytokine receptors and cell adhesion molecules 
(Baeuerle and Henkel, 1994; Chen, et al., 1995; Lafayatis, et al., 1990; Siebenlist, et al.,
1994).
Finally, NO can interact with free radicals such as superoxide anion (O2') and free thiols to 
mediate its effects. The reaction with O2 results in the formation of toxic hydroxyl
radicals (HO) and peroxynitrite (ONOO) which are involved in host defence responses. 
Interactions between thiols and NO result in the formation of S-nitrosothiol derivatives that 
are more stable than their parent compounds and prolong the effects of NO in vivo (Clancy,
et al., 1998; Clancy, et al., 1994; Jia, et al., 1996).
Detection o f NO
The short half-life of NO makes direct measurement difficult in experimental situations; 
therefore techniques have been developed to measure NO activity indirectly. These 
include the Greiss reaction, which measures nitrite, the oxidation product of NO (Green, et
al., 1982). The protein and mRNA for each of the three isoforms of NOS can be localised
by immunocytochemistry and in situ hybridisation, respectively. Quantification of tissue 
NOS mRNA and protein can be achieved by Northern and Western blots respectively. The 
identification of the gene sequences of each of the NOS isoforms has permitted the
detection of NOS mRNA using the reverse transcription polymerase chain reaction (RT- 
PCR). The total activity of NOS in a tissue can be quantified by measuring the conversion 
of radio-labelled L-arginine to L-citrulline, in the presence of added co-factors. 
Identification of NADPH diaphorase activity in vitro has been used to identify NOS 
activity within a tissue since, certainly in neuronal tissue, NADPH diaphorase activity co- 
localises with NOS (Hope, et al., 1991). However, it is now recognised that not all 
NADPH diaphorase activity is NOS, so casting doubt on the validity of this technique 
(Tracey, et al., 1993). More recent techniques based on chemiluminescence have been
developed for the measurement of NO gas produced either directly e.g. in lung tissue or 
following enzymatic conversion of nitrate and nitrite, but expense currently precludes their
widespread use (Persson, et al., 1994).
The role o f  nitric oxide in inflammation
Inflammation was first described by Celsus in the first centuiy AD as demonstrating the 
clinical signs of rubor, tumor, calor and dolor. The cellular events involved in these 
responses have been extensively studied and nitric oxide has recently been shown to be 
involved. Inflammation is associated with an increase in vascular flow, alterations in the 
endothelium and extravasation of proteins and leukocytes at the site of injury with the 
activation of various effector mechanisms. There is increasing evidence that nitric oxide is 
involved in each of these stages of the inflammatory response.
While it has long been recognised that NO is involved in homeostatic vascular smooth 
muscle relaxation (Furchgott, et al., 1990), it is now recognised that a number of 
inflammatory mediators including IL-1 induce cNOS activity and vasodilatation in the 
early stages of inflammation (Lyons, 1995). Studies suggest that these mediators increase
influx into cells, resulting in kinase activation and serine phosphorylation of cNOS 
protein which is then translocated from its membrane bound position into the cytosol 
(Michel, et al., 1993). There it interacts with the haem moiety of guanylate cyclase and
mediates cGMP-dependent smooth muscle relaxation. Once increased blood flow is 
initiated, vasodilatation is maintained by an autocrine effect on endothelial NO production 
(Cooke, at al., 1991). The mechanisms whereby nitric oxide is shut off in this process are
unclear. However, since cNOS activation is controlled by phosphorylation and calmodulin 
binding, there is the potential for kinases and local alterations in the availability of calcium 
to modulate nitric oxide production.
In severe inflammation, high levels of inflammatory mediators act on smooth muscle cells, 
which in turn transcribe iNOS protein. Once initiated, iNOS mediated production of NO 
lasts for several hours with the attendant risk of prolonged profound hypotension. It has 
been suggested that NO inhibitors may have a therapeutic effect in the management of this
condition (Thiermermann, et al., 1993; Wright, et al., 1992). However the decrease in nitric
oxide production in other organs may limit the clinical effectiveness of this therapy. Indeed 
in experimental models, treatment of severe sepsis with NOS inhibitors has been 
associated with severe liver and intestinal damage with no effect on subsequent survival
rates (Kilboum, et al., 1997).
There is widespread debate as to the role of nitric oxide in the control of vascular 
permeability. The conflicting evidence however suggests that eNOS produced in low 
amounts in the early stages of inflammation inhibits plasma protein and leukocyte leakage 
into the tissues, while iNOS is responsible for enhancing vascular permeability as the 
inflammatory process progresses. In the rat intestine, it has been shown that during the first 
two hours of endotoxin-induced increased vascular injury, vascular permeability is 
increased by inhibitors of NOS, while after three hours, when iNOS activity is present.
LPS-induced vascular permeability is reduced by such agents (Laszlo, et al., 1994). 
Similarly, NOS inhibitors have been shown to inhibit carrageenan or dextran induced paw 
oedema in rats (lalenti, et al., 1992). However in human studies, the involvement of nitric 
oxide in vascular leak is less clear.
While excessive NO production in the vasculature may promote tissue injuiy, cNOS 
appears to be intimately involved in protecting the integrity of the endothelium. NO has 
been shown to inhibit platelet aggregation, the adhesion of neutrophils to endothelial 
monolayers and to inhibit the production o f leukocytic superoxide anion (Clancy and
Abramson, 1995; Clancy, et al., 1992; Kubes, et al., 1991). Although the precise biological
relevance of these findings remains to be determined, the vascular defensive properties of 
NO have been demonstrated by its capacity to protect against tissue injury in myocardial 
ischaemia-reperfusion injury and the adult respiratory distress syndrome (Bloomfield, et
al., 1997; Lefer, 1992). Although NO appears to inhibit leukocyte adherence in normal
homeostasis, further studies have shown that neutrophil produced oxidants promote
leukocyte adhesion to endothelium (Kurose, et al,, 1994; Salvemini, et ai., 1991). Thus in
inflammation, excess superoxide generation may overwhelm the available scavenging NO, 
promoting mast cell degranulation and release of mediators which upregulate adhesion 
molecules and therefore enhance inflammatory cell infiltration of target tissues.
Lastly, NO seems to have an important functional role as an effector molecule in the 
immune response. In eukaryotic cells, NO inhibits mitochondrial respiration (Brown,
1997) and interferes with DNA synthesis through inhibition of ribonucleotide reductase 
(Lepoivre, et al., 1990). NO has also been shown to activate all three parallel mitogen- 
activated protein kinase (MAPK) cascades (Lander, et al., 1996) in Jurkat T cells (the 
stress activated protein kinase/c-Jun N-terminal kinase), the stress-activated p38 MAPK
cascade and the classical ERK/ MAPK cascade as well as the JAK/signal transducer and
activator of transcription (STAX) pathway (Duhe, et ah, 1998). These complex pathways
then trigger the phosphorylation of nuclear proteins involved in the inflammatory response. 
NO has critically been shown to control the transcription of the chemokines IL-8, TNF-a
and MIP"l(Muhi and Dinarello, 1997; VanDervort, et al., 1994; Villarete and Remick, 
1997), to regulate the expression of vascular endothelial growth factor (VEGF), a growth 
factor which mediates angiogenesis and controls vascular permeability (Tsurumi, et al.,
1997) and to initiate apoptotic cell death, all fundamental processes in inflammatory 
responses.
Clinical uses o f  NO
Nitrovasodilators, such as glyceiyl trinitrate and sodium nitropmsside (SNP), which have 
been employed in the treatment of angina pectoris for over 100 years, are now known to 
produce their clinical effects by releasing NO. These drugs, known as NO donors, release 
NO either spontaneously, (e.g. SNP) or after metabolic conversion, (e.g. glyceryl 
trinitrate). The clinical effects of other drugs may also be related to the L-arginine-NO 
pathway. Angiotensin converting enzyme inhibitors inhibit the breakdown of bradykinin, 
which in turn results in an increased production of NO from endothelial cells. The 
administration of inhaled NO itself has recently been shown to be of therapeutic benefit in 
the treatment of pulmonary hypertension and adult and neonatal respiratory distress
syndromes (Kinsella and Abman, 1997).
Endogenous NO levels can be raised by administration of the NO substrate L-arginine. 
Analogues of L-arginine, such as N^-nitro-L-arginine methyl ester (L-NAME) and N^- 
monomethyl-L-arginine (L-NMMA), attenuate the effects of NOS by competing with L-
arginine for the active site of the NOS (Furchgott, et aL, 1990). In experimental systems,
NO may be inhibited by the addition of oxyhaemoglobin, or the effects of NO on the 
second messenger system, guanylate cyclase, may be blocked by methylene-blue. 
Aminoguanidine is a selective iNOS inhibitor that has been used to investigate the role of
NO in various inflammatory pathologies (Furchgott, et ai., 1990). Inhibitors of NO may
have important future therapeutic implications in the treatment of states attributable to NO
overproduction such as septic shock and cerebral ischaemia (Vallance and Collier, 1994).
Pregnancy and the role of nitric oxide
NO was first identified in the human reproductive system by Ignarro et aL, (1990) 
(Ignarro, et al., 1990) who demonstrated that NO was generated in response to non-
adrenergic/non-cholinergic neurotransmission-mediated penile erection. Since then, the L- 
arginine-NO system and each of the thiee isoforms of NOS, have been identified in the 
female reproductive system, suggesting that locally synthesised NO is directly involved in 
the physiology of reproduction. A decrease in the production and/or alteration in the 
uterine responsiveness to NO within the uterus may precede the onset of labour. This 
mechanism may be important in both the pathophysiologies of term as well as preterm 
labour. Furthermore, NO may play a role in ripening the uterine cervix prior to the onset 
of parturition. The remainder of this review will focus on these two specific areas of 
investigation.
Nitric oxide and the uterus
A number of experimental studies suggest that NO is generated within uterine tissues and 
provide us with evidence that NO has a role in the control of uterine contractility during
pregnancy. These studies have concentrated on the evidence for the presence of the NO- 
cGMP system within the uterus and on the effects of NO administration on uterine 
contractility both in vivo and in vitro.
NOS enzyme activity within the uterus
Animal studies, using the Greiss reaction, have shown that rat and rabbit uterus produce 
large quantities of NO (Dong and Yallampalli, 1996; Yallampalli, et al., 1993). NOS 
activity in the pregnant rat and rabbit uterus has been detected using the radiolabelled 
arginine to citrulline conversion assay (Natuzzi, et al., 1993; Sladek, et al., 1993;
Yallampalli, et al., 1994). This technique has also shown NOS activity within the pregnant 
guinea-pig uterus (Weiner, et al,, 1994). In all these studies, both calcium-insensitive 
(iNOS) and calcium-sensitive (eNOS and/or bNOS) activity were identified.
Pregnant and non-pregnant human myometrium can generate nitrate/nitrite in culture 
(Buhimschi, et al., 1995). NOS activity is present in human pregnant myometrium
(Buhimschi, et al., 1995; Thomson, et al., 1997), placental villous trophoblast (Di lulio, et 
al., 1996; Ramsay, et al., 1996) and fetal membranes (Di lulio, et al., 1996; Thomson, et 
al., 1997). This expression and distribution of NOS isoforms within the uterus and the 
fetal membranes suggests that NO is involved in the regulation of uterine contractility.
Localisation of uterine NOS
NADPH diaphorase staining has been used to localise NOS within the pregnant and non­
pregnant uterus of various species and essentially identical patterns of staining have been 
found, with myométrial and vascular smooth muscle nerve bundles, vascular endothelium.
endometrial epithelium and leukocytes staining positively (Ekerhovd, et al., 1998;
Schmidt, et al., 1992; Telfer, et al., 1995; Yallampalli, et al., 1994).
Using immunocytochemistry, bNOS has been localised to the endometrial epithelium 
(Schmidt, et al., 1992), perivascular neurones (Grozdanovic, et al., 1994; Majewski, et al.,
1995), myométrial neurones (Grozdanovic, et al., 1994; Majewski, et al., 1995; Papka, et
al., 1995), myocytes, the vascular endothelium and smooth muscle of blood vessels
(Thomson, et al., 1997) with confirmation in myocytes by Western blotting (Norman, et
al., 1999).
eNOS protein has been immunolocalised to vascular endothelium, endometrial glandular 
epithelium and endometrial stromal cells but has not been consistently detected in 
myométrial smooth muscle cells (Campa, et al., 1998; Myatt, et al., 1998; Norman, et al.,
1999; Telfer, et al., 1997; Thomson, et al., 1997). The expression of eNOS protein within
these tissues has been confirmed by Western blotting and in situ hybridisation (Gangula, et
al., 1996; Norman, et al., 1999; Telfer, et al., 1997). Using RT-PCR, e/c NOS mRNA has
recently been identified in human myometrium (Dennes, etal., 1999).
iNOS has been identified in stromal macrophages and myométrial mast cells (Huang, et al.,
1995), glandular epithelial cells, in areas between myométrial cell bundles (Dong, et al.,
1998) and the vascular smooth muscle of the myometrium and endometrium (Telfer, et al., 
1997; Thomson, et al., 1997). Although there is some debate as to whether human 
myométrial smooth muscle cells contain NOS (Sladek, et al., 1997), iNOS has been 
immunolocalised to human myocytes by several investigators (Bansal, et al., 1997;
Thomson, et al., 1997). Western blotting and RT-PCR have also recently been used to 
confirm the presence of iNOS protein and mRNA respectively in human myometrium 
(Bansal, et al., 1997; Dennes, et al., 1999).
The expression of each of the three isoforms of NOS has also been described in human 
placenta and fetal membranes using immunohistochemistry (Myatt, et al., 1993; Norman,
et al., 1999; Schonfelder, et al., 1996; Thomson, et al., 1997) Western blotting (Norman, et
al., 1999; Schonfelder, et al,, 1996; Zarlingo, et al., 1997) and in situ hybridization
(Conrad, et al., 1993), while NOS enzyme activity has been confirmed using the L-
arginine-citrulline conversion assay (Thomson, et al., 1997), and by measuring NADPH-
diaphorase activity (Eis, et al., 1995). eNOS and iNOS mRNA have been identified by
RT-PCR in amnion and chorio-decidua (Dennes, et al., 1997).
Thus, all three isoforms of NOS have been identified in the uterus and placentae of various 
species including humans (Table 1.1). This supports a role for NO not only in the 
regulation of myometi ial conh actility but also in the regulation of placental blood flow and 
the inhibition of platelet aggregation at the interface between the maternal and fetal 
circulations.
Relaxation o f myometrium by nitric oxide
In vitro studies
NO is a powerful smooth muscle relaxant. Various in vitro studies have shown that it is 
capable of relaxing the myometrium during pregnancy and may be responsible for uterine
quiescence during this period (Buhimschi, et al., 1995; Izumi, et al., 1993; Lee and Chang,
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1995; Longo, et al., 1999; Norman, 1996; Sladek, et al., 1997; Yallampalli, et al., 1993).
Studies carried out on isolated human and animal myométrial smooth muscle strips have 
shown that uterine relaxation occurs with NO, delivered as NO gas, NO substrates and NO 
donors (Buhimschi, et al., 1995; Izumi, et al., 1993; Lee and Chang, 1995; Longo, et al.,
1999; Norman, et al., 1997). Furthermore, contractility can be increased by competitive
inhibitors of NO synthesis such as L-NAME and N-nitro-L-arginine (Franchi, et al., 1994;
Lee and Chang, 1995; Yallampalli, et al., 1993; Yallampalli, et al., 1994). These studies
raise the possibility that endogenous NO inhibits contractility in vivo (Buhimschi, et al.,
1995; Lee and Chang, 1995).
The effects of NO releasing agents on the frequency of myométrial contractions appears 
complex. A study using the NO donors, sodium nitroprusside (SNP) and glyceryl trinitrate 
(GTN), found that the magnitude of contractions was reduced by around 50% at the 
highest concentrations of the drugs used (Norman, et al., 1997). Paradoxically the 
frequency of myométrial contractions was increased by SNP at concentrations above 30 p,l, 
although the reason for this is unclear.
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Table 1.1. Detection of the nitric oxide system within the uterus
Reference Method used Species Tissue used
Yallampalli et al.  ^ 1993^4 Greiss reaction rat whole uterus
Yallampalli et a l, 1994"^ ^ arginine to citrulline 
Greiss reaction 
NADPH diaphorase
rat whole uterus
Sladek et a l, 1993'^^ arginine to citrulline 
Greiss reaction
rabbit decidua
Natuzzi e ta l, 1993"^ ^ arginine to citrulline rat whole uterus
Weiner et a l, 1994^^ arginine to citrulline guinea-pig whole uterus
Buhimschi et a l, 1995^® Greiss reaction 
arginine to citrulline
human cultured myometrium
Thomson a/., 1997^^ arginine to citrulline 
immunocytochemistry
human myometrium
placenta
fetal membranes
Ramsay et a l , 19 9 6 ^ 2 arginine to citrulline human myometrium
placenta
D iln lioe ta l, 1996^3 arginine to citrulline human fetal membranes 
placenta
Telfer et a l, 1995^ NADPH diaphorase 
immunocytochemistry 
in situ hybridisation
human non-pregnant
endometrium
non-pregnant
myometrium
Schmidt et a l , 1992^4 NADPH diaphorase 
immunocytochemistry
rat endometrium/
myometrium
Ekerhovd et a/., 1998^5 NADPH diaphorase human cervix
Grozdanovic eta/., 1994^6 immunocytochemistîy mouse uterus and cervix
Majewski et <2/., 1995^^ immunocytochemistry cow
pig
uterus and cervix
Papka e ta l, 1995^^ immunocytochemistry rat uterus and cervix
Norman et a l, 1999^^ immunocytochemistry 
Western blotting
human myometrium
Myatt et a/., 1998^® immunocytochemistry human myometrium 
(placental bed biopsies)
Campa et a l, 1998^1 immunocytochemistry human m yom étrial vascular 
endothelium
Gangula et û:/., 1996^2 Western blotting 
Griess reaction
rat cultured rat myométrial 
cells
Dennes et a l, 1999^3 RT-PCR human myometrium
Huang et a l, 1995^4 immunocytochemistry mouse non-pregnant uterus
Telfer et a/., 1997^^ immunocytochemistry human non-pregnant
endo/myometrium
Bansal et a l, 1997^^ immunocytochemistry 
Western blotting
human myometrium
Myatt et a l , 1993^^ immunocytochemistry 
NADPH diaphorase
human placenta
Schonfelder et a l , 1996^^ immunocytochemistry 
Western blotting
human placenta
Zarlingo et a i, 1997'^^ Western blotting human,
monkey,
baboon,
guinea
pig, rat,
sheep
placenta
Conrad et a i, 1993^^ in situ hybridisation 
NADPH diaphorase
human placenta
Eis et al., 199572 immunocytochemistry 
NAPDH diaphorase
human placenta
Dennes et a l , 1997^3 RT-PCR human fetal membranes
In contrast to previous studies (Buhimschi, et al., 1995; Lee and Chang, 1995), Norman et
al., (1997) (Norman, et al., 1997) found no effect on myométrial contractions in response
to the NO inhibitor L-NAME, suggesting that there is no endogenous NO activity in the 
myometrium in vitro. This data was further supported by the work of other investigators 
(Jones and Poston, 1997). The conflicting results from these studies may be attributable to
a number of factors. For example, in the studies demonstrating an increase in myométrial 
contractility in response to NO inhibitors, the muscle strips being tested may not have been 
free of fetal membranes, decidua or endometrium which generate NO. Buhimschi et a i, 
(1997) (Buhimschi, et al., 1997) have shown that the spontaneously releasing NO donor,
diethylenetriamine-NO (DETA-NO), has contrasting effects in vivo and in vitro. In vitro 
studies of rat myométrial contractility showed decreased inhibitory responses to DETA- 
NO in tissues collected during spontaneous labour compared with tissues collected before 
the onset of labour. In contrast, studies in vivo showed that the NO donor could decrease 
uterine contractility even more effectively during delivery, suggesting that the feto-
placental unit increases the availability of NO in vivo. This concept is further supported by
Segal et a i, (1997) (Segal, et al., 1997) who demonstrated in an organ bath system that the
addition of placental tissue markedly increased the sensitivity of rat myometrium to the 
relaxant effects of GTN. A further explanation for these conflicting results is differences 
in myométrial sampling sites, as the production of NO within uterine tissue is not uniform. 
Despite these findings the role of NO in the endogenous control of myométrial contractility 
in vivo has not been established.
Growing evidence suggests that the effect of NO on myométrial contractions is dependent 
on whether the tissue is collected before or after the onset of labour. The same dose of L- 
arginine was found to completely inhibit spontaneous contractions of rat myometrium for 
longer when the tissue was obtained before the onset of labour, compared with tissue 
collected during labour (Yallampalli, et al., 1993). Furthermore, L-arginine completely
inhibited contractions induced by the muscarinic agonist carbachol when myometrium was 
collected at mid-gestation, but had no effect when myometrium was removed during
deliveiy (Izumi, et al., 1993). Similarly, one concentration of 8-bromo-cGMP, a cell
permeable analogue of cGMP, had a profound inhibitory effect on contractions of rat 
myometrium removed at mid-gestation, but concentrations of 1000 times higher were 
required to produce a similar inhibitoiy effect when myometrium was removed from
labouring animals at term (Izumi, et al., 1993). Buhimschi et a l, (1995) (Buhimschi, et al.,
1995), have demonstrated a reduction in sensitivity to the tocolytic effect of NO in human 
myometrium collected following the onset of labour and Okawa et a l, (1998) (Okawa, et
al., 1998) have demonstrated similar effects in rats. Therefore, NO donors used for the
treatment of preterm labour would theoretically have maximal effect at gestations where 
they would be of most therapeutic benefit. However it would appear that the
concentrations of NO donors required to arrest labour are much greater than those required 
to prevent the onset of labour.
In vivo studies
It has long been recognised that in the clinical arena, NO donors relax the human uterus. 
As early as 1882, Barnes reported the use of amyl nitrite to facilitate manual removal of a 
retained placenta. More recently, intravenous glyceryl trinitrate (GTN) has been reported 
in uncontrolled case reports to allow correction of uterine inversion (Altabef, et ai., 1992;
Dayan and Schwalbe, 1996), to facilitate intrapartum external cephalic version (Belfort,
1993), and to allow internal podalic version of a second twin (Wesson, et al., 1995). The 
use of intravenous nitroglycerin has also been reported to facilitate delivery of a retained 
20-week dead fetus following abruptio placentae and uterine hypertonus (Dessard, et al.,
1998). In a prospective observational study, intravenous GTN produced relief of
intrapartum fetal distress related to uterine hyperactivity (Mercier, et al., 1997). This agent
has also been used to facilitate fetal delivery during Caesarean section (Mayer and Weeks,
1992), although a recent randomised trial found that administration of GTN led to no
clinically relevant effect on fetal extraction (David, et al., 1998).
Two uncontrolled, observational studies and one randomised controlled pilot study have 
investigated the effects of GTN patches in women with a diagnosis of preterm labour
(Lees, et al., 1994; Rowlands, et al., 1996; Smith, et al., 1999). Although these studies
concluded that GTN can arrest preterm labour, further controlled trials and side effect data
are required before these agents are adopted as tocolytic agents (Dudley and Elbourne,
1994; Norman, 1996; Sladek, et al., 1997). A multicenter world-wide randomised 
controlled trial was commenced in 1994 to investigate the efficacy of GTN in comparison
with ritodrine for the management of preterm labour (Lees, et al., 1997). These data 
suggest that GTN is as effective as ritodrine on contractility but just as with fl-mimetics, no 
direct benefit in terms of improvement in neonatal morbidity or mortality has been shown 
(Danti, et al., 1997; Lees, et al., 1999).
One randomised controlled trial conducted in the United States has examined the tocolytic 
effects of intravenous GTN in the treatment of preterm labour (El-Sayed, et al., 1999). In
this study however, GTN was found to have a higher tocolytic failure rate than magnesium 
sulphate. Furthermore, the high incidence of persistent hypotension in the GTN treated 
group may limit the use of this therapy for this purpose although previous studies 
examining the fetal and maternal effects of GTN administration have reported no adverse
effects (Lees, et al., 1998; Ramsay, et al., 1994),
The role o f  nitric oxide in parturition
Animal studies suggest that NO 'withdrawal' may be involved in the timing of parturition. 
Several studies have demonstrated an up-regulation of uterine NO production during 
pregnancy, and down-regulation during term and preterm labour (Dong and Yallampalli,
1996; Sladek, et al., 1993; Yallampalli and Garfield, 1994; Yallampalli, et al., 1993). 
Hence, there is a consensus for a decrease in uterine NOS activity at term, although the 
precise timing of this is not clear. NOS activity is high during rabbit pregnancy and 
progressively decreases, (by 80%), in decidua during the last 4 days of gestation (Sladek,
et al., 1993). Other studies, comparing 16 (Natuzzi, et al., 1993) and 18 days’ gestation 
(Yallampalli, et al., 1993) with labouring rats (22 days), have reported that NOS activity 
decreases with advancing gestation in whole rat uterus, decidua and myometrium.
However, these studies leave a 4- to 6-day window in which the decline in rat uterine NOS 
activity takes place. Examining this window, Sladek and Roberts, (1996) (Sladek and
Roberts, 1996) found that NOS activity decreased between days 15 and 21 of gestation and
did not decrease further at term (day 22). These workers propose that the decrease in 
pregnant rat uterine NOS activity coincides with the preparation of the uterus for 
parturition i.e. prelabour rather than the final activation of labour. Data from gene 
knockout animals suggests that an absence of any single isoform of NOS has no effect on 
the normal gestational period (Huang, et al., 1995; Huang, et al., 1993; Wei, et al., 1995).
Changes in NOS activity appear to be less important during pregnancy in the guinea pig
(Weiner, et al., 1994). In this species, there was no significant difference in NOS activity,
measured by the arginine to citrulline conversion assay, between pregnant and non­
pregnant animals. Despite this, there was a 200-fold increase in cGMP content from mid- 
to late-pregnancy, suggesting that factors other than NO are responsible for the changes in 
cGMP.
In human pregnancy, the L-arginine-NO system has been identified within myometrium, 
placenta, and fetal membranes. NO derived from each of these tissues may regulate 
myométrial contractions. However, because of its short half-life of a few seconds and its 
reactivity, it seems likely that NO produced within the myometrium itself, or tissues in 
close apposition, will influence myométrial contractility. Several studies have attempted to
determine whether a change in NOS activity occurs at the onset of human parturition (Di
lulio, et al., 1996; Ramsay, et al., 1996). Examining tissues collected at Caesarean section,
('before' labour and 'during' labour), and assessing NOS activity using the arginine to 
citrulline conversion assay, these studies concluded that there was no significant fall in 
NOS activity during human parturition. Indeed, Ramsay et a l, (1996) (Ramsay, et al.,
1996) found a slight increase in NOS activity in myometrium collected during labour
compared with that collected before labour. Further studies performed on tissue obtained 
immediately before and after the onset of labour at term found no difference in the 
expression (as assessed using immunocytochemistîy) or activity (as measured by the L-
arginine to citrulline conversion assay) of NO within the uterus or placenta (Thomson, et 
al., 1997). However, in vitro techniques of assessing of enzyme activity, may not reflect 
the in vivo situation (Sladek and Roberts, 1996) where cofactor availability and paracrine
activation mechanisms may be important. It is feasible that while NOS activity or 
expression are not reduced during human parturition, NO may still play a role in the onset 
of labour by means of a decrease in sensitivity of the myometrium to NO’s tocolytic 
effects.
Other biological mediators, such as superoxide dismutase (SOD), may be important in 
governing the activity of NO within the uterus at the time of parturition. SOD is 
responsible for scavenging superoxide anions and hence prolongs the biological effects of 
NO. At the onset of labour, a decrease in the activity of SOD would reduce the availability 
of NO within the uterus and lead to an increase in uterine contractility. Xanthine oxidase 
(XO), the enzyme responsible for superoxide synthesis, may attenuate the biological 
activity of NO as 0% combines with NO to form perioxynitrite. However, Telfer et al., 
(1997) have failed to show any difference in the activity or expression of SOD in the 
uterus, placenta or fetal membranes before or aft;er the onset of labour (Telfer, et al., 1997). 
Similarly, XO expression was not altered in these tissues as assessed using 
immunohistochemistry. Therefore, whilst SOD and XO do not seem to alter during 
parturition, their presence within the fetomatemal system suggests that they may be 
important in controlling the effects of NO during pregnancy in its maintenance of uterine 
quiescence.
While there does not seem to be any dramatic decrease in production of NO at the onset of 
labour, there would appear to be a down regulation of constitutive NOS (cNOS) and iNOS 
in the myometrium during the third trimester of pregnancy. Bansal et a l, (1997) (Bansal,
et al., 1997) reported that myométrial iNOS expression, assessed by
immunohistochemistry and Western blotting was decreased in the late third trimester (37- 
41 week’s gestation) in non-labouring myometrium compared to samples obtained in the 
early third trimester (26-34 weeks gestation) or in the non-pregnant state. These data 
suggest that an increase in myométrial iNOS expression might contribute to the 
maintenance of uterine quiescence during pregnancy. In contrast to this, Dennes et al,
(Dennes, et al., 1999) recently demonstrated no change in cNOS and iNOS expression
using semi-quantatative RT-PCR during pregnancy or at the onset of parturition. Further 
studies however, using immunohistochemistry and Western blotting, support the work of 
Bansal et a l and it would appear that eNOS and bNOS are upregulated in the early third 
trimester myometrium compared to the non-pregnant state. eNOS, but not bNOS, is 
reduced at term compared to preterm (Norman, et al., 1999). It would seem that a decrease
in NOS activity within the uterus occurs in the third trimester as part of a conditioning 
phase for the onset of labour. This conditioning phase, which seems to occur in the third 
trimester of pregnancy, encompasses changes within the myometrium, such as up- 
regulation of receptors and the formation of ion channels, which allow the uterus to
become more responsive to uterotonic agents at the onset of labour (Garfield, et al., 1999).
These data suggest that agents devised to affect preterm labour would therefore be of 
benefit at this stage, prior to the onset of active labour.
Control o f uterine NO activity
Factors controlling the up-regnlation in uterine NOS expression during pregnancy remain 
uncertain. In animals both oestrogen and progesterone have been proposed as regulators of
NOS in vivo. Oestrogen upregulates guinea pig constitutive NOS expression (Weiner, et 
al., 1994). In sheep uterine arteiy, oestrogen enhanced endothelial NOS activity, and in rat 
hypothalamus, oestrogen increased bNOS expression (Ceccatelli, et al., 1996; Veille, et al., 
1996). In studies of women treated with a Gonadotrophin hormone Releasing Hormone
analogue together with either oestrogen replacement or placebo, fasting plasma nitrate 
concentrations were higher in the oestrogen treatment group, suggesting that oestrogen 
stimulated NO production (Ramsay, et al., 1995). In human pregnancy, increased
oestradiol concentrations may contribute to uterine quiescence through an increase in NOS 
expression. However, as oestrogen levels are maintained or increase in humans at term, 
other factors must be responsible for the control of myométrial synthesis of NO. In animal 
studies, progesterone has been shown to increase iNOS production within the uterus 
(Buhimschi, et al., 1996). Treatment with antiprogestins has been shown to decrease
uterine NO production and hence cause an increase in myométrial contractions. Although 
human parturition is not associated with a decline in progesterone concentration it is clear 
from the role of antiprogestins that a more subtle mechanism may be present such as 
changes in progesterone receptor expression or competition from an endogenous 
antiprogestagen. Thus progesterone withdrawal may be a regulatory factor in the onset of 
parturition.
Nitric oxide and cervical ripening
Cervical ripening, the process whereby the cervix undergoes softening, effacement and 
dilatation during pregnancy is crucial to the control of events in normal labour. At this
time, changes in cervical structure are believed to be due to alterations in the underlying 
connective tissue composition. Changes in collagen concentration, an increase in tissue 
water content and an alteration in matrix glycosaminoglycans result in dissociation of the
connective tissue structure (Caider and Greer, 1992). Evidence is accumulating that this
process is mediated by an inflammatory mechanism involving vasodilatation, altered
vascular permeability and neutrophil influx into the tissue (Junquiera, et al., 1980; Leppert,
1992; Li g gins, 1981). Various agents may be involved in the control of this process 
including prostaglandins, cytokines, steroid hormones and relaxin.
NO and ceiwicai ripening in animals
The results of recent animal studies on NO production and NOS expression in the cervix 
indicate that NO may play a role in ceivical ripening. The NO generating system is 
present in the rat cervix and in contrast to the body of the uterus, it is down-regulated 
during pregnancy, but up-regulated during term and preterm labour (Buhimschi, et al.,
1996). The expression of iNOS was upregulated in both term and preterm labouring
cervices, while bNOS was only upregulated in term labouring samples. This may reflect 
the presumed infective/inflammatory aetiology of preterm labour. Treatment of pregnant 
guinea-pigs with the NOS inhibitor L-NAME induced preterm labour but delayed
physiological cervical ripening resulting in prolonged deliveries (Chwalisz, et al., 1994).
Furthermore, L-NAME treatment of pregnant rats significantly prolonged the duration of 
labour, suggestive of cervical dystocia, whilst a decrease in cervical extensibility was 
observed after in vitro incubation with L-NAME (Buhimschi, et al., 1996). Chwalisz et
a i, (1997) (Chwalisz, et al., 1997) demonstrated that the local application of the NO donor
sodium nitroprusside, produced effective ripening of the guinea-pig cervix, assessed by 
both force resistance measurements and morphological evaluation. It seems that, at least in
animal pregnancy, NO represents a final metabolic pathway of cervical ripening. It has 
been suggested previously that prostaglandins, particularly those of the E series, are the 
final common mediators of cervical ripening. However, cervical ripening brought about by 
anti-progestins cannot be blocked by the action of specific cyclooxygenase inhibitors
(Qing, et al., 1996; Radestad and Bygdeman, 1992). This suggests that other agents such as
NO must be inherently involved in this process.
The proposed mechanism of NO induced cervical ripening remains unclear. Induction of 
iNOS at the sites of inflammation results in the production of large quantities of NO which 
are responsible for vasodilatation and changes in vascular permeability. As cervical 
ripening is essentially an inflammatory response, this may be the mechanism by which NO 
operates. Administration of SNP to guinea pigs results in lymphocyte, granulocyte and 
macrophage accumulation within cervical tissue associated with stromal oedema and 
arterial dilatation (Qing, et al., 1996).
NO may also exert its effects through stimulation of matrix metalloproteinases (MMPs). 
While NO has not yet been shown to influence the activity of MMPs in cervical tissue, in 
both human and animal studies in other tissues NO has been shown to be capable of 
stimulating the activity of a number of these MMPs (Murrell, et al., 1995; Sasaki, et al.,
1998; Trachtman, et al., 1996).
There is an alteration in the glycosaminoglycan composition of the cervix during 
pregnancy and this may be important in the ripening process. The amount of hyaluronic 
acid present in the cervix increases and the chondroitin sulphate and dermatan sulphate 
composition falls. These changes bring about an alteration in the binding affinity to
collagen thus altering tissue hydration and hence cervical extensibility (Rechberger, etal..
1996). NO has the potential to suppress proteoglycan synthesis (Hauselmann, et al., 1994;
Hauselmann, et ai., 1998), and its mechanism of action within the cervix may reflect its 
ability to alter the composition of proteoglycan molecules within this tissue.
The process o f programmed cell death or apoptosis has been implicated in cervical 
ripening (Leppert, 1995). Recent studies in rats have shown that apoptosis occurs in
cervical smooth muscle cells (Romero, et al., 1990) and fibroblasts (Leppert, 1998) during 
ripening and evidence from other tissues suggests that this process may be stimulated by 
NO (Brune, et al., 1998; Nicotera, et al., 1997).
The process of cervical ripening has been shown to involve other inflammatory mediators 
including prostaglandins and cytokines. In particular IL-1, IL-8, IL-6 and TNFa have been
shown to be produced in the cervix and to be involved in the ripening process (Sennstrom, 
et al., 1997). There appears to be considerable interaction between NO and these 
inflammatory cytokines (Chwalisz, et al., 1994; Liew, 1995), suggesting that self-
regulatory paracrine mechanisms between such inflammatory mediators may be important 
in providing overall control.
NO has also been shown to induce the enzyme cyclooxygenase (COX)-2 (Salvemini, et al.,
1993; Sautebin, et al., 1994) and hence elevate PG levels in various models of
inflammation. Interestingly, both COX-2 and iNOS can be upregulated by similar 
inflammatory mediators and may act in concert during the ripening process under steroid 
control.
NO and cervical ripening in humans
There are few published studies examining the effect of NO on human cervical ripening. 
The effects of the NO donor glyceryl trinitrate (GTN), administered sublingually, on the
non-pregnant cervix have been assessed. Yadava, (1990) (Yadava, 1990) reported that
GTN facilitated the transcervical introduction of intra-uterine contraceptive devices.
Shaker et a i, (1993) (Shaker, et al., 1993) found that GTN had no significant effects on the
ease of embiyo transfer after in-vitro fertilization.
Studies in our department have concentrated on the effects of the NO donors GTN and 
isosorbide mononitrate (IMN) on the first trimester human cervix (Thomson, et al., 1997;
Thomson, et al., 1998). The first of these was a randomised controlled trial performed on 
forty eight primigravid women at 8-12 weeks gestation undergoing suction termination of 
pregnancy (Thomson, et al., 1997). The cervical ripening effects of the NO donors IMN
(40mg) and GTN (SOOpg) were compared with that of the prostaglandin analogue 
gemeprost (Img) and a control group given no treatment. The ability of these agents to 
effect cervical ripening was objectively measured using a force sensing apparatus coupled 
to cervical dilators (Anthony, et al., 1982) and the cervical diameter prior to dilatation
measured. The cumulative force required to dilate the cervix to 8mm was significantly less 
in the IMN group compared to controls given no treatment and a higher cervical diameter 
before dilatation was recorded. Further studies are presently in progress to determine 
whether NO is involved in endogenous cervical ripening at term.
Ekerhovd et. al., (1998) (Ekerhovd, et al., 1998) have identified the presence of the NO
system within the first trimester cervix by NADPH diaphorase staining and have suggested 
that NO may have a role in inhibiting smooth muscle relaxation within the cervix although 
the exact physiological significance of this is uncertain. Tschugguel et al., (1999)
(Tschugguel, et al., 1999) have recently shown that iNOS is upregulated in the cervices of
postpartum patients compared to non-pregnant controls, providing further evidence for the 
involvement of NO in the process of human cervical ripening.
Despite the superiority of prostaglandins in effecting cervical ripening NO donors may 
have a significant role in clinical practice, both for cervical ripening in the first trimester 
and at term. Prostaglandins are associated with a high incidence of side effects including 
nausea and vomiting, diarrhoea, abdominal pain and bleeding and an abnormal fetal heart 
rate pattern in 7% of women due to increased myométrial activity when used for induction 
of labour at term (Wing, et al., 1995). Studies presented in chapter 2 of this thesis suggest 
the use of NO donors may result in a more acceptable side effect profile while still being 
clinically effective (Thomson, et al., 1998). Following the administration of IMN in the 
first trimester 70% of women remained asymptomatic compared with only 14% in the 
prostaglandin treated subjects. While more women in the NO treated group experienced 
headache, there were no adverse effects recorded on blood pressure or intra-operative 
blood loss. Further studies presented in chapter 3 examine whether combination therapy 
with a prostaglandin analogue and a nitric oxide donor produces a more clinically effective 
regimen for cervical ripening in the first trimester of pregnancy. Clearly further studies 
need to be performed to confirm the safety of NO donors for cervical ripening but the 
results of these preliminary studies suggest that NO may have a role in this process in the 
future.
The mechanism of action of NO donors in the process of cervical ripening has been 
addressed by a number of in vivo and in vitro studies. While it is possible that ripening of 
the ceivix may be achieved by the interaction of NO with various MMPs, studies presented 
in chapter 5 of this thesis have suggested that MMPs-2 and -9  are not involved. However, 
the effects of NO may be mediated via cross talk with COX and an increase in 
prostaglandin synthesis which in turn would stimulate other inflammatory mediators such 
as IL-8 and secretory leukocyte protease inhibitor (Denison, et al., 1999), This is the 
subject of investigations presented in chapter 6 of this thesis.
Despite such research, the role of NO in the process of endogenous cervical ripening in 
humans remains unclear. This is compounded by the obvious difficulty in obtaining 
human cervical tissue at this time for research. However, it would seem from the various 
in vitro and in vivo studies already performed that NO is involved in this process, acting in 
concert with a variety of other mediators such as cytokines and prostaglandins. Clearly, 
further research in this field will improve our understanding of these key events in the 
initiation of labour and will provide novel therapeutic strategies for inhibiting and initiating 
the process of cervical ripening.
Conclusion
Pregnancy maintenance appears to depend upon a functioning NO-cGMP system within 
the myometrium. Conversely, the onset of labour is dependent upon the increased activity 
of this system within the cervix. The management of preterm and post-dates pregnancy 
remain significant challenges for today's obstetrician, and a greater understanding of the 
role of NO in the pathophysiology of these conditions may contribute to future therapeutic 
advances. Therapies aimed at the management of preterm and post dates pregnancy must
account for the paradoxical opposing effects which NO has on the uterus and cervix and be 
targeted for maximum efficiency in a site specific manner.
In summary, the studies presented in this thesis investigate the role of nitric oxide in 
human cervical ripening and its potential therapeutic role in the clinical manipulation of 
this process.
: ^ 2
A randomised controlled trial o f nitric oxide donors for ripening the 
human uterine cervix in the first trimester of pregnancy: a comparison of 
the side effect profile with a prostaglandin analogue 
Introduction
Cervical ripening before first trimester surgical termination of pregnancy facilitates the 
procedure whilst reducing the operative morbidity (Grimes, et al., 1984; MacKenzie and 
Fry, 1981; Schultz, et al., 1983). Pharmacological agents commonly used for this 
indication include laminaria in North America and prostaglandin analogues in the United 
Kingdom. Whilst prostaglandins produce more effective cervical ripening and are more 
convenient to administer than laminai'ia (Hehn, et al., 1988), they are associated with a 
number of adverse effects including abdominal pain, nausea, vomiting and diarrhoea 
(Henshaw and Templeton, 1991), The ideal cervical ripening agent should be effective, 
easy to administer and have a low incidence of side effects.
The inflammatory mediator nitric oxide, which has been implicated in a wide variety of 
physiological processes (Anggard, 1994), is a fundamental mediator of cervical ripening 
in animals (All, et al., 1997; Buhimschi, et ai., 1996). The nitric oxide donor, sodium 
nitroprusside produces effective ripening when applied locally to the guinea pig cervix 
(Chwalisz, et al., 1997). In a randomised controlled trial, it has previously been shown that 
the nitric oxide donors isosorbide-5-mononitrate and glyceryl trinitrate can induce effective 
cervical ripening compared to no treatment in primigravid women, when administered per 
vaginam in the first trimester of pregnancy (Thomson, et al., 1997). Since these agents are 
smooth muscle relaxants (Norman, 1996), they should induce cervical ripening without 
causing abdominal pain due to myométrial contractions, the most commonly reported side
effect in women receiving prostaglandins in early pregnancy (El Refaey, et al., 1994; 
Heim, et al., 1988; Henshaw and Templeton, 1991).
We hypothesised that nitric oxide donors can effectively ripen the cervix before first 
trimester surgical termination of pregnancy with fewer side effects than prostaglandin 
analogues. We therefore performed a three-group randomised trial to compare the clinical 
effects of the nitric oxide donor, isosorbide mononitrate (IMN, 40 mg and 80 mg) and the 
prostaglandin analogue, gemeprost before first trimester surgical termination of pregnancy. 
In addition, we performed a concurrent observational study to determine whether the 
cervical ripening effects of IMN are clinically sufficient.
Methods
(a) Randomised study to compare the clinical effects of IMN (40 and 80 mg) and 
gemeprost.
Between Januaiy and November 1997, 67 primigravid women scheduled for surgical 
termination of pregnancy by vacuum aspiration in the first trimester were recruited to this 
randomised trial; one woman was excluded before randomisation when she was found to 
be multigravid (Figure 2.1). The study was approved by the local research ethics 
committee and informed consent was obtained from each woman on the morning before 
the operation. Exclusion criteria from the study included: any previous pregnancy, 
previous cervical surgery, signs of threatened miscarriage or concurrent maternal disease. 
The gestation of each pregnancy was determined from both the menstrual history and 
clinical evaluation of uterine size. The women were randomly allocated to one of three 
treatment groups: the nitric oxide donor IMN 40 mg (Elantan® 40, Schwarz Pharma Ltd., 
Bucks., UK), IMN 80 mg, or the prostaglandin analogue gemeprost Img (16 ,16-dimethyl- 
trans delta 2 PGEi methyl ester, Farillon, Essex, UK). Block randomisation was
performed using sequentially numbered, sealed, opaque envelopes prepared using random 
number tables and 22 women were allocated to each treatment group. The envelopes were 
opened and the treatment allocated by one investigator after consent was obtained. Each 
medication was administered by the same investigator to the posterior vaginal fornix three 
hours prior to surgery. Treatment allocation was concealed from patients until the end of 
the study period.
67 registered patients
1 not randomised 
because multlgravi
66 randomised
22 assigned 22 assigned 22 assigned
gemeprost 1 mg IMN 40 mg IMN 80 mg
22 completed triaj 22 completed triaij 22 completed tria
Figure 2.1 Flow chart showing the women's progress through the randomised 
study. IMN = isosorbide-5-mononitrate.
The primary outcome measures were the development of adverse symptoms for each active 
treatment group. These were assessed using a symptom questionnaire administered before 
the medication was given and again immediately prior to surgery. The same investigator 
administered the symptom questionnaire on each occasion. At these time points, 
peripheral arterial pulse rates and mean arterial blood pressure recordings were obtained
using an automated electronie device, (Dinamap Plus®, Critikon, Florida, USA). For all 
women, general anaesthesia was induced using an intravenous injection of propofol.
(Diprivan®, Zeneca Pharma, Cheshire, UK), and alfentanil, (Rapifen®, Janssen, Bucks., 
UK), and maintained with intermittent repeat doses as required. Secondary outcome 
measures were the cervical diameter before surgical dilatation and the force required to 
dilate the cervix to 8mm measured with a force sensing apparatus coupled to cervical 
dilators, as previously described (Anthony, et al., 1982; Richardson, et al., 1989). All the 
procedures and recordings were performed by two experienced operators who were blind 
to the treatment given. Each of the treatments dissolved completely in the vagina, further 
ensuring that the operators were blinded to the treatment group. Suction evacuation of the 
uterus was then undertaken and the total volume lost, including both blood and products of 
conception, was measured from a calibrated suction jar.
Using Altman's nomogram (Altman, 1982), we calculated that by studying 66 women (22 
in each active treatment group), the study has a power of 85%, at the 5% significance level, 
to show a reduction of two thirds in the incidence of abdominal pain between the active 
treatment groups. This calculation is based upon a 70% incidence of abdominal pain 
occuiTing in the gemeprost group (Helm, et al., 1988). We considered that such a reduction 
in the frequency of abdominal pain would be clinically significant.
(b) Observational study to determine whether the cervical ripening effects o f IMN are 
clinically sufficient
It is current practice to omit preoperative cervical ripening in parous women undergoing 
first trimester termination of pregnancy (Royal College of Obstetricians and 
Gynaecologists, Guideline no. 11, 1997), since the force required to dilate the parous 
cervix is significantly less than that required for the primigravid cervix (Anthony, et al.,
1982). We considered that for a cervical ripening agent to be considered clinically effective 
in primigravid women, it should reduce the cervical resistance to a level similar to that 
measured in parous women. We therefore recruited 22 consecutive parous women
scheduled for surgical termination in the first trimester as a reference group for cervical 
resistance. The study was approved by the local research ethics committee and informed 
consent was obtained from each woman on the morning before operation. Each woman had 
had at least one normal vaginal delivery and exclusion criteria included previous cervical 
surgery and signs of threatened miscarriage. In these women, the primary outcome 
measures were the cervical diameter before surgical dilatation, the cumulative force 
required to dilate the cei’vix and the intraoperative blood loss, which were measured as 
described above.
Statistics
One factor ANC VA was used to compare the patient characteristics (age, gestation and 
interval between treatment and surgery), pulse and blood pressure data between the 
treatment groups. Data on intraoperative blood loss, cervical diameter and forces required 
during cervical dilatation were analysed using the Kruskal-Wallis test or the Mann- 
Whitney U test. The incidence of pre-operative side-effects was compared using Fisher's 
exact test.
Results
(a) Randomised study to compare the clinical effects o f IMN (40 and 80 mg) and 
gemeprost.
The mean age, gestation and interval between pretreatment and surgical dilatation, in each 
active treatment group are shown in Table 2.1.
Table 2.1 Clinical details of the women participating in the study.
Data are given as mean (standard deviation).
*
Gemeprost
(n -2 2 )
IMN 40 mg
(n = 22)
IMN 80 mg
(n = 22)
Parous group 
(n = 22)
Age (years) 21.8(4.1) 22.6 (6.6) 21.9 (6.2) 27.0 (4.9)
Gestation (weeks) 9.0 (1.2) 9.3 (1.1) 9.3 (1.0) 9.1 (1.0)
Interval between pre-treatment 169 (24) 169(37) 170(42) -
and surgical dilatation (min)
IMN = isosorbide-5-mononitrate.
Table 2.2 shows the incidence of new symptoms, which occurred after the administration 
of the ripening agent. Sixty-eight per cent of women in the IMN 40 mg group and 59% in 
the IMN 80 mg group remained asymptotic, significantly more than the 14% of women in 
the gemeprost group (p<0.001 and p<0.005 respectively). Significantly more women who 
received the prostaglandin analogue gemeprost experienced abdominal pain (p<0.0001) 
and vaginal bleeding (p<0.01) when compared with either of the IMN groups. More 
women in each of the IMN gi'oups developed a headache (p<0.05) when compared with 
the gemeprost group. No significant difference was found between the IMN 40 mg and 80 
mg groups in reported symptoms. No significant difference in the change in mean arterial 
blood pressure or pulse rate was detected among the groups after treatment.
The efficacy of each agent to dilate the cervix and reduce the cervical resistance is shown 
in Table 2.3. Pretreatment with gemeprost was more effective at ripening the cervix than 
either dose of IMN. Gemeprost increased the diameter of the cervical os before surgical 
dilatation compared with the 40 mg IMN group (p<0.05), and was associated with a lower 
cervical resistance than either dose of IMN (p<0.02). There were no significant
differences in the cervical resistance between the two IMN groups. Pretreatment with 
gemeprost resulted in significantly less (p<0.0005) measured intraoperative blood loss 
compared with either dose of IMN (Table 2.3).
Table 2.2 Incidence of new symptoms occurring after administration of the cervical 
ripening agent.
Gemeprost 
(n = 22)
IMN 40 mg 
(n=22)
IMN 80 mg 
(n = 22)
n(%) n(%) n(%)
Asymptomatic 3(14) 15 (68) a 13 (59) a
Abdominal pain 16 (73) l(5 )b 0(-)b
DiaiThoea 2(9) 0(-) 0(-)
Dizziness O(-) 3(14) 1(5)
Headache 0(-) 5(23)c 7 (32) d
Nausea/vomiting 4(18) 1(5) 2(9)
Palpitation 0(.) 1(5) 3(14)
Vaginal bleeding 7(32) 0(-)e 0 (-)e
a. significantly greater than gemeprost group, p<0.005
b. significantly less than gemeprost group, p<0.0001
c. significantly greater than gemeprost group, p<0.05
d. significantly greater than gemeprost group, p<0.01
e. significantly less than gemeprost group, p<0.01
Table 2.3 Results of the intra-operative recordings for both the randomised 
comparison and the observational study.
Data are given as the median (interquartile range). IMN = isosorbide mononitrate.
Gemeprost
(n -2 2 )
IMN 40 mg 
(n = 22)
IMN 80 mg 
(n = 22)
Parous group 
(n = 22)
Cervical diameter before 6 5 5 5
surgical dilatation (mm) (5-7)* (4 -5 ) (5 -5 ) (3 -6 )
Cumulative force to 21 40 36 34
dilate cervix to 8 mm (7-38)** (23 - 54) (27 - 60) (18-61)
(N)
Intra-operative blood 58 143 160 135
loss (ml) (45 - 90)*** (90 - 220) (105-295) (50 - 225)
(*) significantly greater than IMN 40 mg and parous groups, p<0.03
(**) significantly less than IMN 40 mg, IMN 80 mg and parous groups, p<0,02
(***) significantly less than IMN 40 mg, IMN 80 mg and parous groups, p<0.0005
(b) Observational study to determine whether the cervical ripening effects o f IMN are 
clinically sufficient.
Pretreatment of primigravid women with IMN resulted in a cei’vical resistance similar to 
that in the parous group (Table 2.3). There was no significant difference in the measured 
intraoperative blood loss between each IMN group and the parous group of women (Table 
2.3). Furthermore, no woman in any group required plasma volume expansion, blood 
transfusion or reoperation for vaginal bleeding and no woman in the study had a blood loss 
greater than 500 ml.
Discussion
This randomised study demonstrates that the niti'ic oxide donor IMN has fewer side effects 
than the prostaglandin analogue gemeprost when used to ripen the cervix before first 
trimester surgical termination of pregnancy. The nitric oxide donor is associated with a 
lower incidence of abdominal pain and pre-operative vaginal bleeding and a higher 
proportion of patients remaining asymptomatic. However, more women receiving the 
nitric oxide donor experienced a headache. The prostaglandin analogue produced a greater 
reduction in force and was associated with a lower intraoperative blood loss than either 
dose of the nitric oxide donor. The concurrent observational study demonstrated that 
pretreatment of primigravid women with IMN results in a cervical resistance similar to that 
of the parous group, whilst the intraoperative blood loss was similar in the IMN and parous 
groups.
The side effect profile of prostaglandin analogues administered in the first trimester of 
pregnancy is well characterised and includes nausea, vomiting, diarrhoea, abdominal pain 
and vaginal bleeding (Heim et al., 1988; Henshaw and Templeton, 1991; Lawrie, et al.,
1996). These effects are thought to arise because the prostaglandins stimulate contractions
of uterine and gastrointestinal smooth muscle. Whilst it has been suggested that 
misoprostol, an orally active synthetic analogue of prostaglandin E i, is associated with 
fewer side effects than gemeprost (El Refaey, et al., 1994), a more recent study has 
reported a high incidence of vaginal bleeding (50%), abdominal pain (47%) and vomiting 
(22%) in women given misoprostol in the first trimester of pregnancy (Ngai, et al., 1996). 
It has been suggested that the antiprogestogen mifepristone represents an acceptable and 
effective cervical ripening agent (World Health Organisation, 1990; Henshaw and 
Templeton, 1991). Whilst this agent has the advantage of being effective after oral 
administration, it is also associated with side effects, (including nausea, vomiting, vaginal 
bleeding and abdominal pain) and requires a latent period of 36-48 hours for the drug to act 
(Ngai, et al., 1996).
The side effect profile of nitric oxide donors administered vaginally has not been
described. Their recognised side effects when administered by other routes (oral,
sublingual, transdermal and intravenous), include headache, dizziness, postural
hypotension and tachycardia (Robertson and Robertson, 1995). Two studies have assessed
the effects of nitroglycerin, a nitric oxide donor, administered either as transdermal patches
or as an intravenous infusion (20 [ig/min), during pregnancy (Lees, et al., 1994; Ramsay, et 
al., 1994). No significant changes in maternal heart rate or systemic blood pressure were
detected, although headache was reported to Lees et al. (1994) by one third of the women. 
Other groups have found that larger doses of nitric oxide donors administered during 
pregnancy have significant adverse effects on the maternal cardiovascular system. 
Intravenous nitroglycerin, up to 5 pg/kg per minute (Cotton, et al., 1986; Grünewald, et al., 
1995) and a single 5mg dose of sublingual isosorbide dinitrate increased maternai puise 
rate and decreased mean arterial blood pressure (Thaler, et al., 1996).
In our study, when IMN was administered locally to the cervix, 60 - 70 % of women 
remained asymptomatic and there were no significant changes in mean arterial blood 
pressure or pulse rate. This low incidence of side effects may reflect the first uterine pass 
effect whereby vaginal drug administration results in high uterine and low serum 
concentrations (Bulletti, et al., 1997). It has previously been shown that vaginal 
administration of IMN allows effective ripening of the uterine cervix (Thomson, et al.,
1997), and the study reported here indicates that such an approach is associated with 
minimal systemic side effects.
An accumulation of nitric oxide donor in the uterine smooth muscle would be expected to 
relax the myometrium (Norman, 1996) thereby minimising preoperative abdominal pain 
and vaginal bleeding. One potential disadvantage of this effect is that myométrial 
relaxation, or lack of stimulation to contract during surgical evacuation might result in an 
increased intraoperative blood loss. Haemostasis in the placental bed depends not on the 
coagulation system, but rather myométrial contraction, the so-called living ligature, in the 
first instance. Prostaglandin analogues such as gemeprost, which cause myométrial 
contractions, are associated with a lower intraoperative blood loss when compared with 
placebo (Greer, et al., 1992). We found that the measured loss in each IMN group was not 
significantly greater than in a parous group of women receiving no treatment. Blood loss 
was lower in the gemeprost group, as would be expected with an agent provoking uterine 
contractility, than either the parous group or the groups receiving IMN. These data suggest 
that although the uterotonic effects of prostaglandins are associated with a reduction in 
measured blood loss, the myométrial relaxant effects of nitric oxide donors do not result in 
an increased blood loss compared with the pai'ous conti*ol group. Moreover, no woman in 
any of the groups had a clinically significant intraoperative blood loss as assessed by the 
need for plasma volume expansion, blood transfusion or reoperation for blood loss.
The efficacy of the prostaglandin analogue gemeprost to ripen the cervix is significantly 
better than either dose of IMN. Our results suggest that the ability of IMN to ripen the 
cervix is not dose dependent, although we have assessed only two doses of the nitric oxide 
donor. Previous work, which included a primigravid, control group given no treatment, has 
shown that IMN 40 mg and gemeprost 1 mg reduced the cervical resistance by 40 % and 
70 % respectively (Thomson, et al., 1997). Whilst it is widely accepted that a reduction in 
the force required to dilate the cervix reduces both operative morbidity and long term 
effects of cervical damage (Grimes, et al., 1984; MacKenzie and Fry, 1981; Schultz, et al.,
1983), there are no data on how much force is considered acceptable. In the absence of 
such data, we propose that the force required to dilate the parous cervix is a clinically 
acceptable target for ripening agents since it is current practice to omit preoperative 
cervical ripening in these women (Royal College of Obstetricians and Gynaecologists, 
Guideline no. 1Î, 1997). We have shown no significant differences in the cervical 
resistance of primigravid women pretreated with IMN and untreated parous women, 
suggesting that the cervical ripening effects of IMN are clinically sufficient. One caveat to 
this conclusion is that the comparison between the IMN groups and the parous group was 
made in an observational study since randomisation was not possible for the group of 
parous women. It seems essential that any cervical ripening agent used, should have 
minimal side effects. As we demonshate in this paper, the nitric oxide donor IMN appears 
to be such an agent.
This study has demonstrated that the nitric oxide donor IMN has fewer side effects than 
gemeprost when used to ripen the cervix in the first trimester of pregnancy. Later in 
pregnancy, cervical ripening is commonly employed to facilitate induction of labour. 
Whilst prostaglandins are the agents most commonly used to prepare the cervix at term, 
they are associated with excessive myométrial activity and an abnormal fetal heart rate 
pattern in 7% of women (Wing, et al., 1995). Nitric oxide donors relax the myometrium.
and these agents may have advantages over the prostaglandins to ripen the cervix later in 
pregnancy (Norman, et al., 1998). However, the safety of nitric oxide donors in the third 
trimester must be established before their efficacy for this indication is determined.
C h ap ter 3
A randomised controlled trial to compare isosorbide mononitrate, 
misoprostol and combination therapy for first trimester preoperative 
cervical ripening. 
Introduction
We have demonstrated in the previous chapter that cervical ripening in the first trimester of 
pregnancy can be effected by the nitric oxide (NO) donors isosorbide mononitrate (IMN) 
and glyceryl trinitrate (Thomson, et ah, 1998). Further, pretreatment with IMN is
associated with fewer side effects than gemeprost treatment, although the cervical ripening 
effects of the prostaglandin analogue are significantly better. Clearly, the ideal agent for 
preoperative cervical ripening should be clinically effective but have a low incidence of 
side effects.
We hypothesised that the cervical ripening effects of NO donors and of prostaglandins 
might be additive. If this hypothesis were correct, this would allow a small dose of NO 
donor to be given in combination with a small dose of prostaglandin to effect cervical 
ripening. Such a strategy might reduce the side effects associated with larger doses of each 
agent used alone. Combination therapy may therefore produce an optimal therapy for first 
trimester preoperative cervical ripening. Gemeprost is the only prostaglandin currently 
licensed for preoperative cervical ripening in the United Kingdom, but reports indicate that 
misoprostol, a synthetic 15-deoxy-16-hydroxyl-16-methyl prostaglandin El analogue, 
represents an inexpensive and effective alternative (Baird, et al., 1995; El Refaey, et al.,
1994; Jain and Mishell, 1994). Furthermore, misoprostol is associated with fewer side
effects than gemeprost (Henry and Haukkamaa, 1999). We therefore performed a three
group randomised controlled trial comparing the clinical effects of misoprostol (400pg), 
the NO donor IMN (40mg) and combination therapy with these two agents before first 
trimester surgical termination of pregnancy.
Methods
6 6  primigravid women undergoing surgical termination by vacuum aspiration in the first 
trimester of pregnancy ( < 1 2  weeks gestation) were recruited to the study over a seventeen- 
month period (December 1997 to April 1999). Gestational age was established on the 
basis of mensti'ual history and confirmed by vaginal examination or pelvic ultrasound 
examination. The local research ethics committee approved the study and written 
informed consent was obtained from each woman prior to inclusion in the study. A history 
of any previous cervical surgery or threatened miscarriage excluded women from 
participation in the trial. Women were recruited to one of three treatment groups as 
follows;
(i) The nitric oxide donor, isosorbide mononitrate (IMN) (Elantan®, Schwarz Pharma 
Ltd., Bucks, UK), 40 mg
(ii) Misoprostol (Cytotec®, Searle, High Wycombe, Bucks, UK), a prostaglandin El 
analogue methylated at C-16,400 pg
(iii) IMN 40 mg in combination with misoprostol 400 pg
Figure 3.1. Flow chart showing the women’s progress through the randomised study.
IMN ~ isosorbide-5-mononitrate
2 2  assigned 
misoprostol 400 pg
6 6  registered patients
6 6  randomised
2 2  assigned 
IMN 40 mg
2 2  assigned misoprostol 
400 pg & IMN 40 mg
1 withdrew after 
randomisation
2 2  completed trial 2 2  completed trial 2 1  completed trial
Women were randomised to each of the three treatment groups using sequentially 
numbered sealed opaque envelopes prepared using random number tables and 2 2  women 
were allocated to each group. The envelopes were opened and treatment allocated on the 
morning of surgery by myself. Each treatment was administered per vaginam, to the 
posterior vaginal fornix approximately 3h prior to surgery. One patient withdrew from the 
study after administration of treatment having decided not to proceed with termination 
(Figure 3.1). Treatment allocation was concealed from the patients until completion of the 
study. The development of adverse symptoms was recorded for each treatment group using 
a symptom questionnaire. The symptom questionnaire involved a structured series of 
questions regarding the recognised side effects of each agent. The questions were read 
ft'om a script before medication was given, and again prior to induction of anaesthesia. 
Women were asked to respond “Yes” or “No” to the questions, and their responses were 
recorded. Mean arterial blood pressure and peripheral heart rate recordings were also made
on admission and again immediately prior to surgery using an automated electronic device 
(Dinamap Plus®, Critikon, Florida, USA). For ail women, the procedures were performed 
under general anaesthesia induced with intravenous propofol (Diprivan®, Zeneca Pharma, 
Cheshire, UK) and alfentanil (Rapifen®, Janssen, Bucks., UK) and maintained with 
intermittent repeated doses as required. Gestation was confirmed by bimanual examination 
under general anaesthetic. The procedures were performed by experienced operators who 
were blind to the treatment given. The force required to dilate the cervix to 8  mm was 
recorded using a force sensing apparatus coupled to cervical dilators, as described 
previously (Anthony, et al., 1982; Richardson, et al., 1989). Suction evacuation of the
uterus was performed and the total volume lost, including blood and products of 
conception, measured using a calibrated suction jar. For the purposes of this study, blood 
loss was taken as the total volume lost, and compared between the three groups.
Using Altman’s normogram (Altman, 1982), we calculated that by studying 6 6  women (22
in each active treatment group) the study had a power of 80% at the 5% significance level 
to show a reduction in cervical resistance of 43% when IMN 40mg was combined with 
misoprostol 400pg, compared with misoprostol 400pg alone. This calculation is based on
cervical resistance of 30N in the group treated with misoprostol alone (El Refaey, et al.,
1994), a reduction in cervical resistance to ^ 17N in the group treated with IMN and
misoprostol (reduction in cervical resistance of 43% (Thomson, et al., 1998)), and a 
standard deviation in cervical resistance of 15N.
Statistics
One factor ANOVA was used to compare the patient characteristics (age, gestation, and 
interval between treatment and surgery), pulse and blood pressure. Intraoperative blood 
loss and force required to dilate the cervix were analysed using Kruskal-Wallis tests and
significance determined using Mann-Whitney U tests. The incidence of preoperative side 
effects was compared using Fisher’s exact test.
Results
The mean age, duration of gestation and interval between pretreatment and onset of 
surgery are shown for each of the three treatment groups (Table 3.1.). There was no 
significant difference in these variables for each of the treatments given.
Table 3.1: Clinical details of the women participating in the study.
Data are given as mean (standard deviation). IMN = isosorbide-5-mononitrate.
Misoprostol
(n=2 1 )
IMN
(n-2 2 )
IMN & Misoprostol 
(n=2 1 )
Age (years) 22.4 (5.9) 19.8 (2.7) 21.4 (5.1)
Gestation (weeks) 9.2(1.1) 9.5 (1.1) 9.5 (1.3)
Inteiva! between pre- 169 (29) 150 (28) 157(22)
treatment and surgical
dilatation (min)
The incidences of new symptoms after the administration of each treatment are shown in 
Table 3.2. There was no significant difference in the number of women remaining 
asymptomatic after treatment among the three patient groups. A significantly greater 
number of women given misoprostol experienced abdominal pain when compared to 
treatment with IMN (p=0.006). The proportion of women who complained of headache 
was significantly higher in the IMN than the misoprostol treated group (p=0.01). There 
was no difference in the incidence of abdominal pain between the misoprostol and the 
combination groups. There was no difference in the incidence of headache between the 
IMN and combination groups. Women who received combination therapy experienced the
side effects (headache and abdominal pain) of each agent used alone (Table 3.2). There 
was no significant difference in the change in mean arterial blood pressure or in pulse rate 
among the three groups.
Table 3.2: Incidence of new symptoms occurring after administration of the cervical 
ripening agent. IMN — isosorbide-5-mononitrate.
Misoprostol
(n=2 1 )
IMN
(n=2 2 )
IMN&
Misoprostol
(n=2 2 )
Symptom free 11(52%) 14 (64%) 11(50%)
Abdominal pain 9 (43%)* 1(5%) 7(32%)t
Headache 0 7 (32%)** 8  (36%)*
Dizziness 0 0 1(5%)
Palpitation 0 0 1(5%)
Diaiïhoea 0 0 0
Vaginal bleeding 2  (1 0 %) 0 0
Nausea/vomiting 2  (1 0 %) 0 0
For differences between misoprostol and IMN groups; *p=0.006, **p=0.01 
For differences between IMN and IMN & misoprostol groups; tp=0.04,
For differences between misoprostol and IMN & misoprostol groups; {p=0.002
The forces required to dilate the cervix to 8  mm following each of the three treatments are 
shown in Table 3.3. Pretreatment with misoprostol resulted in lower cervical resistance 
than pretreatment with IMN. Combination therapy with IMN and misoprostol significantly 
lowered the cervical resistance when compared to IMN alone. However, the combination 
of these two therapies was no better in achieving a reduction in cervical resistance than 
misoprostol used alone. There was no significant difference in intraoperative blood loss
between the three groups.
Table 3.3. Intraoperative recordings of force required to dilate the cervix and 
intraoperative blood loss. Data are given as the median (interquartile range). IMN =
isosorbide mononitrate.
Misoprostol
(n=2 1 )
IMN
(n=2 2 )
Misoprostol & IMN 
(n=2 2 )
Cumulative force to 18.5 (5-52) 39(17-54)* 24.5 (10-36)t
dilate
cervix to 8  mm (N)
Intraoperative blood 175 (100-250) 200 (150-350) 250 (90-400)
loss (ml)
* Significantly more than misoprostol group, p=0.04. 
fSignificantly less than IMN group, p=0.035.
Discussion
Prostaglandins are well-established agents for the purpose of cervical ripening in the first 
trimester. However, their administration is associated with side effects such as abdominal 
pain, nausea and vomiting and vaginal bleeding in a significant proportion of women
(Fong, et al., 1998; Singh, et al., 1998). The prostaglandin analogue misoprostol is 
associated with fewer side effects than gemeprost (Henry and Haukkamaa, 1999). The 
efficacy of each of misoprostol (400pg) and IMN (40mg) for preoperative cervical 
ripening has previously been shown in randomised controlled trials (El Refaey, et al., 
1994, Henry and Haukkamaa, 1999; Thomson, et al., 1997; Thomson et al., 1998; Fong et 
al., 1998; Singh et al., 1998). In this study, we have shown that combined therapy using
IMN and misoprostol at doses of 40 mg and 400 pg was no more effective in ripening the 
cervix than misoprostol alone. In addition, misoprostol is a more effective cervical 
ripening agent in the first trimester than the NO donor IMN. This latter finding is in 
agreement with previous studies where gemeprost, a PGEi methyl prostaglandin analogue, 
was found to be a more effective cervical ripening agent than the NO donors IMN (40mg) 
or glyceryl trinitrate (500pg).
The proportion of women remaining asymptomatic was slightly lower in the IMN and 
misoprostol group compared to the IMN alone group although these differences were not 
significant. A much greater sample size o f around 200 patients in each gioup would be 
required for the study to have 80% power to detect such differences at the 5% significance
level (Altman, 1982). The reported incidence of abdominal pain in women treated with 
prostaglandins is up to 70% (El Refaey, et al., 1994; Helm, et al., 1988). This side effect is 
likely to be caused by myométrial contractility induced by the prostaglandin analogue 
(Norman, et al., 1991). Clearly the ideal agent for cervical ripening would induce cervical
softening with limited or no stimulation of uterine activity. We have previously shown 
that 70% of women undergoing surgical termination in the first trimester remained 
asymptomatic following the administration of IMN compared with 14% of women 
receiving the prostaglandin analogue gemeprost. Pretreatment with gemeprost resulted in a 
higher incidence of abdominal pain (73%) and vaginal bleeding (32%) presumably due to 
the contractile effect of this agent on uterine smooth muscle (Norman, et al., 1991;
Williams, et al., 1985). We hypothesised combination therapy might reduce side effects, 
since the smooth muscle relaxant properties of IMN may result in a reduced incidence of 
the side effects attributable to myométrial contractions. However, we have found that the 
addition of IMN does not reduce the incidence of side effects associated with misoprostol. 
In particular, there was no significant difference in the incidence of abdominal pain
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between the misoprostol and combination therapy groups. Moreover, the side effects of 
these two agents appear to be additive, with combined therapy resulting in a greater 
proportion of women complaining of headache in addition to their abdominal pain. These 
findings may be attributable to the mechanism of action of NO donors in the process of 
cervical ripening. NO has been shown to increase prostaglandin production via
upregulation of the enzyme cyclooxygenase (Salvemini, et al., 1993; Sautebin, et al., 
1994). Preliminary studies in vivo discussed in chapter 6  of this thesis have demonstrated 
an increase in activity of PGFa^ in the cervix after administration of IMN (Ledingham, et
al., 1999). Denison et al (1999) (Denison, et al., 1999) have also recently demonstrated a
stimulatory effect of an NO donor on prostaglandin production in vitro in non-pregnant 
cervical tissue. Combination therapy with these two agents could therefore enhance 
prostaglandin mediated side effects rather than exploit the smooth muscle relaxant 
properties of NO donors.
One advantage of prostaglandins such as gemeprost for pre-operative cervical ripening is 
that their use is associated with a reduction in operative blood loss compared to no
treatment, presumably due to the uterotonic effects of this drug (El Refaey, et al., 1994; 
Ngai, et al., 1996; Thomson, et al., 1998). NO donors do not have this advantage. In 
previous studies, the blood loss associated with the use of IMN was similar to that o f no 
tieatment, but greater than that of gemeprost (Thomson, et al., 1998). In the study here, we
have found that there was no difference in blood loss between any of the treatment groups, 
although a trend towards greater blood loss following IMN either alone, or following 
misoprostol was observed. However, the differences are small, compared to the range of 
blood loss. A power calculation indicates that a much larger sample size of around 80 per 
group would be required for the study to have 80% power to detect a difference in blood 
loss of 75ml (that between the misoprostol and the IMN & misoprostol group) at the 5%
significance level. Our study is therefore insufficiently large to draw firm conclusions 
about blood loss.
The cervical ripening effects of NO donors may still have a role in clinical practice in 
women for whom prostaglandins are contraindicated, for example asthmatics with severe 
bronchospasm or women with known hypersensitivity to prostaglandins (Dollery, 1999). 
In the third trimester of pregnancy, the uterotonic side effects of prostaglandins may result 
in fetal distress during cervical ripening particularly in situations such as intrauterine 
growth restriction (Wing, et al., 1995). The use of agents, like NO donors, which do not
stimulate uterine contractility, may be more appropriate in such cases. Randomised 
controlled trials are required to determine the efficacy and side effect profile of NO donors 
for preinduction cervical ripening at term.
C onclu sion s
These data show that misoprostol (400p,g) has the best combination of efficacy and side
effects when used for the purpose of first trimester cervical ripening. There does not
appear to be any advantage in combining misoprostol with the NO donor IMN, either in
terms of improvement in efficacy or in the production of a more acceptable side effect
profile. IMN does not have a better side effect profile than misoprostol when these agents 
are used alone.
C h ap ter  4
The expression o f nitric oxide synthase in the human uterine cervix 
during pregnancy and parturition 
Introduction
In the human, cervical ripening is an inflammatory reaction involving leukocytic 
infiltration, changes in the v/ater content of the extracellular matrix and rearrangement of 
collagen fibres (Junquiera, et al., 1980; Leppert, 1992; Liggins, 1981; Owiny, et al., 1995).
The control of this process remains poorly understood although a number of mediators 
have been implicated, including progesterone withdrawal, prostaglandins, relaxin, and
various inflammatory cytokines (Barclay, et al,, 1993; Chwalisz, et al., 1994).
The inflammatory mediator nitric oxide (NO) has recently been implicated in cervical 
ripening. Previous studies, in both animals and humans, have shown that NO donors can
artificially induce cervical ripening following their local application (Chwalisz, et al., 
1997; Thomson, et al., 1997; Thomson, et al., 1998). In studies using rat models, nitrate 
production along with iNOS and bNOS mRNA expression increases in the cervix during 
labour (Buhimschi, et al., 1996). Tschugguel et al, (Tschugguel, et al., 1999) have also
suggested a role for NO in human cervical ripening. iNOS expression was increased in the 
cervices of women in the postpartum period compared to the non-pregnant state. No 
alteration in the expression of bNOS or eNOS was observed. However, the design of the 
study was such that effects of cervical ripening on NOS expression could not be separated
fi om the possible effects of pregnancy, labour or the delivery of the term infant through the 
ceiwix.
We hypothesised that each of the three isoforms of NOS is expressed in the human cervix 
and that NOS expression is increased during pregnancy, consistent with the involvement of 
NO in physiological cervical ripening. To test this hypothesis we examined the changes in 
expression of each of the three NOS isoforms in the human cervix throughout pregnancy 
using Western blotting. Further, each of the three isoforms was localised in tissue 
specimens using immunohistochemistry.
Materials and methods
Cervical tissue biopsies were obtained from women in four different groups;
(i) women undergoing hysterectomy for benign indications (n=8 )
(ii) women undergoing suction termination of pregnancy in the first trimester of 
pregnancy ( < 1 2  weeks gestation) (n=8 )
(iii) pregnant women delivered at term (>37 weeks gestation) by elective caesarean 
section prior to the onset of labour (n=8 )
(iv) pregnant women delivered at term (>37 weeks gestation) undergoing emergency 
caesarean section after the onset of labour (cervical dilatation > 4 cm) (n=8 )
The study conformed to the Declaration of Helsinki and was approved by the local 
research ethics committee. Written informed consent was obtained from each woman 
prior to recruitment. Pregnant women were excluded from the study if they had a multiple 
pregnancy or evidence of intrauterine infection, as determined by temperature >38°C. The 
indication for caesarean section in the labouring group was fetal distress. Women with 
dysfunctional labour or who had received prostaglandin or oxytocin were excluded. 
Cervical tissue specimens were divided in two, one half was formalin fixed and paraffin
embedded for immunohistochemistry and the other half was flash frozen in liquid nitrogen 
and stored at -70°C for subsequent Western blotting.
In the non-pregnant group, ceiwical biopsies were obtained from the anterior ceiwical lip 
using a scalpel within 1 0  minutes of removal of the uterus. Cervical biopsies from the first 
trimester subjects were taken from the anterior lip of the cervix using a 6 mm biopsy needle 
(Stifle Laboratories, Woobum Green, Bucks, UK) under general anaesthetic after 
evacuation of the uterus. In the pregnant women at term not in labour, biopsies were taken 
from the anterior lip of the cervix prior to delivery of the infant. Biopsies from the 
pregnant women in labour were obtained from the same site in the cervix following 
delivery of the infant.
Immunohistochemistry for eNOS, bNOS and iNOS
Immunohistochemistry was performed on paraffin embedded cervical tissue sections as 
previously described (Thomson, et al., 1997) using antibodies against eNOS, bNOS and 
iNOS as detailed in Table 4.1. Briefly, tissue was fixed at the time of collection in 10% 
neutral buffered formalin and paraffin embedded. Sections were cut to 5p,m thickness, 
dewaxed, rehydrated and endogenous peroxide activity blocked in 0.5% H2O2  (Sigma) in 
methanol for 30 min at room temperature. Sections were washed in Phosphate Buffered 
Saline (PBS) and antigen was retrieved by microwaving in a pressure cooker (Lakeland 
Plastics Ltd, Cumbria, UK) if required (Table 4.1). Tissue sections were then blocked in 
either 20% nonnal horse (SAPU, Carluke, UK) /human serum (eNOS and iNOS) or 20% 
goat/human serum (bNOS) for 30 mins at room temperature and incubated for 16 hr at 4"C 
with the primary antibody diluted in 2 % normal horse serum or 2 % normal goat serum as 
appropriate (Table 1). Sections were washed in PBS then incubated for 30 mins with 
biotinylated horse anti-mouse (Vector Laboratories) diluted 1:200 in 2% normal horse with 
5% normal human serum added (eNOS, iNOS) or with biotinylated goat anti-rabbit 
(Vector Laboratories) at 1:200 in 2% goat serum with 5% human serum added. Sections
were washed in PBS, then incubated with avidin DH/ biotinylated horseradish peroxidase 
H reagent (Vector Laboratories, UK) in PBS for 30 mins before final washing. Antigen 
was localised using Img/ml diaminobenzidene tetrahydrochloride (Sigma, UK), 0.02% 
H2O2 in 50mM Tris-Cl, pH 7.6 and appeared as a brown end product.
Table 4.1. NOS antibodies for immunohistochemistry
Antibody Type Immunogen Dilution Pretreatment Source
eNOS
(N30020)
mouse
monoclonal
IgGl
aa 1030-1209 of 
human eNOS
1 :1 0 ,0 0 0 microwave Transduction
bNOS
(AHP477)
rabbit
polyclonal
aa 1414-1434 of 
human brain synthetic 
peptide
1:25 none Serotec
iNOS
(N39120)
mouse
monoclonal
IgG2
aa 961-1144 of 
murine iNOS
1:50 microwave Transduction
Specificities of each of the antibodies was demonstrated by western blotting on lysates of 
rat cerebellum, human umbilical vein endothelial cells (HUVECS) and LPS/IFN7 
stimulated mouse macrophages using the primary antibodies as tabulated above. The 
positive controls for iNOS, eNOS and bNOS were sections of small bowel from a patient 
with ulcerative colitis (Guslandi, 1998; Kimura, et al., 1997), umbilical cord (Myatt, et al..
1997) and rat brain respectively. Negative control slides were set up for all three
antibodies with omission of the primary antibody. Negative controls were also set up for 
eNOS and iNOS with IgGl and IgG2a immunoglobulins respectively replacing the 
primary antibody.
Immunohistochemistfy for CD45
In order to localise leukocytes in serial sections o f each o f the tissues, 
immunohistochemistry was performed on paraffin embedded cervical biopsies using 
antibody directed against the common leukocyte antigen, CD45 (Dako; M 0701). Briefly, 
biopsies of cervix were prepared and microwaved as above. Sections were blocked in 20% 
normal horse (SAPU, Carluke, UK) /human seium for 30 mins at room temperature and 
incubated for 16 hr at 4"C with anti-CD45 at 1:100 dilution. Sections were incubated for 
30 mins with biotinyiated horse anti-mouse (Vector Laboratories) at 1:200 dilution and 
then incubated with avidin DH/ biotinyiated horseradish peroxidase H reagent (Vector 
Laboratories, UK). Antigen was localised using diaminobenzidene tetrahydrochloride as 
before and counterstained with Harris haematoxylin. Negative controls included slides 
incubated without the primary antibody.
Western blot analysis for eNOS, iNOS and bNOS
Total protein was extracted from the cervical tissue biopsies using the TRIZOL™ method 
according to the manufacturers instructions (Life Technologies, Paisley, UK). Protein was 
quantified using the EGA protein assay reagent (Pierce, Illinois, USA) and UV 
spectrophotometry at 562nm. Samples containing 60 p,g protein were prepared in equal 
volumes of sample application buffer, separated by SDS-PAGE and transferred to a 
nitrocellulose membrane (pore size 450p,m) (Hybond, Amersham Life Sciences, Little 
Chalfont, Buckinghamshire, England) by wet blotting (lOOV for 1 h 50 mins). Gels were 
stained with Coomassie Blue to check protein transfer. Membranes were blocked in 5%
Marvel™ in 0.05% v/v Tween-Tris buffered saline (TBS-T) for at least Ihr prior to 
antibody application. The antibodies were as used for immunohistochemistry at the 
following concentrations: iNOS at 1:10,000, eNOS at 1:2,500 and bNOS at 1:10,000. 
Lysates of IFNy/LPS treated mouse macrophages (Transduction Laboratories), HUVECS 
(Transduction Laboratories) and rat cerebellum were used as the contiols for iNOS, eNOS 
and bNOS respectively. Immunoreactivity was visualised using HRP linked secondary 
antibodies against the appropriate species and the ECL detection system as per the 
manufacturer's instructions (Amersham). Stained molecular weight markers (Biorad) were 
transferred to the nitrocellulose membrane and used to identify and characterise the 
molecular weights of the NOS isoforms examined.
Data analysis
Transmission densitometry was used to quantify NOS activity in the westerns (Bio-Rad 
Multi-AnalysP/PC Version 1.1.), Parallel background readings of equal area were 
obtained in order to calculate relative intensities from the autorads and calculated using 
dedicated software. Readings were only compared between samples run in parallel under 
exactly the same conditions (i.e. same electrophoresis run, same buffers, stains and 
incubation periods). All densitometric assessments were performed within the optimal 
range of sensitivity. Statistical analysis was performed using Kruskal-Wallis Test with 
Mann Whitney-U as a post-hoc test. P<0.05 was regarded as significant.
For immunohistochemical analysis, the slides were examined using light microscopy by 
two independent observers. Staining was localised but there was no attempt to quantify 
staining in the different groups.
Results
Immunohistochemistry
iNOS
In each of the cei*vical tissues sampled from pregnant and non-pregnant women, iNOS 
protein was localised to the vascular endothelium. Immunostaining for iNOS was absent 
from the cervical glands. In biopsies obtained from pregnant women at term, (in labour 
and not in labour), iNOS was identified in cells within the cervical stroma. Co-localisation 
with the common leukocyte antigen CD45, identified these cells as leukocytes. The 
positive control sections (small bowel in ulcerative colitis) showed appropriate localisation 
for iNOS whilst the negative control sections showed no staining, (Figure 4.1).
eNOS
There was no difference in the immunolocalisation of eNOS among the 4 groups of 
women. Immunostaining was identified in the vascular endothelium, the parabasal cells 
of tlie surface epithelium and the cervical glandular epithelial cells in each of the sections. 
The positive control sections (term placenta) showed appropriate localisation for eNOS 
and the negative control sections showed no staining, (Figure 4.2).
bNOS
bNOS was localised in each of the cervical biopsies from non-pregnant and pregnant 
women. Immunostaining for bNOS was identified in the intermediate and superficial cells 
of the surface epithelium. Staining for bNOS was absent in the cervical glands and on the 
vascular endothelium. In cervical biopsies collected from pregnant women at term, bNOS 
staining was identified in leukocytes in the cervical stroma. The positive control sections 
(rat brain) showed appropriate localisation for bNOS and the negative conti’ol sections 
showed no staining, (Figure 4.3).
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Figure 4.1. Immunolocalisation of iNOS in cervical biopsies collected 
from (a) non-pregnant women, (b) women in the first trimester of 
pregnancy, (c) pregnant women at term before the onset of labour, and 
(d) pregnant women at term during spontaneous labour. In each of the 
biopsies, iNOS localised to the vascular endothelium. In biopsies 
collected from pregnant women at term, iNOS was also identified 
within leukocytes (e). The positive control slides, small bowel from a 
patient with ulcerative colitis, showed appropriate localisation of iNOS 
(f). The negative control sections (see text) showed no staining. Scale 
bars (a, b, c, d and f) = 50pm. Figure (e) was obtained using a high 
powered (xlOO) oil immersion lens.
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Figure 4.2. Localisation of eNOS in the human uterine cervix. 
In each of the biopsies, eNOS localised to (a) the vascular 
endothelium, (b) the parabasal cells of the surface epithelium 
and (c) the cervical glands. The positive control slides (d), term 
placenta, showed appropriate localisation of eNOS. The 
negative control slides (e, see text) showed no staining. Scale 
bars (a, c, d and e) = 50 pm, and (b) = 100 pm.
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Figure 4.3. Immunolocalisation of bNOS in the human uterine 
cervix. bNOS protein was absent from the cervical glands (a) but 
was identified within the intermediate and superficial cells of the 
surface epithelium (b). Staining for bNOS was identified within 
leukocytes in biopsies collected from pregnant women at term 
(c). Sections of rat brain were employed as the negative controls 
and showed no staining (d) and the positive control slides (rat 
brain) showed appropriate staining for bNOS (e). Scale bars (a,d 
and e) = 50pm, (b) = 100 pm and (c) = 20 pm.
Western blotting analysis
Western blotting confirmed the presence of protein for each of the three NOS isoforms 
within cervical tissue biopsies.
iNOS
iNOS protein was detected at 130kDa. There was a 2.7 fold greater expression of iNOS in 
the first trimester compared with cervix obtained from non-pregnant subjects (p<0.005). 
There was a further 1.6 fold increase at term prior to the onset of labour (p<0.01). iNOS 
protein expression did not change following the onset of spontaneous labour (p=0.27), 
(Figure 4.4).
eNOS
No significant changes were observed in eNOS expression when comparing the non- 
pregnant and first trimester groups. However, there was an increase in eNOS expression in 
the cervix of those samples obtained from term subjects both not in labour and in labour 
when compared to non pregnant subjects (p=0.002 and p=0.0016 respectively), (Figure 
4.6).
bNOS
In the cei-vix, bNOS protein was represented by positive bands at 160 kDa. bNOS protein 
increased in the first trimester of pregnancy compared to the non-pregnant state (p<0.005). 
There were no fiirther significant changes in bNOS expression at term or with the onset of 
labour, (Figure 4.5).
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Figure 4.4. Western blot analysis of cervical samples collected from non- 
pregnant and pregnant women using an antibody directed against iNOS, (lanes 
1-3, non-pregnant; lanes 4-6, pregnant first trimester; lanes 7-9, term pregnant 
not in labour and lanes 10-12, term pregnant in spontaneous labour). The 
putative iNOS band is seen at 130 kDa. The positive and negative controls are 
shown in lanes 13 and 14 respectively, (see text). The figure shows 
representative bands from 3 out of the 8 women in each group. Densitometric 
analysis showed a significantly greater expression of iNOS in the first 
trimester cervix compared with pregnant subjects. There was a further increase 
by term with no change following the onset of labour.
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Figure 4.5 Western blot analysis of cervical samples collected from non- 
pregnant and pregnant women using an antibody directed against eNOS, 
(lanes 1-3, non-pregnant; lanes 4-6, pregnant first trimester; lanes 7-9, term 
pregnant not in labour and lanes 10-12, term pregnant in spontaneous labour). 
The putative eNOS band is seen at 135 kDa. The positive and negative 
controls are shown in lanes 13 and 14 respectively, (see text). The figure 
shows representative bands from 3 out of the 8 women in each group. 
Densitometric analysis showed a significantly greater expression of eNOS in 
cervical tissue samples collected at term compared with those collected from 
non-pregnant women, (see text).
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Figure 4.6 Western blot analysis of cervical samples collected from non- 
pregnant women using an antibody directed against bNOS, (lanes 1-3, non- 
pregnant; lanes 4-6, pregnant first trimester; lanes 7-9, term pregnant not in 
labour and lanes 10-12, term pregnant in spontaneous labour). The putative 
bNOS band is seen at 160 kDa. The positive and negative controls are shown 
in lanes 13 and 14 respectively, (see text). The figure shows representative 
bands from 3 out of the 8 women in each group. Densitometric analysis 
showed a significantly greater expression of bNOS in the first trimester 
compared with non-pregnant subjects. There were no further changes in bNOS 
expression by term or following the onset of labour, (see text).
Discussion
This is the first study to examine the localisation and expression of the three NOS isoforms 
in the human uterine ceivix in non-pregnant subjects and in pregnant women in the first 
trimester and at term, both before and after the onset of labour. We have shown that the 
three NOS isoforms are present in the human cervix in the non-pregnant and pregnant 
states. Expression of each of the NOS isoforms is increased in pregnancy compared to the 
non-pregnant state. iNOS expression is further increased in the third trimester of 
pregnancy. None of the isoforms of NOS increases following the onset of labour. These 
results suggest that an increase in endogenous cervical NOS enzyme activity in the third 
trimester may be important in physiological cervical ripening in human pregnancy. The 
timing of these events would seem appropriate, given that the changes in the cervix during 
pregnancy are thought to occur at term prior to the onset of labour as part o f a
‘conditioning phase’ before uterine activity can commence (Calder, 1994; Chwalisz and 
Garfield, 1997). At this time the cervix becomes soft and compliant secondary to 
alterations in its water content and constitutive connective tissue matrix components and 
the uterus undergoes changes which allow it to contract in a synchronous manner (Calder,
1994; Ekman, et al., 1991; Gaifteld, et al., 1998; Uldbjerg, et al., 1985).
Previous studies in animals have provided evidence that NO may have a physiological role 
in cervical ripening. The NO generating system has been identified in the rat cervix where
it may also be involved in regulating cervical extensibility (Shi, et al., 2000). Increased
expression of iNOS and bNOS has been demonstrated using western blotting in the 
labouring cervix at term and iNOS expression is increased following onapristone induced
preterm labour (Buhimschi, et al., 1996). Using RT-PCR, Ali et aL, have demonstrated an
increase in iNOS mRNA in the cervix of labouring rats when compared to controls with
only minor changes in the constitutive NOS isoforms during gestation (Ali, et al., 1997). 
In both human and animal studies, nitric oxide donors have been shown to ripen the cervix 
when artificially applied to this tissue (Chwalisz, et al., 1997; Qing, et al., 1996)
(Thomson, et al., 1997; Thomson, et al., 1998). Furthermore, in rats the ripening process
can be inhibited using L-NAME, a nitric oxide synthase inhibitor (Buhimschi, et al., 1996).
Our data therefore support the hypothesis that NO is a pharmacological and physiological 
regulator of cervical ripening in the human.
Recent studies have described NOS expression within the human uterine cervix in samples 
obtained from non-pregnant women and in women following vaginal delivery at term
(Tschugguel, et al., 1999). The authors found an increase in calcium independent NOS
activity (i.e. the inducible NOS activity) within the pregnant cervix following delivery 
using a commercially available arginine to citrulline conversion assay. However there was 
no corresponding change in iNOS mRNA using RT-PCR. The authors suggested that the 
discrepancy between the RT-PCR and the enzyme activity was attributable to the fact that 
the iNOS mRNA may have been replaced by the more stable protein within the cervix thus 
accounting for these findings. A possible concern about this study is the effect of 
confounding variables such as pregnancy, labour and delivery of the baby on NOS 
expression. Our study has examined the expression of protein within this tissue during 
pregnancy and our results are in keeping with the above authors' findings. We have 
demonstrated an increase in iNOS protein at term in the cervix prior to the onset of labour. 
However, we have clarified that the increase in NOS activity occurs prior to the onset of 
labour and is not merely attributable to factors associated with cervical dilatation or 
vaginal delivery of the fetus.
In contrast to studies performed on the rat (Ali, et al., 1997; Buhimschi, et al., 1996), our
studies in the human cervix have demonstrated an increase in expression of iNOS towards 
the end of gestation with no further increase with the onset of labour at term. Similarly, 
eNOS expression is increased at term in pregnancy compared to the non-pregnant state. 
We failed to demonstrate an increase in bNOS expression at term although this isoform 
was increased in the first trimester of pregnancy. This would suggest that in the human 
NO is involved in the gradual changes in cervical extensibility and not in the acute process 
of cervical dilatation, which occurs with spontaneous labour, as has been demonstrated in 
the rat model. This supports the hypothesis that NO is involved in cervical ripening.
Using immunohistochemistry, we have demonstrated iNOS localisation in the cervical 
vascular endothelium. This is in keeping with previous reports where iNOS has been
identified in endothelial cells (Cheung, et al., 1999; Purcell, et al., 2000). We also
demonstrated iNOS immunostaining in a proportion of cells within the tissue collected 
from labouring women. Using antibody directed against CD45, the common leukocyte 
antigen, these cells were identified as leukocytes infiltrating the tissue. This data is also in 
keeping with the findings of Marx et aL, who have recently reported similar findings in the 
pregnant rat cervix (Marx, et al., 2000). Tschugguel et aL, (Tschugguel, et al., 1999) also
reported iNOS immunostaining in epithelial cells and in stromal spindle cells in 
ciyosections of the human ceivix. In comparison, our studies were canied out on paraffin 
embedded sections of cervical tissue as this method of tissue fixation provides better 
morphological specimens for analysis. This however may account for the observed 
differences in tissue localisation. The specificities of each of the NOS antibodies had been 
confirmed for the purpose of our studies using western blotting analysis as previously 
discussed.
We demonstrated the presence of bNOS protein within the cervix of non-pregnant and 
pregnant women using both immunohistochemistry and western blotting. Staining for 
bNOS was identified within the surface epithelium in both non-pregnant and pregnant 
subjects. bNOS was also localised to a proportion of leukocytes invading the cervix in
labouring samples. This is in contrast to the findings of Tschugguel et aî (Tschugguel, et 
al., 1999) who did not demonstrate either bNOS mRNA expression using RT-PCR or the
presence of bNOS protein using immunohistochemistiy. However our results are in 
keeping with studies recently performed in humans reporting the presence of bNOS mRNA 
and protein in the cervix of non-pregnant and pregnant subjects using RT-PCR and 
Western blotting respectively (Bao, et al., 2000). Further, localisation of bNOS in cervical
epithelium has also been confirmed previously in studies on rat uterus (Schmidt, et al.,
1992).
eNOS was confined to the vascular endothelium and the glandular and surface epithelium. 
Previous studies in rats have also shown eNOS immunoreactivity in endothelial and 
epithelial cells in non-pregnant animals (Chatteijee, et al., 1996). Our findings support
those of Tschugguel et al (Tschugguel, et al., 1999) who have also reported the localisation
of endothelial NOS to the vasculature in non-pregnant and pregnant human cervix. 
Tschugguel et al failed to demonstrate eNOS immunostaining in glandular epithelia. The 
discrepancy in these results again may be accounted for by the differences in the tissue 
specimens studied (cryosections vs paraffin sections).
It is now acknowledged that cervical ripening is an inflammatory process involving 
leukocytic infiltration and release of inflammatory mediators such as IL-1, IL- 8  and TNF-
a  (Barclay, et al., 1993; Chwalisz, et al., 1994; Liggins, 1981). It is therefore not 
surprising that the inflammatoiy mediator NO should be involved in these events. The
exact role that NO plays in the ripening process is unclear. However, it is interesting to 
speculate as to the mechanism whereby NO is involved. During ripening the collagen 
content of the tissue decreases secondary to the action of degradative enzymes known as 
matrix metalloproteinases (MMPs) (Junquiera, et al., 1980; Osmers, et al., 1995). The
composition of the constituent proteoglycans is also altered (Uldbjerg, et al., 1983; Von
Maillot, et al., 1979). NO is capable of stimulating MMP activity and suppressing
proteoglycan synthesis in other tissues (Murrell, et al., 1995; Trachtman, et al., 1996
Hauselmann, et al., 1994; Hauselmann, et al., 1998; Sasaki, et al., 1998) and hence may
function in a similar manner in the cervix. In chapter 5 we investigate the potential 
interaction between NO and MMP-2 and -9 in the human cervix during cervical ripening 
(Ledingham, et al., 1999). NO may also contribute to the ripening process via induction of
apoptosis (Brune, et al., 1998; Nicotera, et al., 1997), another mechanism which may be
important in this physiological process (Leppert, 1992). The effects of NO may also be
mediated via cross-talk with cyclo-oxygenase and an increase in prostaglandin synthesis 
which in turn would stimulate other inflammatoiy mediators such as IL- 8  and secretoiy 
leukocyte protease inhibitor (Denison, et al., 1999; Ledingham, et al., 1999). This is further 
investigated and discussed in chapter 6 .
In conclusion, we have shown that all three NOS isoforms are present in the human uterine 
cei*vix in non-pregnant and pregnant individuals. Each of the iso forms of NOS is 
upregulated during pregnancy and a further increase in the expression of iNOS is detected 
prior to the onset of labour at term. This supports a role for NO in the remodelling of the 
cei-vix that constitutes the ripening process. We speculate that, in the future it may be 
possible to influence cervical ripening when it occurs prematurely or is delayed, using 
agents directed against the NO generating system.
Chapter 5
The effects o f n itric oxide donors on the secretion o f m atrix  
metalloproteinases -2 and -9 and their inhibitors (TIMPs) in the human 
uterine cervix. 
Introduction
At the end of pregnancy, during the ripening process, the cervix changes its biochemical 
composition and structure to permit delivery. Ripening has been compared to an
inflammatoiy reaction (Liggins, 1981) in which the tissue develops a marked leukocytic
cell infiltrate (Junquiera, et al., 1980; Owiny, et al., 1995) and the collagen fibres, which
comprise the bulk of the extracellular matrix (ECM) of the cervix, become disorganised. 
Recent research has proposed that these structural alterations may be due to changes in the 
water content of the ECM, alterations in the proteoglycan content and/or changes in
activity of collagenases (Leppert, 1995)
Collagenases, now termed matidx metalloproteinases (MMPs) are a family of at least 17 
different types of zinc-dependent enzymes (Hulboy, et al., 1997) which are also capable of
degrading other ECM components such as proteoglycans, fibronectins and laminin present 
in interstitial matrix and basement membranes. The MMPs are divided into different 
subgroups depending on their domain structures and their substrate specificities. These 
groups comprise the fibrillar collagenases (MMPs -1 ,-8  and -13), gelatinases/type IV 
collagenases (MMPs -2 and -9), stromelysins (MMPs -3, -7, -10 and -11) and membrane- 
type MMPs (MMPs -14, -15, -16 and -17). MMPs are secreted as proenzymes and are 
modulated by activating proteases (Woessner, 1994) and four endogenous tissue inhibitors
of metalloproteinases (TIMPs) which form a 1:1 complex with the MMPs (Herron, et al..
1986).
Collagenolytic activity has been shown to increase in the ceivix during late pregnancy and 
cervical dilatation in both human and animal studies (Rajabi, et al., 1991; Rajabi and
Singh, 1995; Uldbjerg, et al., 1983). Increased levels of proMMP-2 and proMMP-9 have
also been demonstrated in the cervix of rabbits in late pregnancy (Imada, et al., 1997).
Neutrophils and macrophages, both of which invade the cervix during pregnancy and 
ripening, are known sources of leukocyte collagenase (MMP-8 ) and fibroblast collagenase
(MMP-1), respectively (Osmers, et al., 1992) (Maeda, et al., 1998). However the exact
MMPs and TIMPs, which are present in the human cervix in pregnancy, and the 
mechanism by which their activity is controlled in cervical ripening are not fully 
understood.
In previous chapters of this thesis we demonstrated that nitric oxide was involved in human 
cervical ripening and that cervical ripening can be effected using nitric oxide donors. The 
mechanism whereby NO is involved in the ripening process and how it interacts with other 
mediators of cervical ripening remains unclear, although NO has been shown to increase 
the activity o f the gelatinases MMP-2 and -9 in other tissues (Murrell et a l, 1995, 
Trachtman et aL, 1995, Sasaki e ta l,  1998, Tamura e ta l, 1996).
We hypothesised that the process of cervical ripening mediated by NO involves activation 
of MMPs -2 and -9, which facilitate breakdown of type IV collagen in the blood vessel 
endothelium. This would allow neutrophil and macrophage influx into the tissue with the 
release of other agents involved in cei’vical ripening e.g. other MMPs and proinflammatory 
cytokines such as interleukin-1 (IL-1), IL- 8  and prostaglandins. The aims of this study 
were to examine whether MMPs -2 and -9 are released by the cervix and if NO donors.
agents known to cause cervical ripening, regulate these MMPs.
Materials and methods
The studies were approved by the local research ethics committees and written informed 
consent obtained from each woman prior to surgery.
Study Patients
(i) Non-pregnant
Cervical biopsies were obtained from healthy, non-pregnant, premenopausal women 
(n=15) with regular menstrual cycles undergoing a hysterectomy for non-malignant 
conditions. Preliminary studies demonstrated that stage of the menstrual cycle did not 
affect the results. A longitudinal section of the anterior lip of the cervix was taken using a 
scalpel within 10 min o f removal of the uterus. Biopsies were placed immediately in 
RPMI 1640 culture medium at 4°C for transport to the laboratory.
(ii) Pregnant
2 0  healthy women in the first trimester of pregnancy (6 - 1 2  weeks gestation) undergoing 
suction termination of pregnancy were recruited into the study. Women were randomised 
into 2  groups (n= 1 0  in each group) and treatment given as follows:
(i) 40 mg isosorbide mononitrate (IMN) Tablet (Schwarz Pharma Ltd., East Sussex, 
Chesham, Bucks, England), a nitric oxide donor, per vaginam 2-3 h prior to 
surgery.
(ii) a control group given no treatment.
Cervical biopsies were taken from each woman from the anterior lip of the cervix using a 6  
mm biopsy needle (Stiefel Laboratories, Wooburn Green, Bucks, UK) under general 
anaesthetic after evacuation of the uterus. Tissue was immediately transferred into
Dulbecco’s medium (Sigma, Poole, UK) at 4°C prior to transport to the laboratory.
Tissue Culture
The culture media used for these experiments was that used as standard for tissue eulture in 
the respective laboratory sites.
(i) Cervical biopsies from non-pregnant women:
Biopsies, which were approximately 20 to 35 mg in weight, 15-20 mm in length and 2-3 
mm in diameter were washed once in phosphate buffered saline (PBS), dissected into small
pieces (1-2 mm^, 2-4 mg) and cultured in 24-well plates (Costar, High Wycombe, UK) in 
culture medium (RPMI 1640 supplemented with 2 mM L-glutamine; 50 ug/ml 
streptomycin, Gibco, Paisley, UK; 20 ng/ml gentamicin and 50 lU/ml penicillin) for 24 h at 
37°C in 95 % air and 5 % CO2 under humid conditions. Tissue was treated with either (i) 
the NO donor speimine nonoate (50 fxg/ml. Sigma) or (ii) culture medium only. A single 
biopsy from each patient was used for all studies. Biopsies were divided and treatments 
were run in quadruplicate. Supernatant was removed after 24 h and biopsies were weighed 
and paraffin embedded. Media were stored at - 20°C until analysis.
(ii) Cervical fibroblast cell preparation:
Cervical biopsies from non-pregnant women were washed twice in PBS and incubated in 
buffer (80 ^tg/ml gentamicin; 5 ng/ml amphotericin B (Sigma) in PBS) for 1 h at 23°C. 
Biopsies were digested with Dispase I (1 U/ml in PBS; Boehringer Mannheim, Lewes, 
UK) for 2 -3 hours at 37°C with gentle agitation then washed twice in PBS. Next, the 
ecto- and endo-cervical epithelium were sheared off in sheets by scraping with a scalpel 
and the underlying cervical stroma scraped and dissected into small pieces (1 mm^). The
stromal tissue specimens were placed into 75 mm  ^ tissue culture flasks and cultured in 
complete medium (RPMI 1640 supplemented with 10% fetal calf serum; 2 mM L- 
glutamine; 50 pig/ml streptomycin, Gibco, Paisley, UK; 20 p,g/ml gentamycin and 50
lU/mi penicillin) at 37°C in 95 % air and 5 % CO2 under humid conditions. Cervical 
fibroblasts grev/ to confluence within 28 days and were used up to passage 6 . For 
experimentation, confluent fibroblasts were plated out at 2 x 10  ^cells/ml, washed in PBS 
and cultured for 24 h in RPMI cultured for 24 hours in RPMI 1640 with treatments added 
in quadruplicate. Media were stored at -20°C until analysis. Viability was >95 % by 
trypan blue exclusion and >95 % of cells were positive for vimentin immunoreactivity.
(iii) Cei’vical biopsies fr om pregnant women:
Biopsies weighing around 12 mg, 3-4 mm diameter and 10-14 mm length were dissected 
into small pieces (1-2 mm^, 2-4 mg) and cultured in a 24 well plate in Dulbecco's medium 
supplemented with streptomycin 100 ^g/ml, penicillin 100 U/ml and Fungizone 100 U/ml 
in 5% CO2 and 95% air for 24 h at 37°C. A single biopsy from each patient was used for 
all studies and divided for culture with experiments run in quadruplicate. Biopsies were 
weighed after treatment and paraffin embedded. Supernatant was stored in 250 fxl aliquots 
at -20°C for subsequent analysis.
Gelatinase zymography
Gelatinase zymography was used to detect MMP-2 and MMP-9 activities as described 
previously (Rawdanowicz, et al., 1994; Riley, et al., 1999) with minor modifications.
Gelatinase activity degrades the gelatin substrate and therefore appears as clear bands 
against a dark background of Coomassie blue staining. Lyophilised samples of culture 
medium (1ml lyophilised sample reconstituted with 50 pil 0.1% SDS, 7.5 \xl per sample 
loaded onto gel) conditioned by cervical expiants and fibroblasts were separated by SDS- 
polyacrylamide gel electrophoresis (PAGE; 7.5% gels; Minigel apparatus; BioRad, Hemel 
Hempstead, Herts) containing gelatin (1 mg/ml; Sigma) using non-reducing conditions. 
Gels were washed twice using 2.5% (v/v) Triton X-100 (Merk-BDH), then incubated in 
zymography digestion buffer (200 mM NaCl, 50 mM Tris, 5 mM CaCl2, 1 mM ZnCl2,
0.02% (v/v) Brij-35, pH 7.6; all Merck-BDH except Brij obtained from Sigma) for 18 h at 
37°C. Gels were immersed in staining solution comprising 0.5% Coomassie blue R250 
(Bio-Rad) in 30 % methanol/ 1 0  % glacial acetic acid in H2O for 3 h at 23°C, then 
destained (staining solution with Coomassie blue omitted).
Reverse zymography
Reverse zymography was performed for detection of TIMPs using a commercial kit, as 
described previously (University Technologies Inc., Calgary, Canada; (Hampton, et al.,
1995) with some minor modifications. Lyophilised cervical explant and fibroblast samples 
(1ml lyophilised sample reconstituted with 50 |xl 0.1% SDS, 7.5 1^ per sample loaded onto 
gel) were separated according to molecular weight by PAGE using 12% gels containing 1 
mg/ml gelatin and an MMP preparation (from BHK-21 cells that constitutively express 
proMMP-2; University Technologies Inc.) The gels were washed (50 mM Tris, 5 mM 
CaCl2, 2.5% (v/v) Triton X-100; for 2.5 h at 23‘’C), then incubated in reverse zymography 
digestion buffer (50 mM Tris, 5 mM CaCl2) for 17 h at 37°C. The gel was counterstained 
(as for zymography) with staining buffer then destained to detect the presence of protein, 
predominantly the ineorporated gelatin. The presence of TIMPs was determined by their 
discrete inhibition of MMP activity, which was visualised as a darker band on a lighter 
background. TIMPs were identified and characterised by comparison with molecular 
weight markers, with control standards of conditioned medium containing mouse TIMP-1, 
-2 and -3 expressed by transfected BHK cells (University Technologies Inc.) and human 
recombinant TIMP-2 (Calbiochem, Nottingham).
Western blot analysis for MMPs -2 and -9 and TIMPs -1 and -4
Cervical explant and cervical fibroblast culture media samples were dialysed (retention 
size >12 kDa) against water, lyophilised and reconstituted in 0.1 % SDS. Samples (20 i^l) 
were prepared in equal volumes of sample application buffer, separated by PAGE and
transferred to a nitrocellulose membrane, pore size 0.45 utû (Bio-Rad) by wet blotting (100 
V for 1 h). Gels were stained with 0.5 % Coomassie Blue to check protein transfer. 
Membranes were blocked with 5 % BSA in 0.05 % v/v Tween Tris Buffered Saline 
(TTBS) prior to antibody application. The following primary antibodies were used; MMP- 
2 and MMP-9 (mouse monoclonal, Insight Biotechnology, Wembley, Middlesex) at 
1:1000 dilution; TIMP-I and TIMP-4 (Affinity purified rabbit polyclonal. Insight 
Biotechnology) at 1:1000 dilution. These were detected using sequentially a biotinyiated 
horse anti-mouse or goat anti-rabbit second antibody in TTBS (1:200 dilution) as 
appropriate and an avidin-biotinylated peroxidase complex according to the manufacturer’s 
instructions (Vector Labs, Peterborough, UK). 3,3 ’ -diaminobenzidine with nickel chloride 
enhancement was used as chromagen.
Immunocyiochemistry for MMP-2 and -9 and TIMPs -1 and -4
Tissue was fixed at the time of collection in 10 % neutral buffered formalin. Paraffin 
embedded sections o f cervix were cut to 5 fxm thickness, dewaxed, rehydrated and 
endogenous peroxidase activity blocked in 2 % H2O2 (Sigma) in H2O for 30 min at 23°C. 
Sections of fetal membranes obtained at elective caesarean section at term were used as 
positive controls. Slides were washed in 0.01 M PBS for 10 min and blocked in diluted 
normal horse serum or goat serum respectively (Vectastain: Vector Laboratories) for at 
least 30 min. Excess blocking solution was removed and slides were incubated with 
primary antibody (antibodies used as per Western blotting protocol) for 18 h at 4°C under 
humid conditions. Primary antibodies were detected using horse anti-mouse and goat anti­
rabbit biotinyiated secondaiy antibodies (Vectastain) incubated for 1 h at 23^C. Avidin- 
biotin complex (Vectastain) was added according to the manufacturer’s instructions. 
Specific immunoreactivity was identified by the application of the chromagen 3,3’- 
diaminobenzidine (Vectastain) that produces a brown colour. Sections were 
counterstained with haematoxylin prior to mounting.
Data analysis
Transmission densitometry (G-700 Densitometer; BioRad) was used to quantify MMP and 
TIMP activity in the zymograms. Parallel background readings of equal area were 
obtained in order to calculate relative intensities from the zymogram gels and calculated 
using dedicated software (Molecular Analyst, BioRad). Densitometric readings were only 
compared between samples run in parallel under precisely the same conditions (i.e. same 
electrophoresis run, same buffers, stains and incubation periods) and were not used for 
comparisons between the pregnant and non-pregnant groups. Statistical analysis was 
performed using Student’s ‘t’-test with p<0,05 regarded as significant.
Results
Production o f MMP-2 and -9 by cervix
(i) Non-pregnant subjects
Zymography showed gelatinase activities corresponding to MMP-2 and MMP-9 at 72 and 
92 kDa molecular weight, respectively (Fig. 5.1). Cervical tissue explants released 
predominantly MMP-2 (72 kDa latent pro-form, 6 6  kDa active form) with lesser amounts 
of MMP-9 activity (92 kDa latent pro-form, 8 6  kDa active form; Fig 5.1a). Cervical 
fibroblasts released only MMP-2 (Fig. 5.1b). Western blotting confirmed the presence of 
MMP-2 protein in non-pregnant cervical explants and in cervical fibroblasts (Fig. 5.2a). 
MMP-9 protein was not detected in either tissue by Western blotting (Fig. 5.2b). 
Localisation using immunohistochemistry showed that MMP-2 was present predominantly 
in the stromal connective tissue with minimal staining in blood vessels or cervical smooth 
muscle (Fig. 5.3a). MMP-9 was localised weakly in some perivascular cells and 
connective tissue stroma.
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Figure 5.1. Zymography showing gelatinase activity (visualised as light bands) in culture 
media from (a) non-pregnant cervical tissue explants and (b) cervical fibroblasts. Matrix 
metalloproteinase (MMP)-2 activity is observed predominantly at 72kDa (latent pro-form) 
and 66 kDa (active form) in both non-pregnant explants and fibroblasts (a,b). MMP-9 
activity is shown at 92kDa (latent pro-form) (a). MMP-9 activity was not detected in 
cultured fibroblasts (b). Both explants and fibroblasts were either untreated (control) or 
treated with NO donor (+ NO donor), mw, standard molecular weight markers (BioRad) as 
marked (kDa): af, amniotic fluid used as positive control.
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Figure 5.2. Western blot analysis on matched samples from pregnant and non- 
pregnant patients using antibodies to (a) MMP-2; (b) MMP-9; (c) TIMP-1 and (d) 
TlMP-4. MMP-2 is shown at 72 kDa (latent pro-form) and 66kDa (active form). 
MMP-9 is shown at 92kDa (latent pro-form) and 86kDa (active form). MMP-9 
activity was not detected. TIMP-1 and TIMP-4 are shown at 27-30kDa. Samples of 
culture supernatant from pregnant women treated with NO donors {in vivo) and 
untreated (control) are shown. Samples from cervical explants and fibroblasts from 
non-pregnant women include those treated with NO donor in vitro (+NO) and 
controls (c). af, amniotic fluid used as a positive control; mw, molecular weight 
markers.
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Figure 5.3. Immunohistochemical localisation in representative sections of 
cervical tissue of (A) MMP-2 (non-pregnant), (B) MMP-9 (non-pregnant). 
(C) MMP-2 (pregnant), (D) MMP-9 (pregnant), (E) TIMP-1 (non-pregnant), 
(F) TIMP-4 (non-pregnant), (G) negative (non-pregnant) control. In non- 
pregnant samples, MMP-2 was present mainly in stromal connective tissue 
with lesser amounts of staining in blood vessels and smooth muscle (A). 
MMP-9 was weakly present in perivascular cells and connective tissue stroma 
(B). TIMP-1 was localised in blood vessels and connective tissue stroma (E), 
while TIMP-4 was identified predominantly in cervical connective tissue 
stroma (F). In pregnant tissue, MMP-2 and -9  were localised in connective 
tissue stroma, surface epithelium and blood vessels (C,D). The localisation of 
TIMP-1 and -4  were similar to that of the non-pregnant tissue (data not 
shown). Key: a, artery; v, vein; s, stroma; e, epithelium; m, muscle. All scale 
bars are 1 OOpm.
(ii) Early pregnant subjects
Zymography demonstrated that the expiants released MMP-2 but not MMP-9 (Fig. 5.4). 
Expression of MMP-2 protein was confirmed by Western blotting (Fig. 5.2a). 
Immunohistochemistry localised MMP-2 and MMP-9 to the connective tissue stroma, 
surface epithelium and blood vessels.
(iii) Effect of NO donors
Treatment with NO donors in vitro or in vivo had no effect on release of MMP-2 and 
MMP-9, as characterised by zymography (Fig. 5.1), Western blot (Fig. 5.2) or 
immimohistochemistiy (data not shown).
Production o f TIMPs by cervix
(i) Non-pregnant subjects
Reverse zymography detected TIMP secretion by non-pregnant cervical tissue and 
fibroblasts (Fig. 5.5). A band representing the 27-30 kDa TIMPs (which may include 
TIMP-1, -4 and the glycosylated foim of TIMP-3) can be seen in both explant and 
fibroblast groups. Western blotting was performed to further delineate the components of 
the 27-30 kDa band obtained by reverse zymography (Fig. 5.2). This was unlikely to 
consist of TIMP-3 since no discrete banding pattern had been obtained on zymography for 
the unglycosylated 28 kDa form. Analysis for TIMPs -I and -4 therefore was performed 
by Western blotting which confirmed the presence of both proteins in the conditioned 
medium from cervical tissue explants of cervical biopsies from non-pregnant women (Fig. 
5.2). Cervical fibroblasts produced TIMP-1 but not TIMP-4 (Fig. 5.2c and d), TIMP-1 
was localised to blood vessels and connective tissue stroma (Fig. 5.3e). TIMP-4 was 
present predominately in the cervical connective tissue stromal cells (Fig 5.31).
(ii) Early pregnant subjects
Reverse zymography showed a similar pattern of secretion of TIMPs by the cervical tissue 
explants of women in early pregnancy as that described for the non-pregnant group (Fig.
5.6). Cervical tissue released mainly TIMPs in the 27-30 kDa range. Smaller amounts of 
21 kDa TIMP-2 were detected. Western blotting confirmed that the banding pattern in the 
27-30 kDa range on zymography corresponded to both TIMP -1 and -4 protein (Fig, 5.2). 
The localisation of TIMP-1 and TIMP-4 were similar to the non-pregnant (data not 
shown).
(iii) Effect of a NO donor
In vitro and in vivo treatment with a NO donor in biopsies from non-pregnant and pregnant 
women had no effect on TIMP activity as confirmed by reverse zymography (Fig.5.5a and 
b), Western blot (Fig 5.2c and d) or immunohistochemistiy (Fig. 5.3c and d).
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Figure 5.4. (a) Zymography showing gelatinase activity in supernatant 
from culture of matched samples o f pregnant cervical tissue explants 
untreated (control) and treated in vivo with NO donor (+ NO). Matrix 
metalloproteinase (MMP)-2 activity is observed predominantly at 72kDa 
(latent pro-form) and 66 kDa (active form). MMP-9 activity is shown 
predominantly 92 kDa (latent pro-form) and at 86 kDa (active form), mw- 
molecular weight markers as marked (BioRad); af-amniotic fluid used as 
positive control.
(b) MMP-2 activity in pregnant cervical tissues in control and samples 
treated in vivo with NO donor, assessed using densitometry. There was no 
significant difference in MMP-2 activity between the groups. Values 
shown are mean + SEM.
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Figure 5.5. Reverse zymography to detect TIMP (visualised as dark bands) in 
supernatant from matched samples of (a) cervical explants from non-pregnant 
tissue, and (b) cervical fibroblasts either untreated (control) or NO donor treated 
(+ NO). Standards of TIMP 1 and 2 (1 + 2 ; separately identified on the gel by 
arrows) and of TIMP 3 (3; identified on the gel in the 27-30 kDa glycosylated 
form [g3] and 24 kDa unglycosylated form [ung3]). af = amniotic fluid used as a 
control.
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Figure 5.6 (a) Reverse zymography to detect TIMPS in culture supernatant 
from culture of pregnant cervical tissue explants either untreated (control) or 
treated with NO donor (+NO donor). Standards of TIMPS 1 and 2 (1+2; 
separately identified on the gel by arrows) and of TIMP 3 (3; identified on 
the gel in the 27-30 kDa glycosylated form [g3] and 24 kDa unglycosylated 
form [ung3]). af = amniotic fluid, used as a control.
(b) TIMP activity (mean and standard error o f the mean) in control and NO 
treated pregnant cervical tissues assessed using densitometry. The TIMPs of 
mw 27-30 kDa represent TIMPs 1 and 4, the 21 kDa TIMP is TIMP-2. 
There was no significant difference in TIMPs when NO treated and control 
tissues were compared.
Discussion
We have demonstrated that MMPs -2 and -9 and TIMPs -1 ,-2  and -4 are present in both 
the pregnant and non-pregnant human uterine cervix. These MMPs and their endogenous 
inhibitors may play a role in the normal turnover of the ECM type IV collagen, elastin and 
fibronectin in the cervix. Our results are supported by that o f Agarwal et al.  ^ (Agarwal, et
ai., 1994) who have previously demonstrated the presence of MMPs -2 and -9 in cultured
non-pregnant endocervical cells by zymography and Western blotting. MMP-9 activity 
has also been shown to be present in the lower uterine segment, considered by some to 
represent the uterine cervix, and to increase along with MMP- 8  activity during labour
(Osmers, et al., 1995).
These studies did not reveal any differences in secretion of MMP-2 and TIMPs -1,-2 and - 
4 in the cervix from pregnant and non-pregnant women. The activity of MMP-9 present 
was lower in the cervix of the pregnant compared with the non-pregnant subjects. This 
decline in MMP-9 may be related to the increase in circulating progesterone levels during 
pregnancy. Physiological concentrations of progesterone suppress IL-1 and PMA 
mediated production of proMMP-9 at the transcriptional level in rabbit cervical fibroblasts
(Imada, et al., 1997) and a suppressive effect of progesterone on MMP-9 secretion has also 
been shown in the endometrium (Marbaix, et al., 1992; Rodgers, et al., 1994). The
reduction in activity of MMP-9 during early pregnancy in the human cervix may be a 
protective effect mediated by progesterone, to prevent premature cervical ripening
(Salamonsen, 1996). Indeed, inhibition of progesterone stimulates cervical ripening as 
shown by studies using anti-progestogens (Leppert, 1995; Rechberger, et al., 1996).
MMP -9 was localised in the cervix of pregnant women by immunocytochemistry although
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its secretion was not detected by zymography. This may be explained by the fact that 
samples of supernatant used for zymography contained very small quantities of MMP-9 
which were below the detection limits of this method and which were therefore 
substantially less than the levels o f MMP-9 present in the non-pregnant state.
We did not detect MMP-9 secretion by cervical fibroblasts in culture. This suggests that 
these cells are not the source of MMP-9 in the non-pregnant human cervix. These data are 
supported by studies in rabbits where cervical fibroblasts in cell culture did not produce the
gelatin degrading enzyme corresponding to proMMP-9 (Imada, et al., 1997). In normal
cycling human endometrium MMP-9 protein has been localised to eosinophils, neutrophils
and monocyte-macrophages by immunohistochemistry (Jesiorska, et al., 1996). It is
probable, therefore, that bone marrow derived cells and not fibroblasts are the source of 
MMP-9 located in the non-pregnant cervix. In this study we used zymography as a semi- 
quantitative measure of the amount of MMP and TIMP activity in our samples. We did 
not attempt to quantitate the protein content o f the samples used for this process although 
tissue samples were all of approximately similar weights (2-4 mg). An alternative 
explanation for the lack of MMP-9 secretion seen in the cervical fibroblast group may 
therefore be that the amount of protein present in the fibroblast preparations was 
considerably less than that in the equivalent whole tissue culture sample.
We used the effects of the potent vasodilator NO on the cervix as a model for cervical 
ripening in our study. NO stimulates cervical ripening in both humans and animals (AH, et
al., 1997; Buhimschi, et al., 1996; Chwalisz, et al., 1996; Chwaiisz, et al., 1997; Thomson,
et al., 1997) and inhibits human cervical contractile activity (Ekerhovd, et al., 1998).
Previous studies using the NO donor IMN in the first trimester of pregnancy demonstrated 
a reduction in the cumulative force required to dilate the cervix prior to suction termination
of pregnancy (Thomson, et al., 1997). This is an established objective method of 
measuring cervical ripening (El Refaey, et al., 1994; Norman, et al., 1991; Henshaw and 
Templeton, 1991). Since we had used the same NO donor, IMN, under the same
experimental conditions as in our previous clinical studies, we were confident that the 
tissue obtained from pregnant women in these studies represented that from a ripened 
cervix.
It has been postulated that cervical ripening may be mediated by the NO and prostaglandin 
pathways acting in concert (Chwalisz, 1988), although the mechanism of NO induced 
cervical ripening remains unclear. NO has powerful vasodilatory properties as well as the 
ability to function as an immune regulator and inflammatory mediator (Moncada, 1997).
Cervical ripening involves macrophage and neutrophil invasion of the cervix with release 
of inflammatory mediators and activation of MMPs capable of degrading the extracellular 
matrix. The activity of MMPs can be modulated by NO and its reactive metabolites via 
interactions with zinc and calcium residues (Drapier and Bouton, 1996). Thus, it would
seem reasonable that cervical ripening mediated by NO would involve activation of 
MMPs. However the NO donors used in our study, isosorbide mononitrate and spermine 
nonoate, had no effect on activity or protein expression of MMPs-2 or 9 or TIMPs -1,-2 
and -4 in the human uterine cervix when given in vitro to non-pregnant subjects or when 
given in vivo to pregnant subjects. Our findings may reflect the effects of using different 
NO donors compared to those investigated previously. Alternatively, other MMPs may be 
stimulated by NO during physiological cervical ripening in humans. The collagenases 
MMP-1 and MMP- 8  may be activated by NO (Murrell, et al., 1995) and MMP- 8  activity 
has been shown to be increased in the lower uterine segment during labour and delivery 
(Osmers, et al., 1995; Osmers, et al., 1995). Activation of proMMP-1 requires the
secretion of MMP-3 (Ito, et a!,, 1988) and cervical change may therefore also be dependent 
upon the presence of this MMP.
In summaiy therefore, the data presented in this chapter has shown that MMP-2 and -9 and 
TIMPs -1,-2 and -4 are active in the human uterine cervix in the non-pregnant and early 
pregnant state. Cervical ripening mediated by NO does not affect the expression of these 
mediators. It should be emphasised that these studies have been done using an in vitro 
system and may therefore not take account of the effects of other endogenous mediators 
acting via a cascade mechanism. Remodelling of the cervix during pregnancy is likely to 
involve MMPs regulated by a complex interaction between progesterone, cytokines, 
prostaglandins and NO. The interaction between NO, prostaglandins and various 
inflammatory cytokines in the process of cervical ripening is evaluated in the next chapter 
of this thesis.
Chapter 6
The effect o f nitric oxide donors on prostaglandin and cytokine 
expression in the human cervix during the first trimester of pregnancy 
Introduction
A wide variety of mediators have been implicated in the control of cervical ripening, 
including prostaglandins and various inflammatory cytokines. Through observation of the 
effects of various antiprogestins in the cervix, it is clear that progesterone is also
fundamentally involved in the hormonal regulation of these events (Chwalisz, 1994;
Chwalisz and Garfield, 1994). There is evidence that various cytokines are also involved.
IL-8 , a C-X-C chemokine, has been shown in vivo (Sennstrom, et al., 1997) and in vitro
(Barclay, et al., 1993) to be produced in the cervix and to be capable of causing ripening 
when artificially applied to the cervix. IL-1 can induce cervical ripening in animal models 
(El Maradny, et al., 1995) and its mechanism of action may involve the co-induction o f IL-
8  (Uchiyama, et al., 1992). Other cytokines, such as TNFa (Chwalisz, et al., 1994) may 
act in concert with IL- 6  to facilitate neutrophil chemotaxis, IL-1 gene expression and 
endothelial adhesion molecule upregulation (Rees, 1992) during this process.
Prostaglandins (PCs) were previously thought to be the final common mediators of 
cervical ripening. Prostaglandin synthesis is controlled by the enzyme cyclooxygenase 
(COX) which converts arachadonic acid to the prostaglandins (PG), prostacyclin (PGI2 ) 
and thromboxane A2 (TXA2 ). COX-1 is the constitutive form of the enzyme while COX-2 
can be induced by a number of other mediators including proinflammatory cytokines and 
growth factors (DeWitt, 1991). PGE2  and PGp2a have both been used to artificially
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mediate cervical ripening in the first trimester of pregnancy and at term (Calder, 1990; 
Neilson, et al., 1983). However other agents must also be fundamental to this process since 
the ripening action of antiprogestins in the cervix cannot be blocked by the use of 
indomethacin (Radestad and Bygdeman, 1992) or the specific cyclooxygenase (COX)-2
inhibitor, flosulide (Shi, et al., 1996). Candidate agents for cervical ripening include 
inflammatory cytokines and NO.
The mechanism of action of NO in the inflammatory cervical ripening process remains 
unknown. NO has been shown to stimulate prostaglandin production via induction of 
COX-2 (Salvemini, et al., 1993; Sautebin, et al., 1994) and also cytokine release (Brady, et
al., 1998; Cuthbertson, et al., 1998) possibly through activation of the transcription factor
Nuclear Factor Kappa B (NF-k B) (Nathan, 1992; Umansky, et al., 1988).
The purpose of this study therefore was to test the hypothesis that NO mediates cervical 
ripening as part of an inflammatory reaction and that it does so via induction of a variety of 
inflammatory cytokines and prostaglandins. We also attempted to compare the effects of 
NO on the production of cytokines and prostaglandins with that of other known mediators 
of cervical ripening.
Materials and methods
All studies were approved by the local research ethics committees and written informed 
consent obtained from each woman prior to surgery.
Subjects
(i) Pregnant women
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Healthy women in the first trimester of pregnancy (7-12 weeks gestation, agel7-41 years, 
mean age 28, n=2 0 ) undergoing suction termination of pregnancy were recruited to the 
study. Women were randomised into 2 groups and treated with either:
(i) 40 mg isosorbide mononitrate (IMN) Tablet (Schwarz Pharma Ltd., East Sussex, 
Chesham, Bucks, England), an NO donor, per vaginam 2-3 h prior to surgery 
(n=1 0 )
(ii) no treatment (controls, n=1 0 ).
Biopsies were taken from the anterior lip of the cervix using a 6  mm biopsy needle (Stiefel 
Laboratories, Wooburn Green, Bucks, UK) under general anaesthetic after evacuation of 
the uterus. Tissue was immediately transferred into Duibecco’s medium for transport. All 
reagents were from Sigma, Poole, UK unless otherwise stated.
(ii) Non-pregnant women
Non-pregnant healthy pre menopausal women undergoing hysterectomy for benign disease 
(ages 34-49, mean age 41, n=10) were recruited to the study. A longitudinal section of the 
anterior lip of the cervix was taken using a scalpel following removal o f the uterus. 
Biopsies were placed immediately in Dulbecco's medium for transport to the laboratory.
Tissue Culture
(i) Cervical biopsies from pregnant women:
Biopsies (12 mg weight, 3-4 mm diameter and 10-14 mm length) were dissected into 14-15 
small pieces (1-2 mm^) and cultured in a 24 well plate in 1.5 mis Duibecco’s medium 
supplemented with streptomycin 100 pg/ml, penicillin 100 U/ml and ftmgizone 100 U/ml 
in 5% C02 and 95% air for 24 h at 37°C. Biopsies were weighed after treatment and tissue 
was either snap frozen in liquid nitrogen and stored at -80°C, or formalin fixed and 
paraffin embedded. Culture media were divided in two portions and either frozen in 250 pi
aliquots at -20°C or treated with methyloximating solution (O.IM methoxylamine 
hydrochloride in 10% alcohol diluted in IM sodium acetate, pH 5.6) prior to freezing.
(ii) Cervical biopsies from non-pregnant women:
Biopsies (20 to 35 mg weight, 15-20 mm length and 2-3 mm diameter) were dissected into
small pieces (1-2 mm^) and cultured in 24-well plates (Costar, High Wycombe, UK) in 
Duibecco’s medium as previously described. Expiants were treated with one of the 
following: (i) Medroxyprogesterone acetate 10”^  M, (ii) Medroxyprogesterone acetate 
(MPA) 10~^  M with Mifepristone 175ng/ml (Roussel Uclaf, Cedex, France) PGEi 1.0 
pg/ml, (iii) Lipopolysaccharide (EPS) 1.0 pg/ml with interferon 7  (IFN 7 ) 60 U/ml, (iv) the 
nitric oxide donor S-nitroso-N-acetyl-D, L-penicillamine (SNAP) at 100 pM or (v) SNAP 
at 200 pM. Experiments were run in triplicate, cultured and stored as previously described.
ELISA assays
IL-}p assay
96 well plates (Costai*, High Wycombe, UK) were passively coated overnight at 4“C with 4 
pg/ml IL-lp capture antibody (R&D Systems, Abingdon, Oxon, UK; diluted in phosphate 
buffered saline (PBS), pH 7.2). Plates were washed after incubation in cold water, coating 
solution added (Polyvinyl pyrollidone 2%, BSA 5 mg/ml, preservatives [(ImM 2- 
methylisothiazolone and ImM bromonitrodioxane) Boehringer Mannheim UK Ltd., 
Lewes, East Sussex, UK; 0.1%, (EDTA 5mM, Tris 50mM)] at 100 pi /well for 30 mins, 
plates were then rewashed, air dried and stored at 4 °C. Plates were washed once in cold 
water prior to adding standards (diluted in ELISA buffer [lOmM TRIS pH 7.2,
preseivatives, BSA 2mg/ml, 300 pi 0.5% Phenol Red solution/1, Na Cl 9 g/1, EDTA 2mM, 
Tween-20 0.05% to final pH 7.2]) and added at 100 pl/well with 250 pg/well as top 
standard. Samples were added (undiluted - 100 pi / well) and incubated overnight at 4“C.
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After washing x4 in wash buffer (0.05% Tween-20, 9g/l NaCi, 100 mM tris, pH 7-7.5) 
detection antibody (25 ng/ml) was added (100 pi /well) and plates were incubated on an 
orbital shaker (1.5 hrs at 23“C) then washed x4 as before. Streptavidin peroxidase 
(Boerhinger Mannheim) was then added at 0.2U/ral and plates were incubated at room 
temperature for 30 mins. Plates were washed again and lOOpl tetramethyl benzidine 
(TMB) substrate added to each well. Plates were left for 20 mins before quenching with 
50pl 2N sulphuric acid and were read at 450 nm within 30 mins of quenching.
IL-8 assay
IL- 8  ELISA was performed as previously described (Denison, et al., 1999) using paired 
capture and biotinylated labelled detection antibodies. Capture antibody was used at
4pg/ml with 100 pi /well and detection antibody at 30ng/ml (both R & D  Systems).
Standards were donated from Toray Industries Inc, Tokyo, Japan with 500pg/well as top 
standard. Streptavidin peroxidase was added to each well at 0.2U/ml and antibody binding 
was detected using TMB as substrate. Detection limit of the assay was 15pg/ml. The intra- 
and inter-assay coefficients were 9.1% and 11% respectively.
IL-6 assay
A  similar protocol was followed for the detection of IL- 6  with the use of capture and 
biotinylated secondary antibodies. Capture antibody was used at 4pg/ml and detection 
antibody at 50 ng/ml. Recombinant standards (R&D Systems) and samples were added to 
wells with 250 pg/ml as top standard. Plates were read and detected as before.
MCP-Î assay
MCP-1 ELISA was as previously described (Denison, et ai., 1997). Capture antibody 
(gifted from Toray) was used at 4 pg/ml and peroxidase coupled detection antibody added
at 60 pEwell. Top standard was 500 pg/well. Plates were read and detected as before. The
intra- and inter-assay coefficients were 6.3% and 8 .6 % respectively. Detection limit of the 
assay was 7.5 pg/ml.
IL-Î 0 assay
IL-10 assay was performed as previously described (Denison, et al., 1999). Capture 
antibody (Pharmingen, Sandiego, USA) was used at 200 ng/ml and detection antibody at 
125ng/ml. Recombinant standards (Pharmingen, Sandiego, USA) were added with 500 
pg/ml as top standard. Poly-peroxidase (CLB Laboratories, Amsterdam, Holland) was used 
at 1 ng/ml in ELISA buffer and plates read and detected as before. The intra- and inter- 
assay coefficients were 6.4% and 10.1% respectively. Detection limit was 15 pg/ml.
IL-Î 5 assay
Anti-human IL-15 capture antibody (R&D Systems) was used diluted in O.IM NaHCOs 
pH 8.4 and incubated overnight at 4 “C. Capture antibody was removed, plates were 
blocked (10% PCS in PBS at 200 pi /well at 37 °C for 2 hrs) washed (x2 in PBS/Tween) 
and standards [diluted in 10% PCS in PBS with I.5pg/ml as top standard (Gifted by Dr A 
Gracie, Dept of Medicine, Glasgow Royal Infirmary)] and samples added (100 pi /well). 
Plates were incubated (37“C for 2 hrs) washed x4 as before and detection antibody added 
[(R&D Systems); diluted at 200 ng/ml; 100 p i /well and incubated at 37°C for 2 hrs]. 
Plates were washed x6  and extravidin-peroxidase (SAPU 1/1000) diluted in 10% PCS in 
PBS added at 100 pi /well. Plates were detected and read as described previously.
TNF~a
Paired capture (4 pg/ml) and detection antibodies [(100 ng/ml); both R&D Systems)] were
used to detect bound standards and samples. Standards (R&D Systems) were added with 
5000pg/well as top standard,
PGE2 Assay
PGE2  assay was performed as previously described (Denison, et al., 1999). The intra- and 
inter-assay coefficients were 7.8% and 15 % respectively and the ED50 was 195 pg/ml.
PGEM assay
A similar protocol was used to detect PGEM. Peroxidase conjugated PGEM was added at 
1 in 50,000 diluted in ELISA buffer and anti-sera at 1.0 xlO^ in assay buffer. Standard 
range of the assay was 1280pg/ml to 2.5 pg/ml. Methyloximating solution was present in 
all standards and samples at a final concentration of 12.5%. ED50 was 220 pg/ml.
6-OXO-PGF2a
6 -OXO-PGp2a  was detected using a similai' protocol. Peroxidase conjugate was added at 1 
in 2.0 X 10  ^ and antisera added at 1 in 10, 000. The standard range of the assay was 10240 
pg/ml to 5 pg/ml. 25% methyloximating solution was present in all samples and standards.
Thromboxane B2
Assay was perfoimed using the same protocol. Peroxidase conjugate was used at 1 in 1.25
X 1 0  ^ and antisera at 1 in 25, 0 0 0 . Standard range of the assay was 327.7 ng/ml to 0.04 
ng/ml. Methyloximating solution was present in all standards and samples at a final 
concentration of 12.5%.
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PGF2a
Peroxidase conjugated PGF2Ct was added at 1 in 1.0 x 10  ^ and antisera at 1 in 20,000. 
Standard range of the assay was 5120 to 10 pg/ml. ED50 was 220 pg/ml.
PGFM
Peroxidase conjugated PGFM was added at a concentration of 1 in 40, 000 and antiserum 
at 1 in 50,000 diluted in ELISA buffer. The standard range of the assay was 327.7 ng/ml to 
0.04 ng/ml.
RNA extraction
Total RNA was isolated from cervical tissue explants using an adaptation of the method of 
Slater et aL, (Slater, et al., 1995). Briefly, 1ml trizol (Gibco Life Technologies, Paisley, 
UK) was added to tissue samples and incubated overnight. RNA was isopropyl alcohol- 
chloroform (BDH, Glasgow, UK) precipitated and the supernatant removed. The pelleted 
RNA was washed in 75% ethanol and resuspended in DEPC-treated water. The RNA yield 
was determined spectrophotometrically at 260/280nm.
Reverse transcriptase-polymerase chain reaction (RT-PCR) analysis 
Reverse transcription was used to identify expression of COX-1 and COX-2 in cervical 
tissue explants by an adaptation of the method of Slater et al, (Slater, et al., 1995). 3 pg 
total RNA was reverse transcribed into cDNA using Superscript II reverse transcriptase 
(Gibco Life Technologies) in 20pl of reaction buffer [(lOxPCR buffer, 25pM MgCl2, O.IM 
DTT (Gibco Life Technologies), 10 mM dNTP and 50ng/ml random hexamers 
(Boehringer Mannheim)]. 5 p\ cDNA was used for PCR amplification with either COX-1,
COX-2 or glyceraIdehyde-3-phosphate dehydrogenase (GAPDH) primers (Gibco), Primer 
sequences were: COX-1 (sense) 5’- TGCCCAGCTCCTGGCCCGCCGCTT-3’, COX-1
(antisense) 5’-CCATGGCCCAAGGCCTTG-3’ (Slater, et a l,  1998); COX-2 (sense) 5'- 
TTCA A A TG A G A TTG TG G G A A A A TTG CT-3', COX-2 (an tisen se ) 5'- 
CCACCCATGGCAAATTCCATGGCA-3' (Iniguez, et aL, 1998); GAPDH (sense) 5'- 
CCACCCATGGCAAATTCCATGGCA-3',5'-TCTAGACGGCAGGTCAGGTCCACC-3’ 
(Slater, et aL, 1998). PCR was performed in a 50 pi volume of reaction buffer containing 
lOxPCR buffer, 25mM MgCl2,2mM dNTPs, 1.3 jaX primer 1,1.0 /^ 1 primer 2, 5% dimethyl
suiphoxide (DMSO) and 0,l//d taq polymerase (Gibco Life Technologies). The reaction
was amplified by 35 cycles of 94'^C for 1 min, 60'C for 1 min and 12‘^C for 1 min. Products 
were run on agarose gels and bands visualised using ethidium bromide.
Immunohistochemistry
Immunohistochemistry protocols for the detection of IL-1 j8, IL-6, IL-10, IL-15, MCP-1, 
TNFa, COX-1, COX-2, and prostaglandin dehydrogenase (PGDH) were established to 
determine the correct conditions for optimal staining (Table 6.1). PGDH is a nicotinamide 
adenine dinucleotide (NAD^)-dependent 15-hydroxy-prostaglandin dehydrogenase 
responsible for prostaglandin metabolism.
Table 6.1.
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Antigen Clone Pretreatment Dilution Supplier
COX-1 monoclonal nil 1/750 Cayman
Chemical
COX-2 AA 585-604 nil 1/750 Santa Cruz
PGDH monoclonal nil 1/1500 Cayman
Chemical
IL-lp rhIL-lp microwave 1/50 R&D Systems
IL-6 rhIL-6 microwave 1/150 R&D Systems
IL-8 natu ra l IL -8 , 
rhIL-8
microwave 1/25 R&D Systems
IL-10 rhIL-10 microwave 1/350 R&D Systems
ÏL-15 monoclonal microwave 1/150 R&D Systems
TNFa rhTNFa microwave 1/150 R&D Systems
MCP-1 77AA MCP-1 NBF 1/400 Gifted
COX-2, ÎL-îp, IL-6, IL-8, IL-10 and TNFa.
Sections 5pm thick were cut from paraffin embedded cervical samples and mounted on
silane coated slides, heated to 60 “C for 35 min, deparafïînised in xylene and rehydrated in 
graded alcohol series. Sections were placed in 0.5% hydrogen peroxide in methanol to 
block endogenous peroxide activity. If required, sections were pre-treated to retrieve the 
antigen by microwaving at full power for 5 mins in 0.0IM citrate buffer pH 6.0. Sections 
were washed in PBS (PBS +0.1% saponin for microwaved sections) then blocked in 20%
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rabbit serum with 20% human serum for 30 mins at room temperature. Slides were then 
incubated overnight at 4°C with the primary antibody diluted in 2% normal rabbit serum 
with 5% normal human serum. Sections were washed in PBS (+/- 0.1% saponin) before 
incubation with biotinylated anti-goat (Vector Laboratories) diluted 1:200 in 2% normal 
rabbit serum with 5% normal human serum added. The sections were washed as before in 
PBS (+/- 0.1% saponin) then incubated for 30 mins with avidin/ biotin horseradish 
peroxidase reagent (Vector Laboratories, Peterborough, UK) in PBS before final washing. 
The antigens were localised by incubating slides for 10 mins with 1 mg/ml 
diaminobenzidene tetrahydrochloride (DAB), 0.02% H2O2 in 50mM Tris HCl, pH 7.6 and 
appeared as a brown end product. Sections were then counterstained with Harris 
haematoxylin.
Negative controls included sections incubated without the primary antibody. Kidney and 
endometium (Jones, et al., 1997) were used as positive controls for COX-2 and tonsillar 
tissue was used as a positive control for IL-lp, IL-6, IL-8, IL-10 and TNFa. To assess the
specificity of the staining for COX-2 and TNFa representative slides were included where 
the primaiy antibody was preabsorbed with the appropriate peptide (COX-2 blocking 
peptide from Santa Cruz Biotechnology, sc-1745P; recombinant human TNFa from R&D 
Systems, 210-TA-010) as per the method of Van Noorden (Van Noorden, 1993).
IL-15, COX-1 and PGDH
Paraffin embedded sections were prepared as before and pretreated in order to retrieve the 
antigen if necessary (Table 6.1). Sections were then preincubated in 20% goat serum and 
20% human serum for 30 mins at room temperature. They were then incubated with the 
appropriate monoclonal antibody diluted in 2% normal goat serum in PBS (+/- saponin) 
with 5% human serum added and left overnight at 4°C. Primary antibody was omitted from 
the negative control slides. Sections were then washed in PBS (+/- saponin) and incubated
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with biotinylated goat anti-mouse (Dako) diluted 1/200 in 2% normal goat serum in PBS 
(+/- saponin) with 5% normal human serum added for 30 mins at room temperature in a 
humidified box. Sections were washed and incubated again with streptavidin peroxidase 
(Dako, Cambridge, UK) diluted 1/400 in PBS (+/- saponin) before washing and final 
treatment with DAB as before.
MCP-1
MCP-1 was localised in frozen tissue sections as described previously (Jones, et a l, 1997). 
Tonsillar tissue was used as positive control and negative control slides were set up with 
either no primary antibody or non-immune rabbit IgG.
Analysis
Statistical analysis of IL-lp, IL-6, IL-8, IL-10, IL-15, M C P -1, T N F a , P G F ia , PGE2, 
PG F M , PG E M , 6-O X O -P G F 2a  and T X B 2 levels in culture media was performed using 
analysis of variance (Statview SE + Graphics v.1.04. Abacus Inc; Berkley, CA, USA). 
Significance was determined using Scheffe’s F-test as a post-hoc test.
Results are expressed as mean level pg/ml ± s.e.m with p<0.05 taken to indicate 
significance.
Results
Effect o f NO donors on pregnant first trimester human cervix:
(i) I L - lp , IL -6 , IL -8, IL -10 , IL -15 , M C P -1 , T N F a release:
Tissue explants of first trimester cervix released IL-6, IL-8, IL-10, IL-15, MCP-1 and 
T N F a  (Figure 6.1). IL-1^ was not released. In vivo treatment with the N O  donor isosorbide 
mononitrate did not significantly alter the release of these cytokines from the first trimester 
cervix in culture.
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(H) Immunohistochemistry for IL-lp, IL-6 , IL-8 , IL-10, IL-15, M C P -I , TN F a: 
Immunohistochemistry localised staining for IL-lj8 to the epithelium, glands and blood 
vessel endothelium (Figure. 6.2a). IL- 6  was present in the epithelium and in perivascular 
structures (Figure 6.2b). Staining for IL- 8  was confined to the epithelium and blood vessel 
endothelium (Figure 6.2c). IL-10 stained strongly in the epithelium and weakly in the 
blood vessels (Figure 6.2d). IL-15 stained strongly in the epithelium and blood vessels and 
more weakly in the cervical connective tissue stroma (Figure 6.2e). Staining for T N F a  was 
localised to the surface epithelium with a small amount of perivascular staining also being 
present (Figure 6.2f). MCP-1 staining was present strongly in perivascular stiuctures and in 
the surface epithelium (Figure 6,2g).
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Figure 6,1 The effect o f in-vivo treatment with the nitric oxide (NO) donor isosorbide mononitrate (IMN) on 
cytokine levels in cervical tissue in the first trimester o f pregnancy. Concentrations of interleukin (IL)-6, IL-8, IL- 
10, IL-15, monocyte chemoattactant protein (MCP)-l, tumour necrosis factor-a (TNF)-a in supernatant from 
cervical explants o f 10 control patients and 10 patients treated with the NO donor IMN 40mg in vivo were 
measured by enzyme linked immunosorbent assays. The increase in IL-8 concentration in the NO donor treated 
group was not statistically significant.
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Figure 6.2 Immunostaining of interleukin (IL)-l (a), IL-8 (b), IL-15 (c), 
monocyte chemoattractant protein-1 (MCP-I) (d), IL-6 (e), IL-10 (f). tumour 
necrosis factor (TNF)-a (g) in cervical tissue biopsy specimens from early 
pregnant subjects, bv = blood vessels, e = epithelium, s = stroma. Original 
magnification: (a, e, f) x94, (b,g) x48, (c) x60, (d) x75
139
O)Q.
(D
%
0)
2
Ç
yc
35
Io
4000
3000
□  Control
■  NO
2000
1000
PGF2a PGE2 PGFM PGEM 6 -0X 0  19-OH TXB2
Prostaglandin
Figure 6.3 Tlie effect of in-vivo adiiiiiiistration o f tlie nitric oxide (NO) donor isosorbide mononitrate (IMN) on 
prostaglandins in tlie cervix in the first trimester of pregnancy. Concentrations of prostaglandin (PG) Fzoc, PGE2 , 
PGFM, PGEM, ô-OXO-PGFsa, and tliromboxane (TX)Bz were measured in supernatant from cultured cervical 
explants by enzyme linked iimnunosorbent assays in 10 control patients and 10 patients treated with the NO 
donor IMN 40 mg in vivo. Treatment with IMN stimulated PGF^a release (P < 0.05) and hihibited TXB2  release 
(P < 0.01). Values are expressed as pg/ml ± SEM.
(iii) PGF2 0 , PGE2 , PGFM, PGEM, 6 ~OXO~PGF2 a and TXB2  release:
Cervical expiants from first trimester cervix released PGF2«, PGE2 , PGFM, PGEM, 6 - 
OXO-PGF2a and TXB2  (Figure 6.3). Treatment with the NO donor IMN in vivo stimulated 
PGF2a  release (P<0.05) and inhibited TXB2  release (p<0.01). There was no significant 
effect of the NO donor isosorbide mononitrate on the levels of PGE2 , PGFM, PGEM and 
6 -OXO-PGF2CL.
(iv) Immunohistochemlstry for COX-1, COX-2 and PGDH:
Immunohistohemistry was performed to localise the enzymes COX-1, COX-2 and 
prostaglandin dehydrogenase (PGDH) to the cervical tissue in both NO treated and control 
patients (Figure 6.4).
Staining for COX-1, COX-2 and PGDH was present in both NO treated and control 
subjects. COX-1 was localised strongly to the superficial layers of the surface glandular 
epithelium and weakly to the connective tissue stroma (Figure 6.4a). COX-2 staining was 
also strong in the glandular epithelium and perivascularly with weaker staining in the 
stroma (Figure 6.4b). Staining for PGDH showed a similar pattern (Figure 6.4c).
(v) RT~PCRfor COX-I and COX-2:
RT-PCR was performed to identify the presence of mRNA for COX-1 and COX-2 in the 
cervix. The primer pairs yielded amplified products of the expected sizes: 304 bp for COX- 
1, 305 bp for COX-2 and 598 bp for GAPDH. Gel electrophoresis for COX-1 and COX-2 
is shown (Figure 6,5; Figure 6 .6 ). There was no contamination by amplified cDNA as 
assessed by appropriate negative controls. COX-1 was present in the pregnant cervix. 
Treatment with NO donors in vivo had no apparent effect on COX-1 expression. COX-2 
was not present in cervical tissue samples obtained from pregnant women in the first
trimester (n=2) but was expressed in two of three samples obtained after treatment with the 
NO donor isosorbide mononitrate.
Effect o f NO donors in vitro on non-pregnant human cervix
(i) IL-6 , IL-8 , IL-10, IL-15, MCP-1, T N F a release:
Non pregnant cervical explants released IL -6 , IL -8 , I L -10, I L -15, M C P -1, T N F a  as 
assessed by E L IS A  (Figure 6.7). The production of these cytokines was not affected by 
treatment with either the nitric oxide donor S N A P  at concentrations of lOOjJiM or 200|jiM, 
by bacterial LPS and IF N  y in combination, by P G E i, by M P A  or by mifepristone + M P A  
(data not shown).
(ii) PGF2 0 , PGE2 , PGFM, PGEM, 6 -OXO-PGF2 a and TXB2  release:
In contrast to the in vivo pregnant group, non-pregnant cervical explants treated with the 
NO donor SNAP in vitro did not show any significant change in the release of PG F2a or 
TXB2 (Figure 6.8). RT-PCR for COX-1 and COX-2 confirmed the presence of mRNA in 
non-pregnant control ceiwical tissue and tissue treated with the NO donor SNAP (Figure 
6.5, Figure 6 .6 ).
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Figure 6.4. Immunostaining of cyclooxygenase (COX)-l (a), 
COX-2 (b) and prostaglandin dehydrogenase (c) in cervical tissue 
biopsies from early pregnant subjects, bv = blood vessels; e = 
epithelium; s = stroma. Original magnification: (a) x94; (b) x83; 
(c) x65.
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Figure 6.5 Reverse transcription-polymerase chain reaction showing COX-1 
expression in cervical tissue biopsies from non-pregnant [± the NO donor S- 
nitrosos-N-acetyl-D,L-penicillamine (SNAP) in vitro] and pregnant subjects [± the 
NO donor isosorbide mononitrate (IMN) in vivo]. Lane 1: molecular weight 
markers.Lane 2: positive control. Lanes 3-6: non-pregnant control tissue. Lanes 7 
and 8: pregnant control tissue. Lanes 9-11: pregnant tissue treated with IMN in 
vivo. Lanes 12-14:non-pregnant tissue treated with SNAP in vitro. Lanes 15 and 
16: positive controls. Control lanes for GAPDH are also shown. COX-1 mRNA is 
expressed in all tissue samples.
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Figure 6.6 Reverse transcription-polymerase chain reaction showing COX-2 
expression in cervical tissue biopsies from non-pregnant [± the NO donor S- 
nitroso-N-acetyl-D,L-penicillamine (SNAP) in vitro] and pregnant subjects [± the 
NO donor isosorbide mononitrate (IMN) in vivo]. Lane 1; molecular weight 
markers. Lane 2-4 non-pregnant control tissue. Lanes 5 and 6: pregnant control 
tissue. Lanes 7-9; pregnant tissue treated with IMN in vivo. Lanes 10 and 11 ;non- 
pregnant tissue treated with SNAP in vitro. Lane 12; positive controls. Control 
lanes for GAPDH are also shown. COX-2 mRNA was present in non-pregnant 
tissue ± the NO donor SNAP given in vitro. In pregnant tissues COX-2 mRNA 
was not detected in the two control samples shown (Lanes 5 and 6). COX-2 
mRNA was detected in two of the three samples from pregnant women treated 
with the NO donor IMN in vivo (Lanes 7 and 8).
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Figure 6.7. The effect of in vitro administration of the nitric oxide donor SNAP on cytokine production in the 
non-pregnant cervix. IL-6, IL-8, IL-10, IL-15, TNF and MCP-1 levels were measured by enzyme linked 
immunosorbance assay in supernatant from cultured cervical tissue explants treated in vitro for 24 h with 
Iipopolysaccharide and interferon y (LPS+IFNy); SNAP at lOOpM; or SNAP at 200pM. Tissue treated with 
culture medium only acted as controls. Values are expressed as pg/ml ± s.e.m.
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Figure 6.8. The effect of in vitro administration of the nitric oxide donor SNAP on prostaglandin production in 
non-pregnant cervical explants in culture. Prostaglandin production was measured in tissue culture supernatant 
after 24 hour's culture by enzyme linked immunosorbance assay. Explants were either untreated (controls) or 
stimulated with lipopolysaccharide and interferon y (LPS+IFNy ). SNAP at lOOpM or SNAP at 200p.M. Values 
are expressed as pg/ml + s.e.m.
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Discussion
The data presented here shows that the in vivo administration of the NO donor, IMN, in the 
first trimester of pregnancy stimulates increased cei^ical production of PG F2a. Therefore 
previously reported effects of IMN in inducing cervical ripening seem to be in part 
mediated through the production of PG F2a. Our findings are in agreement with previously 
published reports where NO has been shown to activate PG F2a in human microglial cells 
(Janabi, et ah, 1996).
Cervical ripening in pregnancy is known to involve increased production of the prostanoids 
PGE2 PGF2« and PGI2  within the cervix (Ellwood, et ah, 1980). Although PGE2 is
considered to be the most important of these (Calder and Greer, 1992), PG F2a may also be
fundamentally involved. Animal studies have shown that the histological changes, which 
occur in the cervix after the administration of PG F2a are comparable with the changes 
observed in control animals undergoing spontaneous labour. Studies in humans have also 
shown that PG F 2a can be used to artificially induce cervical ripening in both the first
trimester of pregnancy prior to suction termination (Arias, 1984; Rath, et ah, 1982) and at 
term (MacLennan, et ah, 1994; MacLennan and Green, 1979). PG E2 and PG F 2a have 
similar effects on cervical ripening when used in equipotent doses (MacKenzie and
Embrey, 1979; Keirse, 1993) but PGE2 remains the most commonly used agent for this
purpose due to the reduced incidence of side effects encountered using a clinically 
effective dose.
We postulated that any increase in P G F 2a in the cei'vix might be mediated via either an 
increase in COX activity or expression. The NO and COX systems have often been shown
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to be present in concert in inflammatory conditions (Saivemini, 1997) and NO may 
activate cyclooxygenase through a cGMP independent mechanism (Saivemini, et ah, 1993; 
Uno, et al., 1997). ïmmunohistochemistiy localised COX-1 to the superficial epithelium
and to the connective tissue stroma while COX-2 was localised in the cervix in a similar 
pattern. RT-PCR on first trimester cervical tissue did not attempt to be quantitative and 
showed the presence of mRNA for COX-1 in both NO treated patients and controls but 
only showed the presence of mRNA for COX-2 in two of the samples from the NO treated 
group. The difference in the control and NO treated groups should be interpreted with 
caution because of the small number of patients studied. NO may directly interact with 
COX-2 to cause an increase in PGF2abut whether this is achieved by an increase in 
enzyme activity via free radical stimulation of COX-2 or an increase in enzyme production 
requires fijrther study.
In vitro, SNAP appeared to have no effect on prostaglandin production. We hypothesise 
that this may be due to lack o f paracrine interaction in the in vitro situation. During 
cervical ripening, NO may act as an inflammatory mediator causing vasodilatation, 
changes in vascular permeability and activation of cytokines and other proinflammatory 
mediators. Although the role of NO in the process of lymphocyte trafficking is unclear, it 
has been suggested that high levels o f NO produced in response to iNOS upregulation 
during acute inflammation contribute to leukocyte and platelet adhesion to the vascular
endothelium (Clancy, et al., 1998). NO is also involved in lymphocyte signalling through
enhanced activation of a tyrosine kinase p56 (Clancy, et al., 1998). Thus the lack of active
tissue perfusion and hence the inability for such complex interactions to take place within 
the in vitro tissue culture system may explain the lack of effect witnessed in the group 
treated with SNAP in vitro. Alternatively, the difference between the groups could be 
related to the fact that the in vivo studies were carried out on pregnant cervix and may
149
therefore reflect changes which may occur in the maternal immune response during 
pregnancy designed to prevent fetal allograft rejection (Wegmann, et al., 1993).
Other previously published reports however show that NO donors in vitro are capable of 
stimulating prostaglandins in non-pregnant cervix (Denison, et al., 1999). This may reflect
the different NO donors used in these studies compared to those that we employed. Under 
different in vitro experimental conditions it has also been shown that NO can either have
no effect on prostaglandin release (Curtis, et al., 1996; Tsai, et al., 1994) or can actually 
inhibit prostaglandin production at high concentiations (Swierkosz, et al., 1995). The
discrepancies between our own and other reported studies may reflect differences in cell 
types, alterations in the active state of the cells examined and differences in the amount of 
iNOS and COX-2 present as well as variation in the type and doses of the NO donors used.
Our studies have also demonstrated that IMN administered to the first trimester cervix 
causes a decrease in thromboxane B2 release. Thromboxane 8 2  is the metabolic break 
down product of the arachadonic acid derivative thromboxane Â2 which plays a crucial 
role in platelet functioning. Following platelet activation, the release of TXA2 causes 
vasoconstriction and stimulates platelet aggregation. Organic nitrates such as IMN are 
known to reduce platelet adhesion and aggregation as well as causing vasodilatation
(Parker and Parker, 1998) and endogenous NO has similar effects (Radomski, et al., 1987; 
Saivemini, et al., 1990). Our studies suggest that the effect of NO in inhibiting platelet
aggregation may be in part mediated by a decrease in thromboxane synthesis. Alternatively 
the decrease in thromboxane 8 2  after treatment with NO may reflect substrate shift the 
arachadonic acid pathway being preferentially driven to increase production of PGF2a.
Our studies failed to show any significant effect of in vivo or in vitro administration of NO 
donors on cytokine production within the cervix. In vivo administration of IMN to the
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pregnant cervix resulted in an increase in IL-8 release, which was not statistically 
significant. Using other NO donors, NO has been shown previously to stimulate IL-8
production in both the cervix (Denison, et al., 1997) and in peripheral blood monocytes 
(Cuthbertson, et al., 1998). However, this relationship seems to vaiy with the NO donor 
used as Cuthbertson et al. (Cuthbertson, et al., 1998) also showed that 3-
morpholinosydnonimine (SIN), a combined NO and superoxide donor, was capable of 
decreasing IL-8 release from blood monocytes. Our results may be attributable to the 
specific effects of the NO donors used or to the small sample size studied.
In summary, this study has shown that the effects of the nitric oxide donor IMN when used 
to effect cervical ripening in pregnancy may be in part mediated by an increase in PG F2a. 
T X B 2 release is inhibited during this process. We suggest that the paracrine interaction of 
NO with other inflammatory mediators and growth factors is important in this process 
since the same effect was not seen in the in vitro situation. Further studies are required to 
examine how NO interacts with cytokines and prostaglandin metabolites 
in the process o f endogenous cervical ripening at term during pregnancy and how 
interactions occur with NO and PG F2a at a molecular level.
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Chapter 7
Changes in cell adhesion molecule expression in the human uterine cervix 
and myometrium during pregnancy and parturition 
Introduction
In chapter 4 of this thesis we showed that at least part of the increase in NO production 
within the cervix during ripening is attributable to increased expression in invading 
leukocytes. Accumulating evidence suggests that parturition in the human represents an 
inflammatory process involving a wide variety of mediators, with leukocytes now 
recognised to play a crucial role (Bokstrom, et al., 1997; Junquiera, et al., 1980; Liggins, 
1981; Owiny, et al., 1995; Thomson, et al., 1999). The placenta, fetal membranes and 
decidua develop a leukocytic infiltrate and leukocytes, predominantly neutrophils and 
macrophages, infiltrate the cervix during ripening (Bokstrom, et al., 1997; Junquiera, et al., 
1980; Liggins, 1981; Owiny, et al., 1995) and the myometrium during spontaneous labour 
(Thomson, et al., 1999;Halgunset, et al., 1994; Rosenberg, et al., 1996),
The factors controlling leukocyte infiltration into the uterus and cervix during parturition 
are incompletely understood. However, in other tissues leukocyte infiltration from the 
vasculature is controlled by the expression of a number of cell adhesion molecules present
on both the leukocyte cell surface and the vascular endothelium (Frenette and Wagner, 
1996; Zimmerman, et al., 1997). During inflammation, increased expression of these cell
adhesion molecules controls the aggregation and extravastation of leukocytes. Cell 
adhesion molecules of the selectin, integrin and immunoglobulin families are involved in 
this complex process which involves leukocyte slowing, rolling, activation and migration 
into tissues (Bevilacqua, 1993; Imhof and Dunon, 1995; Ley, et al,, 1998; Springer, 1990;
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Tedder, 1995). Recent evidence suggests that cell adhesion molecules have a variety of 
other biochemical and physiological functions including the regulation of cellular 
differentiation, gene transcription, angiogenesis, apoptosis and cell signalling (Bischoff,
1997; Buckley, et ah, 1998; Cavenagh, et ah, 1998; Freemont, 1998; Gumbiner, 1996;
Zimmerman, et al., 1997).
Clearly an improved understanding of the mechanisms involved in controlling the 
inflammatoiy events in both the cervix and myometrium is crucial to our understanding of 
the control of parturition. Previous immunohistochemical studies have described changes 
in cell adhesion molecule expression in the vascular endothelium of human lower segment 
myometrium during parturition (Thomson, et ah, 1999; Winkler, et ah, 1998). More
recently, Winkler et ah, (Winkler, et ah, 2000) have reported a significant increase in
intercellular adhesion molecule-1 (lCAM-1) protein levels in lower segment myometrium 
following the onset of labour, determined using enzyme-linked immunosorbent assay. 
Whilst cell adhesion molecules have been reported in non-pregnant human ceiwix,
(Coleman and Stanley, 1994; Johansson, et al., 1999), their expression in the cervix during
pregnancy and parturition has not been determined.
We hypothesised that cell adhesion molecules are fundamental to the control of leukocyte 
infiltration in the human cervix and myometrium, during late pregnancy and the onset of 
labour. Further, we hypothesised that changes occurring in the cervix are fundamentally 
different from those occurring in the myometrium, reflecting the functional and structural 
differences between these tissues (Bokstrom, et al., 1997; Calder, 1994; Danforth, 1947;
Thomson, et al., 1999). The aims of this study were therefore (1) to examine the expression 
of ICAM-1, vascular cell adhesion molecule (VCAM), platelet-endothelial cell adhesion
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molecule (PECAM) and E-selectin in human uterine cervix during pregnancy and 
parturition using both qualitative (immunohistochemlstry) and quantitative (Northern 
blotting) methods; (ii) to determine whether expression of these adhesion molecules in 
cervix and myometrium is influenced by pregnancy, (by analysing samples from non­
pregnant and pregnant women); and (iii) to identity whether cells within myometrium and 
cervix, other than the vascular endothelium, express adhesion molecules during pregnancy 
and labour.
Materials and Methods 
Subjects
Non pregnant women undergoing hysterectomy and pregnant women undergoing 
Caesarean section were recruited to the study. The study was approved by the local 
research ethics committee and written informed consent was obtained from each woman 
prior to the onset of surgery. Biopsies of cervical tissue and of myometrium were obtained 
from three gi oups of women:
(i) Non pregnant women with regular menstiual cycles undergoing hysterectomy for 
benign disease (n=8)
(ii) Pregnant women at term (>37 weeks gestation) undergoing elective Caesarean 
section prior to the onset of labour (n=8)
(iii) Pregnant women at term undergoing emergency Caesarean section during 
spontaneous labour (cervical dilatation >4cm and <9cm) (n=8)
Cervical biopsies in group (i) were obtained from the anterior cervical lip immediately 
following hysterectomy. In group (ii) biopsies were obtained from the lower part of the 
cervix per vaginam prior to Caesarean section. Cervical biopsies in group (iii) were 
obtained after the delivery of the infant, the cervix being approached via the uterine
154
incision. Myométrial biopsies in group (i) were obtained from the anterior wall of the 
lower uterine body following removal of the uterus at the time of hysterectomy. In groups
(ii) and (iii), the biopsy of myometrium was obtained from the upper margin of the lower 
uterine incision at Caesarean section. In all myométrial biopsies, myometrium was 
separated from surrounding structures i.e. endometrium and decidua, by sharp dissection.
The cervical and myométrial samples were divided; half was snap frozen in liquid nitrogen 
and stored at -70 C for use in Northern blotting and half was fixed in 10% neutral buffered 
formalin and paraffin embedded for immunohistochemlstry.
Characterisation of biopsies
Immunohistochemistiy using anti-myosin smooth muscle antibody (Table 7.1) was 
performed to confirm tissue origin by quantifying the smooth muscle content of paraffin 
embedded sections of cervical and myométrial biopsies (see Immunohistochemistry 
methods). The presence of leukocytes in the tissue in each of the three groups was 
examined using immunohistochemistry with an antibody directed against CD 45, the 
common leukocyte antigen (Table 7.1).
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Table 7.1 Primary antibodies used in immunohistochemistry
Antibody Clone Section type 
(pretreatment)
Dilution Source
E-Selectin polyclonal paraffin
(microwave)
1:500 R+D (Abingdon,UK)
ICAMl polyclonal paraffin
(microwave)
1:1000 R+D (Abingdon,UK)
PECAM clone JC/70A paraffin
(microwave)
1:500 Dako (Cambridge,UK)
CD 45 2B11+PD7/26 paraffin
(microwave)
1:100 Dako (Cambridge,UK)
VCAM polyclonal paraffin 
(no pretreatment)
1:1000 R+D (Abingdon,UK)
Myosin hSM-V paraffin
(microwave)
1:250 Sigma (Poole,UK)
Northern analysis of myometrium
Total RNA was extracted from the myométrial samples (n=5 in each group) using the 
RNAzoff^ B method according to the manufacturers instructions (Biogenesis, 
Bournemouth, UK). The isolated RNA was redissolved in diethylpyrocarbonate (DEPC)- 
treated distilled water and quantified by UV specti'ophotometiy. The integrity of the RNA 
was confirmed as being free of protein and DNA by having a ratio of >1.8 (optical density 
at 260nm/280nm) and by the presence of intact 18S and 28S bands on the agarose gels. 
RNA sample loading buffer (Sigma, UK) was added to lOpg of total RNA and separated 
on 1.2% agarose gels containing 6% formaldehyde and 20mmol/L MOPS (0.2 moi/L 3-[N- 
Morpholino] propane-sulphonic acid; 0.05 mol/L Na acetate pH 7.0; 0.01 mol/L
Na2EDTA). Gels were electrophoresed at 60 volts for 2.5 hours. RNA was transferred 
overnight onto Hybond-N nylon membranes (Amersham, Buckinghamshire, UK) in 20 x 
SSC (3mol/L NaCl; 0.3 mol/L NasCitrate, pH 7.0) and fixed to the membrane by ultra 
violet irradiation. Membranes were prehybridised for a minimum of 4 hours in 12ml of the 
prehybridisation buffer; 5 x SSC; 5 x Denhardf s solution (50 x Denhardt’s is 1% ficoll 
(Pharmacia Biotech, Hertfordshire, U.K.), 1% polyvinylpyrolidone and 1% BSA [factor 
V]); 0.5% sodium dodecyl sulphate (SDS); 10% dextran sulphate and lOOpg/ml boiled 
salmon sperm DNA.
Nylon filters were hybridised in the same buffer overnight with the appropriate labelled 
(Oligolabelling kit, Pharmacia Biotech) cDNA added to the prehybridisation buffer. The 
ICAM-1 (1.8Kb insert), VCAM (1.9Kb) and PECAM (2.5Kb) cDNA were a gift from Dr. 
Simmons, Oxford, UK. The E-Selectin (1.2Kb) cDNA was a gift from Dr. M. Bevilacqua, 
California, USA. The cDNA probe for the house-keeping gene human glyceraldehyde-3- 
phosphate dehydrogenase (GAPDH; 1.1Kb) was purchased from Clontech Laboratories 
UK Ltd (Basingstoke, UK). Nylon filters were washed to a final stringency of 0.5 x SSC,
0.1% SDS at 65 C and autoradiography was carried out with Fuji X-ray film at -70 C for 3 
days. The intensity of the bands on the autoradiographs for each of the cell adhesion 
molecules was compared with GAPDH and the ratio determined.
Human umbilical vein endothelial cells (HUVECs) were isolated by collagenase digestion. 
Once confluent, the cells were incubated in medium containing IL-lp (10 lU/ml) for 4 
hours and used as a positive control for the expression of ICAM-1, VCAM, PECAM and 
E-Seiectin. Total RNA was extracted as above, and loaded at 5 pg/lane.
Northern analysis of cervix
Total RNA was extracted from the cervical samples (n=6 in each group) using the 
Trizol™ method according to the manufacturers instructions (Life Technologies, Paisley, 
UK). The RNA was quantified by UV spectrophotometry and the integrity of the RNA 
confirmed as before. RNA sample loading buffer was added to lOpg of total RNA and 
separated on 1.2% agarose gels as for myométrial samples. Gels were electrophoresed at 
60 volts for 2.5 hours. RNA was transferred overnight onto Hybond-N nylon membranes 
in 20 X SSC and fixed to the membrane by ultra violet irradiation. Membranes were 
prehybridised for 1-2 hours, at 42 C, in 12ml of Ultrahyb™ (AMS Biotechnology, Oxon, 
UK) and then hybridised with the appropriate ^^p labelled (Oligolabelling kit, Pharmacia 
Biotech, Hertfordshire, U.K.) cDNA added to the prehybridisation buffer. Nylon filters 
were washed in 0.5 x SSC, 0.1% SDS at 65 C and if necessary a further wash was carried 
out in 0.1 X SSC, 0.1% SDS at 65 C. Autoradiography was carried out with Fuji X-ray 
film at -70 C for between 2 and 7 days.
Human umbilical vein endothelial cells (HUVECs) were used as a positive control for the 
expression of each cell adhesion molecule as before.
Immunohistochemistry
Immunohistochemistry was performed on paraffin embedded cervical and myométrial 
biopsies (n=8 in each group) using antibodies against ICAM-1, VCAM, PECAM, E- 
selectin, smooth muscle myosin and CD45 as detailed in Table 7.1.
Biopsies of ceivix and myometrium were fixed in 10% neutral buffered formalin (BDH, 
Poole, UK) on collection and embedded in paraffin. 5 pm thickness paraffin sections were 
cut and collected on siiane coated slides. Sections were heated to 60“C for 30 mins, 
dewaxed in xylene and rehydrated through graded alcohols and endogenous peroxide
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activity was blocked with 0.5% hydrogen peroxide in methanol. Sections were washed in 
Phosphate Buffered Saline (PBS) and antigen was retrieved by microwaving in a pressure 
cooker (Lakeland Plastics Ltd, Cumbria, UK) if required (Table 7.1). Tissue sections were 
then blocked in either 20% normal horse (SAPU, Carluke, UK) /human serum (PECAM, 
Myosin and CD45) or 20% rabbit /human serum (ICAM 1, E-Selectin) for 30 mins at room 
temperature and incubated for 16 hr at 4°C with the primary antibody (Table 7.1) diluted 
in 2% normal rabbit serum /2% normal horse serum. Sections were washed in PBS then 
incubated for 30 mins with biotinylated rabbit anti-goat (Vector Laboratories) or with 
biotinylated horse anti-mouse (Vector Laboratories) diluted 1:200 in 2% normal rabbit 
serum or 2% normal horse with 5% normal human serum added. Sections were washed in 
PBS, then incubated with avidin DH/ biotinylated horseradish peroxidase H reagent 
(Vector Laboratories, UK) in PBS for 30 mins before final washing. Antigen was localised 
using 1 mg/ml diaminobenzidene tetrahydrochloride (Sigma, UK), 0.02% H2O2  in 50mM 
Tris-Cl, pH 7.6 and appeared as a brown end product. Sections were then counterstained 
with Harris haematoxylin. Negative controls included slides incubated without the primary 
antibody and sections incubated with a mouse monoclonal antibody against IgGi 
Aspergillus niger glucose oxidase (DAKO Ltd), an enzyme that is neither present nor 
inducible in mammalian tissues. Placenta was used as a positive control for ICAM-1 and
PECAM. Arthritic joint was positive control for VCAM (Littler, et al., 1997) and kidney 
was used for E-selectin (Patey, etal., 1994).
Data analysis 
Northern blotting
The intensity of the bands on the autoradiographs for each of the cell adhesion molecules 
undergoing Northern analysis was compared with GAPDH and the ratio determined using
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the Bio-Rad Multi-Analyst ™ /PC Version 1.1. Statistical analysis of band intensity for the 
Northern analysis was performed using Kruskal-Wallis with Mann Whitney-U as a post 
hoc test. P<0.05 was considered to be significant.
Immunohistochemistry
Each section was analysed by 2 observers who were blind to the source of the biopsy and 
the localisation of staining was recorded for each antibody used. Staining for CD45 was 
used to co-localise leukocytes in the tissues.
Results
Characterisation of biopsies
Staining for anti-smooth muscle myosin was used to deteimine the muscle content of each 
biopsy. Myométrial tissue from non-pregnant and pregnant non-labouring subjects had an 
abundant muscle content and the bundles of smooth muscle were compacted. The staining 
pattern became less compacted in the labouring myométrial samples, consistent with the
disruption of this tissue during labour (Thomson, et al., 1999). In comparison, the smooth
muscle content of ceivical tissue biopsies was sparse as deteimined by immunolocalisation 
o f anti-smooth muscle myosin antibody. There was no change in smooth muscle 
distribution in this tissue during pregnancy and labour (Figure 7.1).
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Figure 7.1. Immunolocalisation of smooth muscle myosin in 
human cervix and myometrium. The smooth muscle content was 
sparse in cervical biopsies collected from each group of women,
(a) non-pregnant, (b) pregnant before the onset of labour and (c) 
pregnant during spontaneous labour. In contrast, myométrial tissue 
from (d) non-pregnant women, (e) pregnant, non-labouring women 
and (f) pregnant labouring women, had an abundant muscle 
content. The negative controls (see text) exhibited no reactivity. 
Scale bars = 50 pm.
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GAPDH 0 0 # # # # # » # #  1.1 kb
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Figure 7.2. Northern blot hybridization of total RNA (10 pg/lane) 
from human myométrial samples (n=5) collected (a) before 
labour and (b) during labour. Intercellular adhesion molecule 
(ICAM)-l hybridization was compared with the housekeeping 
gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
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ïCAM-1 expression and localisation
Northern blotting confirmed the presence of mRNA for ICAM-1 in myométrial and 
cei’vical samples. There was no significant change in the expression of ICAM-1 between 
the pregnant and non-pregnant groups. ICAM-1 was upregulated in labour in both 
myometrium (Figure 7.2) and cervix (p<0.01), (Figure 7.3). Immunohistochemistry 
localised ICAM-1 strongly to the vascular endothelium in both tissues. In pregnant and 
labouring samples, ICAM-1 was present in leukocytes that had infiltrated the tissues, as 
confirmed by CD45 staining, (Figure 7.4). Substantially greater numbers of these cells 
were visualised in the labouring samples from both tissues. Staining was absent in the 
negative control slides.
VCAM expression and localisation
VCAM mRNA was expressed in cervical and myométrial tissues from non-pregnant and 
pregnant subjects. Expression was increased in the cervix during pregnancy (p<0.01) with 
no further increase with the onset o f labour (Figure 7.5). The expression of VCAM in the 
myometrium was not altered during pregnancy. VCAM was localised weakly to the 
vascular endothelium in both the cervix and myometrium from all groups of women 
(Figure 7.6). Significant staining was also seen in some pregnant labouring samples of 
cervix and myometrium in the cellular infiltrate, identified as leukocytes by CD45 staining. 
There was no staining observed in the negative control slides.
PECAM expression and localisation
PECAM mRNA was present in the cervix and myometrium from all three groups of 
women. Expression of PECAM mRNA was significantly elevated in pregnant 
myometrium (p<0.01) with no further change with the onset of labour (Figure 7.7). There 
was no corresponding change in cervical tissue. Immunohistochemistry localised PECAM 
strongly to the vascular endothelium in both tissues and also to leukocytes (Figure 7,8).
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Figure 7.3. Northern blot hybridization of total RNA (10 ^g/lane) 
from human cervical samples (n=6) collected (a) before labour 
and (b) during labour. Intercellular adhesion molecule (ICAM)-l 
hybridization was compared with the housekeeping gene 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
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Figure 7.4. Immunolocalisation of intercellular adhesion molecule (ICAM)-l in 
human myometrium (a) before and (b) during the onset of spontaneous labour at 
term. In each of the biopsies, ICAM-1 localised to the vascular endothelium 
(arrows). Additionally, ICAM-1 was identified within leukocytes, which were 
abundant in tissues collected during labour. The negative controls (see text) 
exhibited no reactivity. Scale bars = 50 pm.
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GAPDH 1.1 kb
VCAM
GAPDH
1 2 3 4 5 6
1.9 kb
1.1 kb
(c)
1 2 3 4 5 6
VCAM « , # # » # » #  #  1 .9kb
GAPDH 1.1 kb
Figure 7.5. Northern blot hybridization of total RNA (10 pg/lane) 
from human cervical samples (n=6) collected from (a) non­
pregnant women, (b) pregnant women before labour and (c) 
pregnant women during labour. Vascular cell adhesion molecule 
(VCAM) hybridization was compared with the housekeeping gene 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The 
expression of VCAM mRNA was upregulated in the cervix during 
pregnancy.
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Figure 7.6. Expression of vascular cell adhesion molecule (VCAM) in (a) cervix 
collected before the onset of labour at term. VCAM localised strongly to the 
vascular endothelium (arrows). VCAM was strongly expressed within (b) arthrite 
joint (positive control), whilst the negative controls (c) exhibited no reactivity. 
Scale bars = 50 pm.
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Figure 7.7. Northern blot hybridization of total RNA (10 pg/lane) from 
human myométrial samples (n=5) collected from (a) non-pregnant women,
(b) pregnant women before labour and (c) pregnant women during labour. 
Platelet-endothelial cell adhesion molecule (PECAM) hybridization was 
compared with the housekeeping gene glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH). The expression of PECAM mRNA was 
upregulated in myometrium during pregnancy.
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Figure 7.8. Immunolocalisation of platelet-endothelial cell adhesion molecule 
(PECAM) in human myometrium, (a) non-pregnant, (b) pregnant before labour 
and (c) pregnant during labour. PECAM antigen was identified on the vascular 
endothelium in all tissues and also in infiltrating leukocytes. The negative controls 
(see text) exhibited no reactivity. Scale bars = 50 pm.
Figure 7.9. Expression of E-selectin on the vascular endothelium of (a) cervix 
collected during spontaneous labour (arrows). E-selectin was not identified in 
non-pregnant cervix nor in cervix collected before the onset of labour. E-selectin 
was expressed within kidney (b) which was employed as the positive control 
(arrows; see text). The negative controls (see text) exhibited no reactivity. Scale 
bars = 50 pm.
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Ë-selectin expression and localisation
There were no significant changes in E-selectin mRNA expression comparing the three 
groups in either myometrium or cei'vix, (Kruskal Wallis test, p=0.065 and p=0.07, 
respectively). Using immunohistochemistry, E-selectin was not expressed in the vascular 
endothelium in either the cervix or myometrium in non-pregnant biopsies or biopsies 
obtained before the onset of labour. However, E-selectin was present in the vascular 
endothelium in four of the eight biopsies from the cervix and four of the eight myométrial 
biopsies obtained during labour (Figure 7.9)
Discussion
This study describes the parallel changes in expression of ICAM, VCAM, PECAM and E- 
selectin in cervix and myometrium during pregnancy and labour. Our findings are in 
agreement with previously published reports describing the expression of these adhesion
molecules in pregnant and non-pregnant tissues (Coleman and Stanley, 1994; Johansson, et 
al., 1999; Thomson, et al., 1999; Winkler, et at,, 1998; Winkler, et al., 2000). ICAM, 
VCAM and E-selectin have been demonstrated in non-pregnant cervix and myometrium 
(Coleman and Stanley, 1994; Thomson, et al., 1999) and in lower segment myometrium
obtained during pregnancy before and after the onset of labour (Thomson, et al., 1999; 
Winkler, et al., 1998; Winkler, et al., 2000), Our results have demonstrated an increase in
expression of ICAM-1 in the cervix and myometrium during labour. VCAM expression is 
increased during pregnancy in the uterine cervix while PECAM expression is increased in 
the lower segment myometrium at this time. These findings support the hypothesis that 
pregnancy and labour represent an inflammatory process with cell adhesion molecules 
playing an important role.
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In view of the technical difficulties involved in obtaining cervical biopsies for research 
purposes, it has been suggested that the lower uterine segment can be taken as 
representative of the cervix (Rajabi, et al., 1988; Winkler et al., 1998; Rechberger and
Woessner, 1993). However, it has long been recognised that the cervix and myometrium
are different during pregnancy and labour, both structurally and functionally (Calder, 1994;
Danforth, 1947). In the cervix at term, a significantly greater number of neutrophils and
macrophages are present compared to the first trimester, with no increase noted following
the onset of labour (Bokstrom, et al., 1997). In contrast, in the myometrium neutrophils
and macrophages are sparse in lower segment myometrium before, and abundant during 
labour (Thomson, et al., 1999; Bokstrom, et al., 1997). This is consistent with cervical 
ripening being an inflammatory process involving leukocytic infiltration of the tissue in
preparation for the onset of labour (Junquiera, et al., 1980; Liggins, 1981; Owiny, et al., 
1995).
In this study, we have characterised the structure of each of the myométrial and cervical 
biopsies by determining its smooth muscle content, and have confirmed that lower segment 
myometrium is composed of substantially more smooth muscle during pregnancy and 
labour in comparison to the cervix. During pregnancy the smooth muscle composition of 
the myometrium was dispersed while that of the cervix remained constant. Our results have 
also shown that changes in cell adhesion molecule expression in cervix and lower segment 
myometiium are not identical. ICAM-1 mRNA expression increases in both cervix and
myometrium during labour. However, the expression of VCAM mRNA is increased in the 
cervix during pregnancy, while PECAM mRNA expression is increased in the 
myometrium at this time. Thus we have provided further evidence that lower segment 
myometrium cannot be considered as being representative of the cervix for the purpose of 
research in this field.
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The expression of cell adhesion molecules on the vascular endothelium of lower uterine 
segment myometrium has been described in previous studies (Thomson, et al., 1999;
Winkler, et al., 2000; Winkler, et al., 1998). In the present study we have investigated
whether other cell types within uterus and cervix can express adhesion molecules. We 
have found that infiltrating leukocytes in the labouring cervix and myometrium expressed 
ICAM-1, VCAM and PECAM. In light of these immunohistochemical findings, we 
conclude that the increase in ICAM-1 mRNA expression within the lower segment 
myometrium and cei'vix with the onset of labour seems to be attributable, at least in part, to 
the leukocytic infiltration occuring in these tissues with the onset of labour. Leukocytic 
influx is a characteristic feature in the cervix and myometrium prior to and at the onset of 
labour. Leukocyte expressed ICAM-1 may be involved in modulating cell signalling 
pathways, activation of cytokines and metalloproteinases, and apoptosis, events which take 
place in the cervix and myometrium around the time of the onset of parturition
We have demonstrated an increase in VCAM expression in the cervix during labour at 
term. VCAM is principally expressed on endothelial cells, but is also found on 
macrophages, dendritic cells and bone marrow fibroblasts and plays a significant role in 
the migration of leukocytes that express VLA-4, that is lymphocytes, monocytes 
eosinophils and basophils. VCAM is not expressed on endothelial cells in the resting state 
but, like ICAM-1, is upregulated by inflammatory mediators such as IL-ip, IL-4, TNF a  
and IL-13. Prostaglandins may also regulate VCAM expression as in vitro experiments 
have shown that it can be induced by phospholipase A 2, the enzyme responsible for
catalysing the release of arachadonic acid from cell membrane phospholipids (Yokote, et 
al., 1993). Prostaglandins, IL-ip and TNF a  are also recognised mediators of cervical
ripening (Chwalisz, et al., 1994; Greer, 1992; Winkler and Rath, 1996), hence the 
increased expression of VCAM in the cervix during pregnancy may reflect one of the
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mechanisms of action of these agents. Increased VCAM transcription in the cervix during 
pregnancy would promote leukocyte recruitment and cervical ripening. The exact timing 
of the increase in VCAM transcription is unclear from the present study.
PECAM is constitutively found on platelets, leukocytes and endothelial cells and mediates 
leukocyte-endothelial and platelet-endothelial interactions. It is essential for the 
transendothelial migration of leukocytes through intracellular junctions of vascular 
endothelial cells. Its transcription is not affected by cytokine release. PECAM mRNA was 
seen to increase in the myometrium during pregnancy with no further increase with the 
onset of labour, PECAM is a marker of endothelial cell differentiation, hence the increase 
in PECAM may refect increased turnover
E-selectin is expressed by cytokine activated endothelial cells and mediates neutrophil, 
monocyte and lymphocyte recruitment (Bevilacqua, 1993; Ley, et al., 1998). In this study,
we found E-selectin was localised to leukocytes in 4 out of 8 cervical biopsies obtained 
after the onset of labour and to 4 out of 8 myométrial biopsies. Quantitative assessment 
using Northern analysis however failed to demonstrate any difference in E-selectin 
expression in either tissue during pregnancy or labour. These results may reflect the small 
sample size studied and further investigations are required to determine whether E-selectin 
is involved in leukocyte recruitment during pregnancy.
Recent research has suggested that cell adhesion molecules may be potential targets for 
therapeutic intervention (Murray, et al., 1999). Antibodies directed against cell adhesion 
molecules may have a major functional role in the treatment of such inflammatory 
conditions as rheumatoid arthritis (Kavanaugh, et al., 1994), allergic airways disease and
asthma (Abraham, et al., 1994), inflammatory bowel disease (Podolsky, et al., 1993) stroke
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(Connolly, et ai., 1996; McCarron, et al., 1994) and ischaemia reperfusion injury (Dragun 
and Haller, 1999). The mechanisms controlling the onset of human parturition remain
unclear. However, our studies have demonstrated that the processes of cervical ripening 
and the initiation of labour constitute an inflammatory response with increased cell 
adhesion molecule expression in both the cervix and the myometrium. Improved 
understanding of the mechanisms involved in these events will ultimately lead to new 
therapeutic strategies for the treatment of preterm labour, which remains a leading cause of 
neonatal morbidity and mortality despite improvements in neonatal intensive care 
facilities. In the future, antibodies directed against cell adhesion molecules in the cervix 
and myometrium may be of benefit in reducing the morbidity and mortality associated with 
preterm labour.
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Conclusions
Cervical ripening in humans is clearly an inflammatory reaction involving a variety of 
mediators. The purpose of this thesis was to investigate the role of the inflammatory 
mediator nitric oxide in endogenous and artificially produced cervical ripening in human 
pregnancy.
Prostaglandin analogues are the most commonly used agents for the purpose of cervical 
ripening prior to suction termination of pregnancy. Nitric oxide donors have recently been
shown in animal and human studies to ripen the cervix in the first trimester of pregnancy.
A randomised controlled trial comparing the nitric oxide donor IMN with the prostaglandin
analogue gemeprost, presented in chapter 2 of this thesis, demonstrate that IMN has fewer
side effects than the prostaglandin analogue gemeprost when administered per vaginam in
the first trimester of pregnancy. The nitric oxide donor is associated with a lower
incidence of abdominal pain and pre-operative vaginal bleeding and a higher proportion of
patients remaining asymptomatic. However, more women receiving the nitric oxide donor
experienced a headache. Although the cervical ripening effects of IMN (40 and 80 mg) are
less than those of gemeprost (1 mg), results from the concurrent observational study
indicate that these agents are clinically sufficient for ripening the cervix at this gestation.
The results of the randomised controlled trial presented in chapter 3 demonstrate that the 
prostaglandin analogue misoprostol and the nitric oxide donor isosorbide mononitrate are 
effective for the purpose o f cervical ripening in the first trimester of pregnancy. 
Combination of these two agents does not improve the cervieal ripening effect. Side
I / o
effects are more common when these two agents are used in combination. These findings 
may be attributable to the mechanism of action of NO donors in the process of cervical 
ripening, as NO donors increase the production of PGF2a, as discussed in chapter 6. 
Combination therapy with these two agents may therefore enhance prostaglandin mediated 
side effects rather than exploit the smooth muscle relaxant properties of NO donors. 
Misoprostol at a dose of 400p,g appears to be the agent of choice for preoperative cervical 
ripening prior to suction termination in the first trimester. However NO donors may be 
useful for this purpose in those individuals for whom prostaglandin therapy is contra­
indicated.
The data presented in chapter 4 of this thesis demonstrates that cervical expression of each
of the NOS isofonns is up-regulated during pregnancy. iNOS and eNOS protein expression
is greater in the third trimester compared to the non-pregnant state. The increased 
expression of NOS isofonns, particularly iNOS, in the cervix in late pregnancy at the time 
when cervical ripening is occuring support the hypothesis that the inflammatory mediator 
NO is involved in the remodelling of the cervix that constitutes the ripening process.
The mechanism of action of nitric oxide in the process of cervical ripening remains 
obscure. Possible interactions are with prostaglandins and other inflammatory agents, 
MMPs, proteoglycans and via stimulation of apoptosis. The data presented in chapter 5 
investigate the interaction between NO donors and MMPs. In artificially mediated cervical 
ripening, the NO donors IMN and spermine nonoate have no effect on the expression of 
MMPs-2 or 9 or TIMPs-1, -2 or -4  in the human cervix when these agents are 
administered in vitro to non-pregnant subjects or when given in vivo to pregnant subjects. 
These data suggest that other MMPs must be involved in the interaction with NO in 
cervical ripening.
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In chapter 6 we investigated the potential interaction between nitric oxide donors, 
cytokines and prostaglandins in the cervix. The nitric oxide donor IMN stimulates 
production of PGF2a in vivo in the pregnant human uterine cervix. Administration of the 
nitric oxide donor SNAP in vitro to non-pregnant cervix does not produce this effect. 
Administration of these NO donors in vivo in the pregnant cervix or in vitro in the non­
pregnant cervix has no effect on the cytokines IL-1, IL-6, IL-8, IL-IO, IL-15, TNFa, or 
MCP-1. The mechanism of nitric oxide induced cervical ripening during pregnancy may 
be mediated in part via an increase in prostaglandin synthesis. Further studies are needed to 
examine whether there is an interaction between NO and prostaglandins / inflammatory 
mediators in spontaneous cervical ripening.
In human pregnancy at term leukocytes infiltrate the cervix and myometrium. These cells 
appear to be the source of nitric oxide involved in ripening the cervix, as demonstrated in 
the studies presented in chapter 4. The mechanisms that control the process of leukocyte 
recruitment in the cervix are incompletely understood although in other tissues cell 
adhesion molecules are intimately involved. In chapter 7 we demonstrate that there are 
changes in the expression of cell adhsion molecule expression mRNA in the cervix and 
myometrium during pregnancy. ICAM-1 expression and VCAM expression are altered in 
the cervix in the third trimester of pregnancy. Immunohistochemistry has confirmed that at 
laest part of the incresed expression of these cell adhesion molecules is attributable to the 
infiltrating leukocytes themselves. In the future, therapeutic strategies for the treatment of 
premature labour may be aimed at preventing cell adhesion molecule expression and 
activity in the cervix and myometrium.
In summary, the changes occuring within the cervix prior to the onset of labour appear to 
be dependent upon a functioning NO-cGMP system. Nitric oxide expression is increased in 
the cervix in the third trimester concurrently with cervical ripening. Therapeutic advances
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in the treatment o f preterm and post-dates pregnancy may be possible through 
manipulation of the NO generating system.
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Chapter 9 
Further Research
The work presented in this thesis provides further insight into the mechanisms involved in 
human cervical ripening. However there are clearly further avenues for future research 
based upon these findings. The role o f the NO generating system in preterm labour remains 
to be established. It would be both interesting and beneficial to investigate whether similar 
changes as those that occur at term are initiated in the preterm cervix. This in turn may 
provide future therapies for the treatment of this condition.
We have shown that NO is upregulated in the cervix at term and that, at least in the first 
trimester, that the cervix can be artificially ripened using the nitric oxide donors glyceryl 
trinitrate and isosorbide mononitrate. Since NO inhibits myométrial contractility, cervical 
ripening at term would be theoretically possible using NO donors, with the added 
advantage of failing to stimulate uterine activity during the ripening process. Preliminary 
data would suggest that NO donors are a safe and effective alternative to prostaglandins in 
this clinical setting (Chanrachakul et al., 2000), but fiirther work is required to confirm 
these findings.
The exact mechanisms by which NO ripens the cervix remains unclear. MMP-2 and MMP- 
9 appear not to be the candidate MMPs involved and further studies should address the role 
of other MMPs, including MMP-8 (neutrophil collagenase) and MMP-1. Cervical ripening 
is characterised by an alteration in the glycosaminoglycan composition of the tissue. NO 
has the potential to suppress glycosaminoglycan synthesis (Trachtmann et al., 1996), and 
the interaction between NO this connective tissue composite therefore also merits fiirther 
investigation. An increase in apoptosis has been observed in rat and human cervix, 
particularly in fibroblasts and smooth muscle cells (Allaire et al., 2000), and the
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involvement of NO remains to be elucidated as NO has been shown to stimulate this 
process in other tissues (Leppert, et al., 1994)
The control of NO expression within the cervix also remains obscure. Of particular interest 
for future studies is the potential role of the transcription factor NF Kappa B. A number of 
proinflammatory cytokines, cell adhesion molecules and reactive oxygen species appear to 
be under the transcriptional control o f the NF Kappa B family members, and they are 
therefore thought to play a central role in inflammatory responses in a number of tissues. 
Data on whether NF Kappa B is present in the human cervix are sparse. However, nuclear 
extracts from cervical cell carcinoma lines contain dimers of the p65 and p50 subunits of 
NF Kappa B (Altenberg et ai., 1999). Further research will examine the role of NF Kappa 
B in cervical ripening and the potential control of NO and COX-2 expression. Future 
therapies directed at the treatment of preterm labour may well involve inhibition of NF 
Kappa B, either by gene transfer of the inhibitor of NF Kappa B (I Kappa B) or by the use 
of I Kappa B kinases, or drugs directed at inhibiting the degradation of I Kappa B (Barnes, 
1999).
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